Body Mass Index and Pathway Dysregulation in Cancer by Takei, Riku
BODY MASS INDEX AND PATHWAY
DYSREGULATION IN CANCER
RIKU TAKEI
A THESIS SUBMITTED FOR THE DEGREE OF
MASTER OF SCIENCE
AT THE UNIVERSITY OF OTAGO, DUNEDIN, NEW ZEALAND
MARCH 31, 2017
Abstract
Obesity has been a major global problem for more than a decade, associated with
many noncommunicable diseases such as cancer. The number of obese people,
both adults and children, has risen in every country of the world and the trend
will likely to continue. Cancers are caused by dysregulation of various molecular
pathways that allow tumour cells to proliferate, survive and migrate. One of the
difficulties associated with the treatment of cancers is the identification of the un-
derlying biological pathways that drive tumorigenesis. This research aims to de-
termine whether gene expression signatures exist that are specific to obesity across
multiple cancer types, and to investigate whether there are any common pathways
being dysregulated in cancers based on these genetic signatures. In this work no
genetic signatures or differentially expressed genes were found between obese
and non-obese patients that were common across multiple cancer types. However,
the Akt, epidermal growth factor receptor (EGFR), transforming growth factor-β
(TGFβ ) and Src pathways may have a role in promoting the tumour progression
in patients that are obese. It is likely that there is some complex mechanism un-
derlying the relationship between obesity and cancer. A better understanding of
the pathways being dysregulated in cancer cells in obese patients may lead to
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Obesity has been a major global problem for more than a decade, associated with
many noncommunicable diseases such as diabetes, cardiovascular diseases and
certain types of cancers (World Health Organisation, 2014). In fact, the risk of
comorbidities increases with an increase in body mass index (BMI), where the risk
becomes severe as the BMI level approaches the obese category (World Health
Organisation, 2000). The number of overweight and obese people, in both adults
and children, has risen in every country of the world and the trend will likely to
continue in the future. Estimated to account for 3.4 million deaths per year and
93.6 million Disability-Adjusted Life Years (DALYs) in 2010, obesity is a serious
disease that continues to grow in our society (Lim et al., 2012).
1.1.1 Definition of obesity
Obesity is defined as an abnormal or excessive fat accumulation that may im-
pair the health of an individual (Garrow, 1988). One common and widely used
approach to categorise obesity is to measure the BMI of the individual. BMI is
a measurement based on the weight-to-height ratio of an individual. It is often
used by clinicians and epidemiologists to classify adults into underweight, nor-
mal weight, overweight, or obese categories. The unit of BMI is defined as the
1
weight in kilograms per square of the height in metres (kg/m2).
The World Health Organization (WHO) (2014) categorise overweight and
obese adults with a BMI of ≥ 25 kg/m2 and ≥ 30 kg/m2 respectively. For children
under the age of 5, overweight and obesity is categorised as a weight-for-height
ratio greater than 2 standard deviation and 3 standard deviation above the WHO
Child Growth Standards median respectively. For children aged between 5 to 19
years, overweight and obesity is defined as BMI-for-age greater than 1 standard
deviation and 2 standard deviation above the WHO Growth Reference Standards
median respectively.
However, the use of BMI as an accurate measure of body fat composition
and/or representation of the metabolic state of an individual remains controversial.
In fact, many studies have suggested that the use of other measurements, such
as waist-to-height and waist-to-hip ratios, to classify the patients into different
categories, as these measurements were better predictors of the diseases related to
obesity than BMI (Dalton et al., 2003; Gelber et al., 2008; Lee et al., 2008). With
that said, BMI is still widely used due to the ease of data collection compared to
other measurements. As a result, most of the publicly available clinical data has
height and weight data of the patients from which the BMI can be calculated.
1.1.2 Prevalence of obesity
From the latest global status report on noncommunicable diseases by the World
Health Organisation (2014):
“In 2014, 39% of adults aged 18 years and older (38% of men and
40% of women) were overweight. The worldwide prevalence of obe-
sity nearly doubled between 1980 and 2014. In 2014, 11% of men
and 15% of women worldwide were obese. Thus, more than half a
billion adults worldwide are classed as obese.”
Approximately 1 in every 14 people in the world were classed as obese in 2014;
therefore, 1 in every 14 people around the world were also at risk of the severe
health consequences associated with obesity. The highest prevalence of over-
weight and obesity was in the American regions, where 61% and 27% of the
2
population were overweight and obese respectively (World Health Organisation,
2014). It was also noted in the report that women were more likely to be obese
than men, and that the prevalence of overweight and obesity increased as the in-
come level of the countries increased (World Health Organisation, 2014).
In addition to this, the worldwide prevalence of childhood obesity has been
increasing steadily since 2000 (World Health Organisation, 2014). The prevalence
of overweight children in those under 5 was estimated to rise from 6.3% in 2013
to 11% by 2025 if the current trend continued (World Health Organisation, 2014).
The current prevalence of obesity in the younger population poses an even greater
risk to the health of the population in the future than the current prevalence of
obesity in the adult population.
In New Zealand (NZ), obesity is a serious problem as approximately one third
(31.6%) of adults in NZ were classified as obese in 2015/2016 (New Zealand Min-
istry of Health, 2016a). The Pacific and Māori populations were affected the most,
where 67% and 47% of the adults, respectively, were obese (New Zealand Min-
istry of Health, 2016a). NZ not only has a high prevalence of obesity compared
to many other countries, but also has a unique health problem that affects Pacific
and Māori populations disproportionately to the rest of the NZ population.
1.1.3 Physiological mechanism of obesity
Obesity is caused by continuous intake of food without expending all of the energy
gained from the food. The key to the problem is the control of food intake and
energy expenditure, and how they are regulated in the body. The role of the hy-
pothalamus is central to the control of satiety and many of the mutations that cause
obesity affects the satiety signals to and/or from hypothalamus. The hypothala-
mus receives both neuronal and hormonal inputs from the body and propagates
the signal to the downstream neurons which ultimately affects the food intake of
the individual (Bell et al., 2005; Spiegelman and Flier, 2001).
There are two types of neurons in the arcuate nucleus (located in the hypotha-
lamus): orexogenic and anorexogenic neurons. Orexogenic neurons are respon-
sible for the promotion of food intake and reducing energy expenditure, whereas
the anorexogenic neurons have the opposite effect (Barsh and Schwartz, 2002).
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When stimulated by, for example, endocrine signals, these two different types of
neurons act on the downstream neurons to promote or reduce food intake and
energy expenditure.
Leptin-melanocortin pathway is the main pathway in which the level of satiety
is controlled and regulated (Spiegelman and Flier, 2001). In this pathway, both
the orexogenic and anorexogenic neurons (located in the arcuate nucleus of the
hypothalamus) have crucial roles in controlling the satiety of the individual, and
therefore their eating behaviour (Barsh and Schwartz, 2002; Bell et al., 2005).
When a satiety-controlling hormone such as leptin reaches the arcuate nucleus
region of the hypothalamus, it can stimulate or inhibit orexogenic, anorexogenic,
or both orexogenic and anorexogenic neurons. Depending on which neurons are
stimulated or inhibited, the hormone will ultimately alter the satiety level of the
individual.
Though there are many hormones that regulate satiety, only leptin and insulin
will be covered here. Leptin is a hormone that signals satiety and reduces food
intake, and is secreted mainly by the white adipose tissue (El-Sayed Moustafa
and Froguel, 2013; Zhang et al., 1994). The circulating concentration of lep-
tin in the body is proportional to the body fat stores (Barsh and Schwartz, 2002;
El-Sayed Moustafa and Froguel, 2013). Leptin signals through the janus kinase
(JAK)/signal transducer and activator of transcription (STAT) pathway via the
long form of the leptin receptor that is present in high expression in the hypotha-
lamus (Ghilardi et al., 1996; Lee et al., 1996). Depending on the type of neurons
the leptin receptor is expressed on, leptin stimulates or inhibits these neurons and
ultimately produces an anorexogenic signal to the downstream effector neurons
(Bell et al., 2005).
Insulin, perhaps the most well-known hormone for its role in glucose home-
ostasis, also has an important role in satiety and food intake regulation. In brief
terms, when insulin binds to the insulin receptor, insulin receptor substrate (IRS)
protein family members are recruited and phosphorylated by the intrinsic tyrosine
kinase activity of the insulin receptor (Saltiel and Pessin, 2002). The phospho-
rylated IRS protein then activates phosphatidylinositol 3-kinase (PI3K), which in
turn activates its downstream targets, causing a rapid signal cascade through the
cell (Saltiel and Pessin, 2002).
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The exact role of insulin in the satiety control was not particularly clear even
though there was evidence of increased food intake with neuron-specific deletion
of insulin receptor (Barsh and Schwartz, 2002; Brüning et al., 2000). The fact
that the insulin level, like leptin, was proportional to the fat mass also suggested
the role of insulin in satiety and body weight control (Barsh and Schwartz, 2002;
Brüning et al., 2000; Woods et al., 1979). This was perhaps due to the fact that
leptin and insulin used two different signalling pathways in the cell: leptin used
the JAK/STAT signalling pathway, whereas insulin used the PI3K pathway for
signalling (Ghilardi et al., 1996). However, leptin, and subsequently insulin, was
shown to activate ATP-dependent K+ channel in glucose-responsive neurons in
the hypothalamus (Spanswick et al., 1997, 2000). The activation of the K+ chan-
nel provided evidence for the two pathways to act similarly on the cell, at least for
an acute response. This suggests a convergence in the pathway response by the
two hormones, and therefore their role in satiety control.
Satiety control is crucial in order to manage and maintain the body weight
in a healthy state. As described above, there are many components that regulate
satiety. Disruption of any part of the satiety controlling pathway can encourage
the development of obesity.
1.1.4 Factors that affect the prevalence of obesity
Individual-level (micro-level) factors
There is much evidence of obesity being caused by individual-level genetic factors
that make some individuals more predisposed to obesity than others. Generally
speaking, there are two classes of genetically-driven obesity: monogenic obesity
and polygenic obesity (El-Sayed Moustafa and Froguel, 2013).
Monogenic obesity is where a single mutation in one of the genes that is di-
rectly involved in the satiety controlling pathway causes severe obesity in that in-
dividual. Since these mutations are usually directly related to the key constituents
in the pathway mentioned earlier (Section 1.1.3), the resulting phenotype from
the mutation causes severe early-onset obesity. However, although these muta-
tions cause a devastating effect on those who carry the mutation, these mutations
occur very rarely in the population.
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An example of a mutation that causes severe early-onset obesity is a mutation
in the leptin gene. Montague et al. (1997) found a single nucleotide deletion
mutation at position 133 of the leptin gene in children with early-onset obesity.
They further showed that the mutation caused a frameshift mutation in the protein,
resulting in an inactive form of leptin that was not able to be secreted (Montague
et al., 1997). As a result, children with this mutation were constantly hungry due
to the lack of anorexogenic signals and became obese at a very early stage of their
lives.
Polygenic obesity is where a combination of variants in multiple genes or
multiple regions of the genome (together with the effect from the environmental
factors) causes obesity in the individual (El-Sayed Moustafa and Froguel, 2013).
Unlike in monogenic obesity, where a single mutation in a gene causes severe
obesity, the variants in some of the genes or genomic regions involved in polygenic
obesity have little effect on the obesity status of the individual by itself. However,
in combination with many other variants and together with environmental factors,
it has a serious obesogenic effect on the individual.
There have been many studies that have investigated the association of genes
and/or genomic regions with obesity. Of those, many of the genome wide as-
sociation studies (GWAS) published in 2007 showed strong evidence of the fat
mass and obesity associated (FTO) gene with BMI and obesity (Dina et al., 2007;
Frayling et al., 2007; Gerken et al., 2007; Scuteri et al., 2007). Until these stud-
ies came out, there has been no common genes or genomic regions found to be
associated with obesity that was reproducible and reliable (Frayling et al., 2007).
Thus, these studies were the first evidence of common variants that contributed to
the polygenic obesity phenotype in the population.
These individual-level genetic factors contribute to the overall increase in the
proportion of the population that are obese. However, it is likely that the envi-
ronmental factors are the most significant contributor to the current global obesity
epidemic (Malik et al., 2013).
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Population-level (macro-level) factors
It is clear that the individual-level factors cannot be accounted for the global epi-
demic of obesity that the world currently observes. For this reason, obesity is
thought to be caused mainly by the environmental factors that act on a population-
level. The first key factor that contributes to the global rise in the proportion of the
population that is obese is the availability and abundance of certain foods in the
country. With the help from government free trade policies, food and other goods
have become easier to trade between countries, helping the economic growth of
many countries around the world (Kearney, 2010). This has led to a greater abun-
dance of food in general, a greater number of food choices and a change in the
overall nutritional status of countries (Malik et al., 2013). This shift in food choice
and availability (and the economic benefit associated with the trade) had a posi-
tive impact on countries, but the growth in the food market also resulted in the
population-wide rise in obesity.
As an example, in the United States of America (USA), the cost of corn and
soy are low due to the fact that they are the raw ingredients for most processed
food and beverages, such as high fructose corn syrups used to sweeten many soft
drinks in the USA (Malik et al., 2013). Moreover, corn and soy are also the
main food for livestock, which results in lower price for meat (Malik et al., 2013).
On the other hand, the prices of fruits and vegetables remain expensive due to the
lack of support by the government to lower the cost associated with the production
(Malik et al., 2013). As a result, more people are inclined to consume food that are
cheap, have little nutritional value and high in energy, than food that are expensive,
nutritional and healthy alternatives. Thus, the population is more likely to become
obese by making poor food choice.
The second factor to consider is the behavioural changes led by urbanisation.
As more people take up urban lifestyle, they are exposed to new environments
with a better range of food selection, as well as technological and mechanical ad-
vancement in transport and other daily chores that may not be available in rural
areas. Although urbanisation has many advantages, such as access to developed
health care systems, education and advanced technologies, the lifestyle change
also imposes negative health behaviour that ultimately can lead to positive energy
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balance and obesity (Malik et al., 2013). Lack of physical activity is one of the
clear components linked with urbanisation. In many urban cities, it is often dif-
ficult to achieve and maintain the recommended level of physical exercise due to
the shift towards sedentary behaviours that are encouraged by developed trans-
port systems, automated household chores and indoor entertainment (Malik et al.,
2013).
The last factor to be mentioned here is the income and socioeconomic status of
the population. As the average income increases, more people are able to buy food
and are likely to take up a sedentary lifestyle. From this, one would expect the
high-income group to have the largest impact from obesity, but on the contrary,
the biggest impact from obesity is seen in the low- and middle-income groups
(Malik et al., 2013). Access to a developed health care system will allow weight
maintenance, but this is likely to be of most benefit to high-income groups. The
reason for this is the cost associated with a visit to the health care system, as high-
income groups are more likely to make a consistent and periodic visit than a low-
or middle-income groups (Malik et al., 2013).
Therefore, for the low- and middle-income groups, the rise in the average
income in these groups allows people to have access to food and activities that
promotes sedentary behaviours, but the limited access to the health care system,
education, and recreational activities (that promote physical activity) ultimately
leads to positive energy balance (Malik et al., 2013). In contrast, the high-income
group of the population have better access to facilities that promote weight main-
tenance, thus have less of an impact compared with the low- and middle-income
groups of the population. All of these population-level environmental factors in
synergy with the individual-level genetic factors have contributed to the global
epidemic of obesity.
1.2 Cancer
“Cancer is a generic term for a large group of diseases that can affect
any part of the body . . . One defining feature of cancer is the rapid
creation of abnormal cells that grow beyond their usual boundaries,
and which can then invade adjoining parts of the body and spread to
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other organs . . . referred to as metastasizing. Metastases are the ma-
jor cause of death from cancer.” (World Health Organisation, 2016)
1.2.1 Prevalence and mortality of cancer
Cancer is considered as one of the leading causes of deaths around the world, ac-
counting for 8.2 million deaths in 2012 (World Health Organisation, 2014). More
than half of cancer deaths are caused by lung, breast, colorectal, stomach and liver
cancers (World Health Organisation, 2014). The leading cause of cancer deaths
in high-income countries is lung cancer for both men and women, then colorectal
cancer and breast cancer for men and women, respectively (World Health Organ-
isation, 2014). Although the levels of mortality vary among different countries,
cervical, liver and stomach cancers make up a large proportion of cancer deaths
among low- and middle-income countries (World Health Organisation, 2014).
Bray et al. (2013) estimated the global prevalence of cancer in the adult pop-
ulation in 2008. Since there was no clear definition for cancer prevalence, Bray
et al. (2013) used limited duration prevalence as an estimate for cancer prevalence,
and measured the incidence of cancer during the period between 2004 and 2008
(5 years). From these estimates, Eastern Asia had the greatest 5-year prevalence
of cancer, with approximately 7 million people with cancer in 2008, followed by
North America and Western Europe with approximately 4.7 and 3 million people
with cancer (Bray et al., 2013). When the population of these regions was taken
into account and the proportion of cancer prevalence calculated, Western Europe
had the highest prevalence proportion of 1.9%, followed closely by Australia/New
Zealand with 1.82% and North America with 1.7% (Bray et al., 2013).
Looking at the prevalence of cancer by specific types, breast cancer was the
most prevalent type of cancer with 5.2 million cases in 2008 (Bray et al., 2013).
Colorectal and prostate cancers were the second and third most prevalent cancer
types, with approximately 3.2 million cases (Bray et al., 2013). Bray et al. (2013)
noted that female-specific cancer types were the most prevalent types of cancer
in 75% of countries in the world. Furthermore, the prevalence of breast, cervix
or prostate cancer is the highest in almost 95% of countries (Bray et al., 2013).
Although these estimates provide a relatively crude measure of cancer prevalence,
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Bray et al. (2013) provided a useful overview of the prevalence of cancer around
the world.
In NZ, the most common cancer types diagnosed for males are prostate, col-
orectal, melanoma, lung and non-Hodgkin lymphoma, which all together ac-
counted for 65% of newly registered cancers in males in 2013 (New Zealand Min-
istry of Health, 2016b). For females, breast (which accounted for 28.3% of all new
female cancer cases), colorectal, melanoma, lung and uterine cancers were the
most common cancer types diagnosed in 2013 (New Zealand Ministry of Health,
2016b). The cancer registration rates were higher in females aged 25-54 years
than males of the same age group, but the registration rates were significantly
higher in males for people who were 60 years or older (New Zealand Ministry
of Health, 2016b). Like with obesity, there is a significant difference in the can-
cer registration rates between Māori and non-Māori. The rates were 1.2 and 1.4
times greater in the Māori population compared to the non-Māori population for
males and females, respectively (New Zealand Ministry of Health, 2016b). Again,
this difference between Māori and non-Māori is unique to NZ, and improved un-
derstanding of the underlying problem is essential for better treatment plans and
outcomes for Māori.
The total number of deaths by non-communicable diseases (including cancer)
is predicted to increase, reaching 52 million deaths by 2030 (World Health Organ-
isation, 2014). With the prevalence of cancer at such high levels around the world,
and with cancer mortality increasing in the future, cancer is a serious challenge
that the world has to face.
1.2.2 Mechanisms of cancer development
It is now commonly understood that cancers are caused by dysregulation of var-
ious molecular mechanisms or pathways that allow tumour cells to proliferate,
survive and migrate. By taking advantage of these pathways, cancer cells are able
to grow and eventually metastasise to other parts of the body. The environment




Extensive research in cancer biology has uncovered many pathways and regu-
latory mechanisms involved in cancer. With more than 100 distinct types and
subtypes of cancers (each with its own distinct developmental mechanisms), it
became difficult to focus on the overarching mechanisms of cancer development
(Hanahan and Weinberg, 2000). To resolve this, Hanahan and Weinberg (2000)
proposed “six essential alterations” that cancer cells usually take advantage of
during development and progression. These six key mechanisms were coined as
being “The Hallmarks of Cancer”, and have been used extensively by many re-
searchers as their guide to target their research in specific areas of cancer biology.
Ten years after the first review where the concept of Hallmarks of Cancer was
proposed, Hanahan and Weinberg revisited these hallmarks and added four more
on top of the six hallmarks presented in 2000 (Hanahan and Weinberg, 2011). The
ten Hallmarks of Cancer are: sustaining proliferative signalling, evading growth
suppressors, enabling replicative immortality, activating invasion and metastasis,
inducing angiogenesis, resisting cell death, avoiding immune destruction, tumour-
promoting inflammation, genome instability and mutation, and deregulating cel-
lular energetics (Figure 1). Each of these hallmarks will be described briefly to
provide an overview of the significance of these mechanisms in tumour biology.
Sustaining proliferative signalling
Cancer is a disease of uncontrolled cell proliferation and division. Normal cells
cannot proliferate without any external mitogenic growth signals, but cancer cells
are able to deregulate these signals to maintain a steady proliferative signal (Hana-
han and Weinberg, 2011).
There are many ways in which cancer cells can maintain this signal. Firstly,
cancer cells can acquire the ability to produce growth factors and express the cor-
responding receptor, creating a positive feedback mechanism that continuously
stimulates the cells to proliferate (Hanahan and Weinberg, 2000). Secondly, they
can express more receptors for a given growth signal, and thus become “hyper-
responsive” to the signal (Hanahan and Weinberg, 2000, 2011). Thirdly, cancer
cells can stimulate the neighbouring normal cells within the tumour microenviron-
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Figure 1: Hallmarks of Cancer. The ten Hallmarks of Cancer as proposed by Hanahan and Wein-
berg in 2011. (Figure adapted from Hanahan and Weinberg (2011))
ment to produce more growth factors that further assist growth (Bhowmick et al.,
2004; Liotta and Kohn, 2001; Wiseman and Werb, 2002). Finally, cancer cells are
able to maintain proliferative signalling by mutating the growth factor receptor
itself, or the downstream signalling targets of the growth factor receptor pathway
(Fuqua et al., 1991; Su Huang et al., 1997; Satyamoorthy et al., 2003). By main-
taining the proliferative signals, cancer cells are able to continuously grow in their
environment.
Evading growth suppressors
As well as maintaining proliferative signals, cancer cells must also evade signals
that inhibit cell growth. The p53 protein is a tumour suppressor protein that has a
role in cell cycle arrest (Hanahan and Weinberg, 2011; Levine, 1997). As Hana-
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han and Weinberg (2011) mention in their review, “TP53 receives inputs from
stress and abnormality sensors that function within the cell’s intracellular operat-
ing systems”. The level of expression and its stability is crucial for the function of
p53 protein, as the abundance of p53 protein in the cell triggers cell cycle arrest
or cell apoptosis, depending on the extent of the cell signal (Fridman and Lowe,
2003; Hanahan and Weinberg, 2011; Levine, 1997). When abundant and active,
p53 protein transcribes the p21 protein which, through series of events in the p16-
cyclin D1-cdk4-retinoblastoma-associated (RB) pathway, triggers cell cycle arrest
(Levine, 1997). In many cancers, the p53 protein is mutated and selected against
to allow continuous growth of the tumour cells.
Resisting cell death
Apoptosis, the natural and controlled death of a cell and is one of many defence
mechanisms in the body to prevent the development of cancer. The triggering
of apoptosis is controlled and maintained by the balance between the pro- and
anti-apoptotic signals that affect the downstream apoptotic proteins (Hanahan and
Weinberg, 2011).
The precise cellular conditions that trigger apoptosis are yet to be uncovered,
but there is a clear evidence of the p53 tumour suppressor playing a key role
in apoptosis initiation. In short, when DNA damage is sensed, the p53 protein
transcribes the pro-apoptotic members of the B-cell lymphoma 2 (Bcl-2) family
proteins, such as Bax, Puma and Noxa (Fridman and Lowe, 2003; Hanahan and
Weinberg, 2011). The fact that the p53 protein is involved not only in the regu-
lation of the cell cycle, but also in the apoptotic pathway shows its importance in
the control of cancer development, and perhaps that is the reason why more than
50% of tumours have a mutation in the TP53 gene (Levine, 1997).
Enabling replicative immortality
When acquired by cancer cells, the previous three hallmarks allow the cells to
continuously grow in an uncontrolled manner. However, this is not the case, as
the disruption in cell signalling on its own does not trigger the rapid expansion
of the tumour; this occurs only when the cells have the capability of replicating
13
infinitely (Hanahan and Weinberg, 2000, 2011).
There are two barriers in achieving infinite replicative capacity: senescence
and crisis (Hanahan and Weinberg, 2011). When cells are grown in a culture, the
cells are able to replicate and grow until a certain point, and the cells reach the
stage of senescence where the cells stop growing but are still viable (Hanahan and
Weinberg, 2011). The cells that manage to bypass this senescence phase by mu-
tating the tumour suppressor proteins such as the p53 protein, undergoes the crisis
phase where the majority of the cells in the culture dies (Hanahan and Weinberg,
2011). Very rarely, some cells are able to survive the crisis phase and acquire
the ability to replicate infinitely, and this transition has been termed “immortali-
sation” (Hanahan and Weinberg, 2011; Wright et al., 1989). Without immortali-
sation, cancer cells are not able to generate macroscopic tumours that are capable
of killing the host organism (Hanahan and Weinberg, 2000, 2011).
Inducing angiogenesis
Like normal cells, cancer cells also require access to oxygen and nutrient supplies
from the blood. However, new blood vessel formation, or angiogenesis, only
occurs in a handful of occasions, and thus the tumour needs to acquire the ability
to stimulate angiogenesis in the microenvironment in which they live (Hanahan
and Weinberg, 2011).
It is thought that the angiogenic ability of the tumour is gained at an early
stage of tumour development by disrupting the “angiogenic switch” (Hanahan and
Weinberg, 2011). Vascular endothelial growth factor-A (VEGF-A) is the major
growth factor that triggers angiogenesis by signalling through the VEGF recep-
tors (though some receptors have an inhibitory effect) (Yancopoulos et al., 2000).
Opposing the effect of VEGF-A is the thrombospondin-1 (TSP-1), a protein that
is known to inhibit the process of angiogenesis by affecting the bioavailability
of VEGF, as well as promoting apoptosis (Kazerounian et al., 2008). In gen-
eral, many cancers stimulate the expression of VEGF-A protein and reduces the
expression of TSP-1 (Kazerounian et al., 2008).
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Activating invasion and metastasis
One of the prime reasons that cancers are so difficult to treat and have a high
mortality rate is due to their ability to metastasise to other parts of the body. Once
metastasised, the clinician not only has to consider the primary tumour site, but
also the second, third, or even fourth tumour sites. These tumours may or may
not have similar tumour biology as the primary tumour, and thus has to consider
multiple treatment plans to cure the patient.
Metastasis is a multi-step process that requires the selection and survival of
cancer cell(s) that is able to metastasise (“seed”), and is also compatible with the
specific target tissue where they prosper (“soil”) (Talmadge and Fidler, 2010).
Once mobile and invasive, the metastatic cancer cell is able to circulate in the
vascular system and eventually invade the target organ, where it must undergo
mesenchymal-epithelial transition (MET) and colonise the site (Hanahan and Wein-
berg, 2011; Kalluri and Weinberg, 2009). There are numerous signals, growth
factors and pathways that initiate the metastatic phenotype in the cancer cell, and
it remains an active field of research (Hanahan and Weinberg, 2011; Kalluri and
Weinberg, 2009).
Genome instability and mutation
Many of the hallmarks are acquired by the cancer cells during tumour growth,
through many genomic changes and mutations of the essential genes that allow
cancer cells to survive, proliferate, invade and metastasise. Thus, it is only log-
ical to deduce that many, if not all, cancers are more prone to genetic mutations
and restructuring, which allows the cancers to subsequently acquire the already
described Hallmarks of Cancer (Hanahan and Weinberg, 2011).
Until recently, the evolutionary progress of cancers have thought to have been
gradual and stepwise, where each driver mutation is acquired over many years,
or even decades (Stephens et al., 2011). There is now evidence that shows other-
wise, whereby a single catastrophic event (termed chromothripsis) occurs in the
chromosome structure, resulting in major structural rearrangements such as inver-
sions, deletions, duplications and translocations (Leibowitz et al., 2015; Stephens
et al., 2011). As it is a one-off chromosomal disruption, chromothripsis (usually)
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cause disruptions in tumour suppressor genes rather than duplications of onco-
genes (Leibowitz et al., 2015).
In addition to this, areas of the chromosome where major structural rearrange-
ments have occurred can be prone to a regional hypermutation, termed kataegis
(Leibowitz et al., 2015; Nik-Zainal et al., 2012). Although the full mechanism in
which kataegis occurs is not yet defined, activation-induced cytidine deaminase
(AID)/APOBEC family proteins, a family of proteins involved in gene editing,
may play a major role in kataegis (Leibowitz et al., 2015; Nik-Zainal et al., 2012).
It is evident that both chromothripsis and kataegis contribute to the genomic aber-
rations and mutations that ultimately encourage the acquisition of many of the
tumorigenic phenotypes.
Tumour-promoting inflammation
While inflammation and immune response may assist in the control of diseases
and injuries, they have been implicated in the progression of tumours and their ac-
quisition of many of the cancer hallmarks (Hanahan and Weinberg, 2011). There
are two key transcription factors of inflammation that ultimately leads to the pro-
motion of many, if not all, of the hallmarks discussed so far: nuclear factor κB
(NF-κB) and signal transducer and activator of transcription 3 (STAT3) (Manto-
vani et al., 2008).
The study by Pikarsky et al. (2004) showed that NF-κB was an essential com-
ponent for the progression of hepatocellular carcinoma, providing the first evi-
dence as to how inflammation may affect the tumour biology. NF-κB regulates
the expression of genes that encode the inflammatory cytokines, angiogenic fac-
tors, and many others, including anti-apoptotic genes (through the activation of
STAT3) (Elinav et al., 2013; Mantovani et al., 2008). STAT3 is a transcription fac-
tor that is activated through a variety of receptors and pathways (Yu et al., 2007,
2014). By increasing the transcription of anti-apoptotic proteins such as Bcl-2,
STAT3 promotes tumour survival and proliferation (Yu et al., 2007). Further-
more, STAT3 is able to increase the expression of inflammatory cytokines (such
as interleukin-6 (IL-6) and IL-10) and VEGF (Yu et al., 2007). These cytokines
provide a positive feedback mechanism for further inflammation (and therefore
16
survival and proliferation signals) and advancement of angiogenesis, respectively
(Yu et al., 2007).
Deregulating cellular energetics
In order to grow and proliferate, cancer cells must adjust their energy metabolism
to match their energy requirement (Hanahan and Weinberg, 2011). Wardburg
(1956) found that even if cancer cells have an abundance of oxygen in the cell,
they utilised the glycolytic pathway instead of the more efficient aerobic respira-
tion, and was later termed “aerobic glycolysis” (Hanahan and Weinberg, 2011). It
seems counterintuitive to limit its full potential of creating adenosine triphosphate
(ATP) by utilising glycolysis over electron transport chain (ETC), as the latter pro-
duces almost 18 times more ATP (Hanahan and Weinberg, 2011; Vander Heiden
et al., 2009). However, it is hypothesised that this inefficiency helps the cell to
generate and direct the molecules required for biosynthetic pathways during cell
growth and division (Cairns et al., 2011; Vander Heiden et al., 2009). By deliber-
ately relying purely on glycolysis (known as the “Wardberg effect”) and slowing
the conversion of phosphoenol pyruvate (PEP) to pyruvate, the cell is able to direct
the carbon molecules into reaction pathways (Cairns et al., 2011; Vander Heiden
et al., 2009). These produce the constituents used to synthesise macromolecules,
such as DNA and lipids (Cairns et al., 2011; Vander Heiden et al., 2009).
The fact that the deregulation of energy metabolism is mediated somewhat
by the genes involved in many of the other hallmarks (such as p53 and Myc)
suggests that the disruption in energy metabolism may be a phenotype caused in
conjunction with those core hallmarks (Hanahan and Weinberg, 2011).
Avoiding immune destruction
Our immune system is constantly monitoring and maintaining normal cell biology
within our body, preventing the emergence of cancer (Hanahan and Weinberg,
2011). With that said, cancers are frequently observed in clinics. This highlights
how the cancer cells can evade the diligent monitoring by the immune system
(Hanahan and Weinberg, 2011).
Immunoediting is a process where the immune system successfully eliminates
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the highly immunogenic cancer cells during surveillance, but fails to eliminate
the weakly immunogenic cells and therefore poses a selective advantage on these
cells (Hanahan and Weinberg, 2011; Teng et al., 2008). In fact, there have been
reports where the cancer cells in the immunodeficient mice were not able to ini-
tiate tumour growth in the immunocompetent mice, but the cancer cells from the
immunocompetent mice were able to do so in the immunodeficient mice (Hana-
han and Weinberg, 2011). One possible reason for this was that the cancer cells
from the immunodeficient mice were not immunoedited to the extent in which the
cells from immunocompetent mice were, and thus unable to evade the immune
system as efficiently as those cells in the immunocompetent mice (Hanahan and
Weinberg, 2011). Though more experiments must be carried out to confirm its
definitive role and mechanisms in which immunoediting contributes to cancer bi-
ology, immune system evasion is no doubt a significant factor that contributes to
tumour progression.
By utilising many, if not all, of these major cancer hallmarks, cancer cells are
able to initiate growth, proliferate, invade, metastasise and eventually kill the host
if untreated. There is an evident need for an efficient way to monitor and treat
cancer patients, and these Hallmarks of Cancers will prove to be the best target
for effective treatment of cancer in the future.
1.2.3 Causes and risk factors of cancer
There are many causes and risk factors associated with the development and pro-
gression of cancer. Like obesity, cancers are dependent on both genetic and envi-
ronmental factors.
Genetic mutations
Any one of the ten Hallmarks of Cancers has the potential to initiate cancer growth
and progression, and every hallmark has their own complex mechanistic path-
ways. Furthermore, every pathway has many proteins associated with its function
or role in the cell and, though their impacts may differ from protein to protein,
mutations in any one of the proteins involved in a pathway have the potential to
18
cause cancer.
Oncogenes are genes that promote or “accelerate” the process of tumorige-
nesis and/or tumour progression, whereas tumour suppressor genes prevent or
“decelerate” those effects (Vogelstein and Kinzler, 2004). Cancers usually mutate
oncogenes in such a way that they become constitutively activated, and mutate the
tumour suppressor genes so that these genes are inactivated and/or have reduced
expression (Vogelstein and Kinzler, 2004). Another thing to note for these genes
is that the oncogenes usually only require a “one-hit” mutation that affects a single
allele, whereas the tumour suppressor genes generally require mutations in both
maternal and paternal alleles to have any effect (Stratton et al., 2009; Vogelstein
and Kinzler, 2004).
Stability genes, also known as caretakers, are genes that are involved in, for
example, mismatch repair (MMR), nucleotide-excision repair (NER) and base-
excision repair (BER); in other words, genes that are involved in DNA repair
mechanisms (Vogelstein and Kinzler, 2004). These caretaker genes help pre-
vent the cell from developing new mutations during DNA replication and mitosis.
However, only the oncogenes or the tumour suppressor genes are able to directly
affect the biology of the cell, and therefore mutations in stability genes tend to
affect the mutation rates of the other classes of genes, ultimately leading to tu-
morigenesis (Vogelstein and Kinzler, 2004).
There are two types of mutations that occur in an individual: germline muta-
tion and somatic mutation. Germline mutations are the mutations that are passed
on from the parents of an individual, and somatic mutations are the mutations
acquired by the cell over the course of the lifetime of an individual.
Unfortunately, there are germline mutations that make the individual more
predisposed to cancer (Vogelstein and Kinzler, 2004). These individuals have a
mutation in one or more of the classes of cancer-related genes, which makes them
more likely to develop a tumour than individuals without the mutation (Vogel-
stein and Kinzler, 2004). In contrast, somatic mutations are acquired during the
lifetime of an individual, and is not passed down to their children. Somatic muta-
tions can either be a driver or a passanger mutation, where a driver mutation helps
tumorigenesis and its subsequent progression (in other words, mutations in onco-
gene, tumour suppressor, or stability gene), and passanger mutation have neither
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a selective advantage nor contribute to tumour progression (Stratton et al., 2009).
Since cancers require multiple driver mutations, somatic mutations are an es-
sential part of tumour development. Perhaps that is one of the reasons why,
in some cancers, germline mutation in the stability genes (such as BRCA1 and
BRCA2 genes) cause greater susceptibility to cancers than mutations in oncogenes
or tumour suppressor genes (Vogelstein and Kinzler, 2004).
Environmental factors
Cancers are developed through many cellular pathways (Hallmarks of Cancers)
that are not fully uncovered yet, with either too many or very few causes associated
with those pathways. Therefore it is difficult to assess how, rather than whether,
a given environmental factor causes a specific cancer. With that said, several
environmental factors have a strong evidence of causing cancer.
Smoking is a known risk factor for many cancers; the main one being lung
cancer (Gandini et al., 2008; Hecht, 1999). For current smokers, the relative risk
is greater than 1.5 in many cancers, including liver, cervix and kidney, and it can
rise up to 8.96 in lung cancer (Gandini et al., 2008). Tobacco smoke contains
many carcinogens which are processed first by cytochrome P450 (CYP) enzymes
(termed metabolic activation) (Hecht, 1999). The resulting product from this reac-
tion can either be processed further to be detoxified completely and cause no harm
to the cell, or alternatively, the product can covalently bind to the DNA, forming
DNA adducts (Hecht, 1999). Unless these adducts are resolved correctly by the
DNA repair mechanisms, it can result in a permanent mutation within the genome
and lead to oncogenesis (Hecht, 1999).
Exposure to ultraviolet (UV) radiation has been significantly associated with
an increased risks of skin cancers (Armstrong and Kricker, 2001; Gallagher and
Lee, 2006). Similar to smoking, the mechanism of how UV radiation may cause
skin cancers is related to the DNA repair system. UV radiation causes the forma-
tion of a dimer in the adjacent pyrimidines, resulting in a covalent bond formation
between these nucleotides (Friedberg, 2003; Hoeijmakers, 2001). These dimers
introduce bulky structures in the DNA that prevent the DNA replication and tran-
scription enzymes from functioning properly, and it may cause lasting mutations
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if not repaired (Friedberg, 2003; Hoeijmakers, 2001). The damage caused by UV
radiation can be relieved by the NER system or the photoreactivation process,
where a photoreactivating enzyme uses light to monomerize the dimeric pyrim-
idines (Friedberg, 2003).
Diet and obesity are also known risk factors for many types of cancers (Ames
et al., 1995; Calle and Kaaks, 2004). Epidemiological evidence of obesity being a
risk factor for many cancers has been well established, yet the mechanisms of its
contribution to cancer is still speculative (Calle et al., 2003; Kelesidis et al., 2006).
Although there are a lot of possible mechanisms, there is growing evidence of the
role of chronic inflammation caused by increased fat mass in the body (Kelesidis
et al., 2006; Lumeng and Saltiel, 2011; Rodríguez-Hernández et al., 2013). Free
fatty acids from excess adipose tissue and/or diet can be recognised by Toll-like
receptor (TLR) (specifically TLR4), which can then activate the NF-κB pathway,
leading to the activation of one of the Hallmarks of Cancer (tumour-promoting
inflammation) (Lumeng and Saltiel, 2011).
In addition to the mechanisms described above, there is a growing body of evi-
dence where some environmental factors may affect the transcriptional regulation
of a set of genes in certain cancer type. A relatively recent review by Pérez-
Solis et al. (2016) describes potential mechanisms in which obesity, alcoholism
and smoking (all lifestyle factors related to obesity) may regulate gene expression
in breast cancer cells. By affecting the so-called “Master” transcription factors,
environmental factors are able to affect the expression of the genes that are down-
stream to the Master transcription factor, and as a result, lead to the development
of cancerous cells (Pérez-Solis et al., 2016). It is not surprising that different en-
vironmental factors affect different Master transcriptional factors, and therefore
have different biological mechanisms of gene regulation.
It is also worth noting here that an individual may be exposed to multiple
environmental factors at any given point of time, and perhaps a combination of
multiple environmental factors may have more significant effect on the individual.
There are many other environmental factors associated with cancers that have not
been mentioned here. Nevertheless, it is evident that limiting the exposure to
detrimental environmental factors is crucial for the prevention of many cancers.
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1.2.4 Treatment of cancer
Traditionally, the treatment of cancer has been surgery, radiation therapy and
chemotherapy. Though surgery is an effective method to remove the tumour from
the patient, there is always risk of metastasis and recurrence. This is why a combi-
nation of surgery with other treatments like chemotherapy is usually considered.
Previously, chemotherapeutic drugs and radiation therapy had a limited effect on
tumours due to their resistance against these treatments (Wilhelm et al., 2006).
However, a better understanding of the pathways and mechanisms used by the
tumour cells have shed light on the development of drugs that are more effective
against tumours. RAF inhibitors are among one of the many chemotherapeutic
drugs.
The RAS-RAF-MEK-ERK signalling pathway is involved in cell survival,
growth and proliferation (Samatar and Poulikakos, 2014; Wilhelm et al., 2006).
The components of this pathway are often mutated in many types of cancer (ap-
proximately a third of cancers contain a mutation in the RAS oncogene), caus-
ing an overactivation of this pathway (Samatar and Poulikakos, 2014). Devel-
opment of drugs that target the downstream RAF and its mutant forms (such
as BRAFV 600E) have been successful, and many RAF inhibitor drugs such as
sorafenib and vemurafenib have been approved for clinical use (Samatar and
Poulikakos, 2014; Wilhelm et al., 2006). Even though the signalling pathways
are well understood and the quality of the drugs that are developed based on this
knowledge is improving, there is always the possibility of the tumour to acquire
resistance to those drugs (Samatar and Poulikakos, 2014).
In fact, there has been evidence of pathway cross-talks between the RAS-ERK
pathway and the PI3K/Akt pathway, which may help the tumour cells achieve re-
sistance to the drugs that block the RAS-ERK pathway (Moelling et al., 2002;
Zimmermann and Moelling, 1999). A study in a Drosophila model showed that
the inhibition of just a single pathway does not necessarily stop the effect of the
pathway, as the signal can flow through other pathways (Dar et al., 2012). Path-
way cross-talk and increased flux through alternative pathways could be one of
the ways in which tumour cells acquire resistance to drugs. The effectiveness of
targeting multiple pathways in humans is yet to be confirmed and further inves-
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tigations are required to solidify the mode of action and its relevance to tumour
biology.
Further understanding of the tumour biology, its mechanism of resistance to
drugs, and the effect of targeting multiple pathways (or targeting effective path-
ways for a patient) will become important in the near future, both for novel drug
development and for better clinical treatment plans for the patients.
1.3 Obesity and cancer
As mentioned briefly in Section 1.2.3, obesity is considered a major risk factor
for many types of cancer. The prevalence of obesity is extremely high around the
world and it is important to establish the link between the risks associated with
cancer.
1.3.1 Cancer risks associated with obesity
Although the mechanisms through which obesity causes cancer are still under
debate, the association between obesity and cancer has long been established.
Perhaps the most convincing evidence was first presented by Calle et al. (2003).
In this study, the link between BMI and variety of cancers was investigated in
900,000 adults between 1982 and 1998 (Calle et al., 2003). The results from this
study showed that morbidly obese men and women (BMI > 40) had a 52% and
62% higher chance of dying from all cancers compared to normal weight adults
(18.5 < BMI < 25) (Calle et al., 2003). BMI was also associated with higher
rates of death from esophageal, colorectal, liver, gallbladder, pancreas, kidney,
and some sex-specific cancers (Calle et al., 2003). Furthermore, the death rates
had a positive linear correlation with increasing BMI in all cancers (Calle et al.,
2003).
Renehan et al. (2008) showed in their meta-analysis study that an increase in
BMI by 5 kg/m2 significantly increased the risks of esophageal, thyroid, colon and
renal cancers in men, and endometrial, gallbladder, esophageal and renal cancers
in women. The summary of the risks associated with various cancers from this
study are shown in Table 1. This meant that the association between BMI and
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cancers were sex-specific, applicable to wide range of cancer types, and generally
consistent across different geographic populations (Renehan et al., 2008; Roberts
et al., 2010). It is undeniable that obesity is a major risk factor for many types of
cancer and it may even be the cause for some of these cancers.
Table 1: Summary of the risk ratios1 associated with each cancer type from the meta-analysis
study by Renehan et al. (2008)2.
Men Women
Colon 1.24 (1.20, 1.28) 1.09 (1.05, 1.13)
Rectum 1.09 (1.06, 1.12) NA3
Gallbladder NA 1.59 (1.02, 2.47)
Leukemia 1.08 (1.02, 1.14) 1.17 (1.04, 1.32)
Malignant melanoma 1.17 (1.05, 1.30) NA
Multiple myeloma 1.11 (1.05, 1.18) 1.11 (1.07, 1.15)
Non-Hodgkin lymphoma 1.06 (1.03, 1.09) 1.07 (1.00, 1.14)
Esophageal adenocarcinoma 1.52 (1.33, 1.74) 1.51 (1.31, 1.74)
Pancreatic NA 1.12 (1.02, 1.22)
Renal 1.24 (1.15, 1.34) 1.34 (1.25, 1.43)
Thyroid 1.33 (1.04, 1.70) 1.14 (1.06, 1.23)
Prostate 1.03 (1.00, 1.09) NA
Post-menopausal breast NA 1.12 (1.08, 1.16)
Endometrial (<27 kg/m2) NA 1.221 (1.084, 1.376)
Endometrial (>27 kg/m2) NA 1.729 (1.598, 1.872)
1 All risk ratios are per increase in 5 kg/m2 BMI; 95% confidence intervals in brackets.
2 Table adapted from Roberts et al. (2010), where the original data in the table was from
Renehan et al. (2008).
3 Not available.
1.3.2 Mechanisms of cancer progression in obese patients
The exact mechanisms by which obesity causes cancer has still not been fully elu-
cidated yet. There are several hypotheses that link obesity with cancer: disruption
of various hormone levels, chronic and sustained inflammation, and the activa-
tion of the insulin/insulin-like growth factor (IGF) pathway (Lumeng and Saltiel,
2011; Roberts et al., 2010).
Adipose tissue has long known to have been a group of cells to store excess
fats, but it has recently become apparent that adipose tissue is also a metaboli-
24
cally active endocrine organ (Roberts et al., 2010). Increased adiposity is known
to influence the bioavailability of endogenous sex hormones, including estrogens,
androgens and progesterone (Calle and Kaaks, 2004). Adipocytes synthesise en-
zymes, such as aromatase, that convert precursor molecules into different forms
of androgens and estrogens (Calle and Kaaks, 2004). Many studies have con-
firmed the mitogenic effect of sex hormones on certain cell types, mainly breast
and endometrial cell types (Roberts et al., 2010). In addition to this, there has
also been evidence of serum from obese patients influencing the gene expres-
sion of sex hormone receptor (estrogen receptor β ) in a breast cancer cell line,
suggesting there may be a gene regulatory effect caused by the obese phenotype
(Bowers et al., 2015). Through the effects of dysregulated levels of hormones and
hormone receptors, obesity may have significant impact on the tumour biology
through changes in gene expression level.
On top of the effects that adipocytes have on circulating concentration of sex
hormones as well as gene expression of sex hormone receptors, adipocytes also
produce adipose tissue-specific hormones called adipokines (Roberts et al., 2010).
Of the many adipokines identified so far, leptin and adiponectin have been studied
the most in terms of cancer development (Renehan et al., 2006; Roberts et al.,
2010). Leptin is known to activate not only the satiety signalling pathway, but
also the JAK/STAT and PI3K/Akt signalling pathways (Garofalo and Surmacz,
2006; Renehan et al., 2006). Activation of these pathways leads to the activation
of the target genes that are involved in cell proliferation and cell survival, as well
as pro-angiogenic factors (Garofalo and Surmacz, 2006).
Adiponectin is a hormone that is synthesised and secreted only by adipo-
cytes (Kelesidis et al., 2006). Unlike leptin, where the concentration of leptin
is higher in those who are obese, adiponectin levels are lower in people that are
obese compared to those with a normal weight (Kelesidis et al., 2006; Renehan
et al., 2006). Adiponectin have anti-angiogenic and anti-proliferative effects on
the cells, and is secreted by mature adipocytes but not by the premature pre-
adipocytes (Gilbert and Slingerland, 2013). During chronic inflammatory state
in obese patients, pro-inflammatory proteins such as transforming growth factor-
β (TGFβ ) and interferon-γ (IFNγ) can block the maturation of the pre-adipocytes,
thus decreasing the level of adiponectin and the accompanying beneficial effects
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(Gilbert and Slingerland, 2013).
Alternatively, or possibly in conjunction with the disruption of hormone lev-
els, inflammation caused by obesity may be associated with a tumour-promoting
environment. TLR4 is a type of pattern recognition receptor (PRR) and, as men-
tioned earlier, is able to recognise circulating free fatty acids and trigger immune
response via the NF-κB pathway (Lumeng and Saltiel, 2011). In addition to
NF-κB pathway, recent evidence has shown that TLR4 could also activate the
JAK/STAT3 pathway (Yu et al., 2014). Activation of these pathways will further
enhance the development of the tumour-promoting microenvironment caused by
these unwanted inflammatory responses brought upon by obesity. Furthermore,
since it is likely that people who are obese have less adiponectin concentration,
obesity-induced inflammation may affect the patients that are obese more than
those with a normal weight.
Finally, the insulin/IGF pathway may have a major role in encouraging tumori-
genesis in obese patients. IGF signalling results in the activation of PI3K/Akt and
extracellular signal regulated kinase (ERK) pathways, resulting in cell prolifera-
tion and reduced apoptosis (Roberts et al., 2010). Though insulin is also capable
of activating these pathways, it is thought that the mitogenic effects are controlled
mainly through the IGF receptors (Roberts et al., 2010). Since insulin reduces
the level of insulin-like growth factor binding protein (IGFBP)-3, the main circu-
lating IGFBP, hyperinsulinemia has been hypothesised to promote tumorigenesis
through the mitogenic effect of insulin and by increasing the level of free IGFs
(Giovannucci, 1995; McKeown-Eyssen, 1994; Roberts et al., 2010). In fact, many
studies have consistently associated the increased concentration of free IGF-I with
obesity and increased risk of some cancers; however the results for IGFBP have
been inconsistent (Basen-Engquist and Chang, 2011).
It is evident that there are many possible mechanisms in which obesity con-
tributes to the progression of cancer by activating many of the Hallmarks of Can-
cer mentioned in Section 1.2.2. Furthermore, these mechanisms are related to one
another and are part of a larger, more complex physiological network (Renehan
et al., 2006). Due to this complexity, it is difficult to confidently explain how
obesity contributes to the tumour development, and therefore the biological link
between obesity and cancer is of great interest.
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1.4 Genetic signatures
One of the difficulties associated with the treatment of cancers is the identification
of the underlying biological mechanisms or hallmarks that drive the cancer pro-
gression. As one can imagine, it is difficult for clinicians to treat a patient if they
do not know what is causing the disease. It is difficult to identify the underlying
biological mechanisms because there are very few reliable biological markers (or
“genetic signatures”) that signify the presence or absence of the causal pathways.
With that said, significant improvements have been made in recent years due to
the advancement in the sequencing technologies. This has allowed researchers to
study the genetic signatures that represent the hallmarks in much greater detail.
1.4.1 Microarray and Next Generation Sequencing technologies
Microarray technology
Microarray technology was first developed by Schena et al. (1995) and has been
used extensively to study the gene expression patterns and single nucleotide poly-
morphism (SNP) identification for over two decades. In short, microarray tech-
nology uses a glass slide with hundreds of thousands of short DNA sequences
attached to it, where fluorescently labelled complimentary DNAs (cDNAs) taken
from the sample messenger RNAs (mRNAs) are hybridised to these immobilised
DNA sequences (Schena et al., 1995; Schulze and Downward, 2001). The fluo-
rescent probes are then detected to measure the gene expression (Schena et al.,
1995; Schulze and Downward, 2001).
One disadvantage of the microarray technology is that it requires previous
knowledge of the genes and SNPs of the samples being investigated (Hurd and
Nelson, 2009). This is due to the fact that the detection of sequences relies on the
hybridisation of the sample sequences with the microarray sequences. Therefore,
the sequences under investigation must be known prior to the investigation to at-
tach the correct sequences to the microarray. Another disadvantage of microarrays
is the potentially erroneous detection of the sample sequences, both in terms of
its sequence and its expression level (Hurd and Nelson, 2009). Again, because
the microarray slides require pre-defined sequences to be attached to it, there is
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always a possibility of hybridisation of similar but different sequence to the slide.
Even if the sequences correctly hybridise to the slide, it may be difficult to mea-
sure the exact amount of particular sequences in the samples, since the amount of
sequences in the sample is measured with the relative strength of the fluorescence
of the dyes (Hurd and Nelson, 2009). Therefore, it is difficult to detect the exact
level of expressions of the sequences that are either very rare or highly abundant
in the sample (Hurd and Nelson, 2009).
Next generation sequencing technology
Next generation sequencing (NGS) technology refers to the high throughput se-
quencing techniques that allows the sequencing of a large quantity of genetic ma-
terial (Metzker, 2010). NGS technology has been developed and improved in the
last decade at a revolutionary pace. This has made it possible for researchers to
study gene expressions and variations in days to weeks, where the same experi-
ment would have taken years to complete before the technology was developed.
Every NGS technology uses the same principle process to sequence DNA sam-
ples. First, DNA samples are fragmented into smaller sizes and universal primers
are attached to the ends of the fragments. These fragments are then amplified into
clusters to make the signals stronger for detection (Metzker, 2010). After the am-
plification step, the clusters of DNA fragments are sequenced and “imaged” using
fluorescently labelled DNA bases, where the incorporation of different bases are
detected by its unique fluorescence (Metzker, 2010).
NGS technology has many advantages over microarray technology. Firstly,
NGS does not require any prior knowledge of the sample like in the microarray
technology, as all genetic materials are attached to universal primers when they
are sequenced; there is no need to pre-define the sequences to be searched and
thus allows the detection of novel genes or transcripts (Hurd and Nelson, 2009).
This also prevents the introduction of experimental bias, as the sequences are not
altered in any way and no specific sequence is searched in any greater detail over
another (Hurd and Nelson, 2009). Another advantage is that NGS produces count
data of the genetic material being sequenced instead of relying on the intensity
of the fluorescence to detect the presence and amount of certain sequence. This
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allows an absolute quantification of the amount of transcripts from the sample,
making it possible for a more accurate comparison of the expression levels be-
tween samples. Lastly, many NGS techniques are capable of sequencing multiple
samples simultaneously with high throughput, generating a tremendous amount
of genetic data in a single run.
The use of NGS technology has significantly improved the workflow of mod-
ern genetic studies and its application in a variety of research areas has made it
possible to dig deeper into the causes of complex diseases, such as cancer. With
the cost of sequencing declining, personalised genome sequencing and treatment
based on the sequence will be a reality in the near future.
1.4.2 Obesity-associated genetic signatures
There is clear epidemiological evidence of obesity being a major risk factor for
many cancer types (Section 1.3), but the genes or pathways that directly contribute
to tumorigenesis in patients that are obese are yet to be clarified. Two studies in
particular, one by Creighton et al. (2012) and another by Fuentes-Mattei et al.
(2014), have investigated whether there were any differences in the genetic com-
position between obese and non-obese patients, specifically in a group of breast
cancer patients. In both studies, the authors were able to identify a set of genes
that were up or downregulated in breast tumours from the patients that were obese.
Creighton et al. (2012) study
Creighton et al. (2012) used 103 breast tumour samples and analysed these sam-
ples using microarrays. The tumour samples were trimmed upon collection, to
ensure all of the samples had ≥ 70% tumour cells before RNA was extracted from
the samples. Of the 103 samples, 35% were from normal weight, 28% were from
overweight and 37% were from obese patients. It was also noted that African-
American patients were more likely to be obese than Caucasian patients. They
compared the gene expression between the tumours from obese patients with the
tumours from non-obese patients and identified 799 gene probe sets (662 unique
genes) with p < 0.01 and with a fold change (FC) > 1.2. The majority of these
genes (725 gene probes) were downregulated and 74 gene probes were upreg-
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ulated in the breast tumour samples from the obese patients compared with the
breast tumour samples from the non-obese patients.
One major concern with this study was the quality of the RNA that was col-
lected from the samples. Ensuring that all of the samples had more than 70%
of tumour cells meant that the RNA was likely from the tumour cells. However,
this did not control for the quality of the RNA that was extracted, as some samples
may have had significantly less tumour volume compared to another, but still have
≥ 70% tumour cells in both samples. Another thing to note from this paper was
the predictive ability of their obesity signatures in other data sets. Creighton et al.
(2012) used six independent breast cancer data sets to test whether their signature
was able to replicate their findings. Although they were able to replicate their re-
sults in one of the data sets, they were not able to find any significant association
in the other data sets.
Fuentes-Mattei et al. (2014) study
Fuentes-Mattei et al. (2014) studied 137 breast tumour samples from estrogen re-
ceptor (ER) positive patients and analysed their transcriptome using microarrays.
Of the 137 patients, 43 patients were obese and 94 patients were not obese. Com-
parison of the gene expressions of the tumour samples from the obese patients
with the tumour samples from the non-obese patients revealed 112 genes that
were statistically significantly dysregulated (62 genes upregulated and 50 genes
downregulated). Furthermore, functional transcriptomic analysis suggested that
the insulin signalling and inflammation affected human ER+ breast cancer. One
minor thing to point out in this paper was that the normalisation procedure carried
out before the differential expression analysis was not clear.
On top of the bioinformatic analysis that was carried out, Fuentes-Mattei et al.
(2014) validated their results using a mouse model, where they compared the ex-
pression level in the breast tumours from the obese mice with those from the lean
mice. Results from this animal model provided strong evidence that obesity sig-
nificantly accelerated tumour growth through Akt/mammalian target of rapamycin
(mTOR) signalling pathway.
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1.4.3 Pathway-associated genetic signatures
Like obesity-associated genetic signatures, there has also been a focus on the iden-
tification of pathways and genes that affect tumour growth. In 2006, Bild et al.
demonstrated that a collection of genes that are involved in a specific pathway
could be used to determine the status of those pathways in tumour samples (Bild
et al., 2006). These pathway specific genes were identified experimentally by al-
tering the expression of one specific gene that is central to the pathway in a model
cell culture system. For example, all of the genes that have altered expression in
the cells that had the MYC gene induced were noted as genes involved in the Myc
pathway.
Gatza et al. (2010) study
Building on the work of Bild et al. (2006), Gatza et al. (2010) used 18 pathway
signatures to classify human breast tumours into more detailed subtypes. The
18 pathways used in this study were: Akt, β -catenin (BCAT), E2F1, epidermal
growth factor receptor (EGFR), ER, human epidermal growth factor receptor 2
(HER2), interferon-α (IFNα), IFNγ , Myc, p53, p63, PI3K, progesterone recep-
tor (PR), Ras, STAT3, Src, TGFβ , and tumour necrosis factor-α (TNFα) path-
ways. This was a significant improvement from their previous work on pathway
signatures (Bild et al., 2006, 2009). Using more pathways in their analysis has al-
lowed them to identify certain pathways that are coactivated (or cluster) together,
suggesting that some of the pathways are related to one another and may have
relevance in identifying the biological causes of cancer.
One thing to note here is that most of these pathway-associated genetic signa-
tures are involved in one or more of the Hallmarks of Cancer (Section 1.2.2). This
means that these pathway-associated signatures can be used to provide insight into
the underlying biological mechanisms of the samples used in this project and help
understand the underlying biology of cancers in obese patients.
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1.5 Aims of the project
This research aims to determine whether gene expression signatures exist that are
specific to obesity across multiple cancer types, and to investigate whether there
are any common pathways being dysregulated in cancers based on these genetic
signatures. A better understanding of the pathways being dysregulated in cancer
cells in obese patients may lead to improved clinical decisions, and contribute
towards personalised treatment in the future.
1.6 Thesis outline
In the following chapter, the detailed methods of all the analyses carried out for
this project is outlined. The results from these analyses are split into two parts,
each presented in a separate chapter. The first part of the results clarify the re-
lationship between the obesity-associated genetic signatures with various cancer
types. The second part of the results consist of the links between the pathway-
associated genetic signatures and various cancer types, as well as the previously
identified obesity-associated signatures. Lastly, the results will be summarised




2.1 R – statistical programming language
All statistical analyses and data manipulation were carried out with R (version
3.3.2 – “Sincere Pumpkin Patch”), a free open-source programming language
and software environment for statistical computing and graphics (R Development
Core Team, 2016).
2.2 Cancer data
The raw microarray data from the Creighton et al. (2012), Fuentes-Mattei et al.
(2014) and Gatza et al. (2010) studies were downloaded from the Gene Expression
Omnibus (GEO) website (Edgar et al., 2002; NCBI, 2016). In addition to these
breast cancer data sets, the raw microarray data set from a cohort of NZ breast can-
cer patients used in the Muthukaruppan et al. (2016) study was downloaded from
the GEO website (abbreviated as New Zealand Breast Cancer (NZBC) data here-
after). RNA-seq and clinical data of multiple different cancer types were down-
loaded from the International Cancer Genome Consortium (ICGC) (ICGC, 2016;
Zhang et al., 2011) and The Cancer Genome Atlas (TCGA) (NCI and NHGRI,
2016) websites, respectively.
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2.2.1 Breast cancer data
Creighton et al. (2012) data
The raw Affymetrix HGU133A microarray gene expression data files from the
Creighton et al. (2012) study were downloaded from the GEO database (GEO
accession ID: GSE24185). Clinical data of the samples (age, ethnicity, tumour
grade, menopause status, BMI, ER status, PR status, HER2 status, and lymph
node (LN) status) were obtained from Supplementary Table 1 of the Creighton
et al. (2012) study. 799 obesity-associated gene probes identified in the Creigh-
ton et al. (2012) study were obtained from Supplementary Data File 1 from the
Creighton et al. (2012) study.
Fuentes-Mattei et al. (2014) data
The raw Affymetrix HGU133A microarray gene expression data files from the
Fuentes-Mattei et al. (2014) study were downloaded from the GEO database
(GEO accession ID: GSE20194). Clinical data for the samples (age, ethnicity,
tumour grade, ER/PR/HER2 statuses, and treatments used) in this study was also
downloaded from the GEO database (same GEO accession ID). Patient height,
weight and BMI information were not available in this data set. 130 obesity-
associated gene probes identified by Fuentes-Mattei et al. (2014) were taken from
Supplementary Table 3 of their paper.
New Zealand Breast Cancer (NZBC) data
To provide an insight into the relevance of the obesity-associated genetic signa-
tures in NZ patient cohort, the NZBC data set used by Muthukaruppan et al.
(2016) were used. The raw Affymetrix HGU133A microarray gene expression
data files from the Muthukaruppan et al. (2016) study were downloaded from the
GEO database (GEO accession ID: GSE36771). Clinical data for the samples
(age, ethnicity, tumour grade, breast cancer subtype, ER/PR statuses, LN status,
BMI and treatments used) in this study was obtained from Prof. Cris Print (per-
sonal communication with Assoc. Prof. Mik Black).
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Gatza et al. (2010) data
The raw microarray gene expression data files from the Gatza et al. (2010) study
were downloaded from the GEO database (GEO accession ID: GSE1456, GSE-
1561, GSE2034, GSE3494, GSE4922 and GSE6596). Only the Affymetrix HGU-
133A microarray samples were included in this project, as the other microarray
data from the Creighton et al. (2012), Fuentes-Mattei et al. (2014) and Muthukarup-
pan et al. (2016) studies were analysed using the Affymetrix HGU-133A platform.
Clinical data for the samples in Gatza et al. (2010) study was not available, as
these samples were a combination of many different datasets. The Akt, BCAT,
E2F1, EGFR, ER, HER2, IFNα , IFNγ , Myc, p53, p63, PI3K, PR, Ras, STAT3,
Src, TGFβ , and TNFα pathway-associated genetic signatures were used by Gatza
et al., and the gene probes of all the pathway-associated genetic signatures were
obtained from Supplemental Table 10 of their paper.
Gene probe ID conversion
All of the microarray data used gene probe IDs to refer to the genes, and there-
fore these probe IDs had to be converted into their corresponding gene symbols.
The gene probe IDs in the raw data were converted into their corresponding gene
symbols using the hgu133a.db package in R (Carlson, 2016b). Since multiple
gene probe sets match back to a single gene of interest in a microarray chip, there
were conflicting expression data for some of the genes after the conversion of
the gene probe sets into gene symbols. For the gene symbols that had multiple
probe set entries, a single probe set was chosen to represent the gene symbol by
using the collapseRows function in the WGCNA package in R, using the default
parameters (which chose the probe set with a maximum mean expression value)
(Langfelder and Horvath, 2008). Likewise, any obesity-associated or pathway-
associated gene probes were converted into gene symbols.
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Table 2: Number of samples in each of the breast cancer microarray data
Data set Number of samples before exclusion1 Number of samples
Creighton et al. 103 103
Fuentes-Mattei et al. 278 278
NZBC 107 99
Gatza et al. 1965 1060
1 See Section 2.2.1 for exclusion criteria.
Table 3: Summary of the clinical variables in the Creighton et al., Fuentes-Mattei et al. and NZBC
microarray data
Clinical variable Creighton et al. Fuentes-Mattei et al. NZBC
Age
Min. 30 26 31
Max. 72 79 92
Mean 49 52 59
Median 48 51 60
Ethnicity
Caucasian 77 176 71
African-American 16 29 0
NZ Māori 0 0 10
Pacific Islands 0 0 14
Asian 10 18 4
Other 0 55 0
BMI status
Normal weight 36 NA1 28
Overweight 29 NA 28
Obese 38 NA 43
Menopause status
Premenopause 49 NA NA
Perimenopause 9 NA NA
Postmenopause 45 NA NA
Tumour grade
1 14 13 11
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Table 3 (continued)
2 35 104 39
3 54 150 49
ER status
ER+ 58 164 72
ER− 42 114 27
Unknown 3 0 0
PR status
PR+ 48 121 62
PR− 50 157 37
Unknown 5 0 0
HER2 status
HER2+ 12 59 NA
HER2− 54 219 NA
Unknown 37 0 NA
LN status
LN+ 14 NA 56
LN− 89 NA 40
Unknown 0 NA 3
1 Not available.
2.2.2 ICGC cancer data
RNA-seq and clinical data
The clinical data for all available cancer types (33 types in total) were down-
loaded from TCGA database (last accessed 1 April 2015) and were checked for
both the height and weight data for each sample. Any cancer type with no height
and/or weight data for the samples was excluded from the project, as no BMI in-
formation can be obtained without these data. Out of these 33 cancer types with
clinical data, 14 cancer types had both height and weight data. However, only 8
cancer types out of these 14 types had RNA-seq data available from the ICGC
database (last accessed 7 September 2015), so only those 8 cancer types were
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downloaded and used in this project. The selected cancer types were: bladder
urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endocervi-
cal adenocarcinoma (CESC), colon adenocarcinoma (COAD), kidney renal clear
cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), rectum adenocar-
cinoma (READ), skin cutaneous melanoma (SKCM), uterine corpus endometrial
carcinoma (UCEC).
Data formatting and processing
The raw RNA-seq data from the ICGC database were formatted so that the count
data of all the genes were listed for one sample, then the count data for all the
genes for the next sample, and so on. This data format was highly inconvenient
for later analyses so the data were reformatted into a “gene by sample” matrix
format using the dplyr package in R.
Another problem with the data was the sample ID in the RNA-seq data. Though
similar to the TCGA sample IDs, the ICGC IDs in the RNA-seq data had an ex-
tra identification code in the sample names. To associate each sample in the raw
RNA-seq data from the ICGC database with the correct samples in the clinical data
from the TCGA database, the ICGC IDs were re-coded to match the TCGA IDs.
After the IDs were re-coded, samples were checked to see if there were any du-
plicates in either the ICGC RNA-seq data or the TCGA clinical data. Where there
was a duplicate in the sample ID, a single sample with the highest mean expres-
sion value was chosen to represent that particular ID by using the collapseRows
function in the WGCNA package in R (Langfelder and Horvath, 2008).
Since some of the samples did not have either height or weight data, these
samples were removed from the analyses. In each of the eight cancer types, the
TCGA sample IDs in the clinical data were cross-checked with the sample IDs in
the RNA-seq data, and vice versa. Any samples that did not have either the patient
BMI information or the RNA-seq data were removed from the analyses. This en-
sured that both BMI and RNA-seq data were available for all of the samples that
were included in this project. See Table 4 for a summary of the total number of
samples included in the analyses for each cancer type. Where missing, Equation 1
was used to calculate the BMI of the samples in all of the cancer data with height
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Samples were classified as normal weight (BMI < 25), overweight (25 ≤ BMI
< 30) or obese (BMI ≥ 30) based on the WHO definition (Table 5). Equation 1
and Table 5 were used to calculate and group the patients from the ICGC cancer
data into appropriate BMI classes (Table 6).
2.3 Data processing
2.3.1 Data normalisation
Any experimental procedure is prone to errors due to differences in experimental
conditions, machinery used to measure signals and technical procedures in differ-
ent laboratories, just to name a few. All of the data were normalised to remove
such experimental bias, errors and noise, so only the true biological signals are
considered in the analyses.
Microarray data
In Affymetrix HGU133A microarray experiments, there are two types of probes
present on the microarray chips: perfect match (PM) and mismatch (MM) probes
(Irizarry et al., 2003). As the name suggests, PM probes represent the probes
that should perfectly match the gene of interest, whereas MM probes have there
13th base pair intentionally altered to measure non-specific binding of the gene
(Irizarry et al., 2003). Various normalisation methods make use of PM and MM,
or “probe pairs”, to identify true signals from the noise.
Microarray analysis suite 5.0 (MAS5) and robust multi array (RMA)-normali-
sation methods are both part of the affy package in R (Gautier et al., 2004). MAS5
uses a difference-based method where it subtracts a value derived from MM from
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Table 4: Summary of the total number of samples included in the analyses for each cancer type















Table 6: Summary of the patient BMI status in the ICGC cancer data
Number of samples
Cancer type Normal weight Overweight Obese Total
BLCA 103 97 61 261
CESC 83 64 77 224
COAD 75 81 70 226
KIRP 26 53 45 124
LIHC 139 76 49 264
READ 22 36 15 73
SKCM 71 74 73 218
UCEC 88 108 286 482
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PM, but this approach may introduce additional noise and/or errors in some cases
(Irizarry et al., 2003). The RMA method is based on the observation that PM is a
mixture of background and true signal, and uses mathematical models to estimate
the expression while correcting for background signals from PM only (Irizarry
et al., 2003). In fact, the RMA method showed better identification of the true
signals than the other methods, including MAS5 method (Irizarry et al., 2003).
The raw microarray data were normalised using both RMA and MAS5 meth-
ods, each done separately on a copy of the data. The reason that the MAS5 method
was used as well as the RMA method was because the MAS5-normalisation
method was used in the Gatza et al. (2010) study. Though the normalisation
methods were not specified in the Creighton et al. (2012) and Fuentes-Mattei et al.
(2014) studies, to allow for data comparison between different datasets and accu-
rate result validation of some of the studies, both RMA and MAS5 methods were
considered for normalising the microarray data.
RNA-seq data
RNA-seq data are fundamentally different to microarray data, as RNA-seq data is
a count data of transcript fragments, while microarray data is a continuous data
based on the intensity of the probe pairs. This means that RNA-seq data must be
processed in a different manner to microarray data. However, by analysing RNA-
seq data as a count data, it limits the range of statistical tools and types of analyses
that can be done on the data, as many tools are designed for normally distributed
data like the light intensity measures from the microarray data (Law et al., 2014).
To overcome this limitation, Law et al. (2014) developed a method called
“variance modelling at the observational level”, or “voom”, that allows any RNA-
seq data to be used in “any statistical pipeline for microarray data that is pre-
cision weight aware”. In brief, voom first constructs a standard deviation trend
from the logged counts per million (cpm) value of the genes (experimental de-
sign, treatment conditions and other factors are taken into account). This trend
is then used to interpolate the standard deviation of the observation based on its
predicted count size, and the inverse square of the predicted standard deviation is
used as the weight for that observation. The weights of the observations and the
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logged cpm can then be used in other statistical pipelines that allow the input of
quantitative weights (Law et al., 2014).
The raw RNA-seq data were normalised in two different ways depending on
the analysis. For gene expression analyses (Section 2.4) and pathway enrichment
analyses (Section 2.5), voom normalisation from the limma package in R was
used to normalise the data (Ritchie et al., 2015). For the purposes of data visu-
alisation (Section 2.8) or the application of the metagene transformation matrices
(Section 2.6.1) on the RNA-seq data, the raw data had 1 added (to prevent logging
of 0) and then logged to the base of 10.
2.3.2 Data standardisation
For metagene creation and data visualisation that used heatmaps, the data were
standardised so that each gene in the data had a mean (µ) of 0 and a standard
deviation (σ ) of 1. Since the expression levels of the genes could vary substan-
tially (some may have very low expression, whereas another may have very high
expression), the direct comparison of the raw expression values between different
genes was not feasible. Standardisation of each gene allowed the expression lev-
els to be on the same scale, thus allowing better visualisation with heatmaps and
comparison between different genes was made possible.
2.3.3 Residual data creation
In some analyses, the Creighton et al. data was adjusted for clinical variables to
remove any confounding effects from the variables. For example, a gene from the
raw data might have a strong association with BMI, but it is possible that other
clinical variables such as ER status and/or tumour grades are also associated with
the gene. To prevent such confounding effect, all of the clinical variables except
those that are of interest were adjusted with the use of linear models.
A linear model was created from the Creighton et al. data with age, ethnicity,
menopause status, tumour grade, hormone (ER, PR, and HER2) statuses and LN
status included in the model. In addition to this model, another linear model
was constructed with the Creighton et al. data with only the Caucasian patients
included in the data to completely remove the effect of ethnicity (same clinical
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variables were controlled for, except ethnicity). Once a linear model was fitted to
the Creighton et al. data, the remaining data, or the “residual data”, represented
the data that had been corrected for the effects of the unwanted variables, and
was used in the analyses that required focus on certain variables without the other
variables affecting the result.
2.3.4 Batch correction
It is most likely that experiments are done at different time period, location and
laboratory environment. These differences between experiments introduces sys-
tematic non-biological differences or “batch effects” into the data, making it dif-
ficult to directly compare the data from different batches (Johnson et al., 2007).
The problem with the batch effect is that the normalisation methods do not control
and adjust for the effect (Johnson et al., 2007). Fortunately, Johnson et al. (2007)
developed a method to correct for batch effects in the data, using an empirical
Bayesian framework.
The data used in Gatza et al. (2010) study was a combination of multiple
microarray data from various studies, so the batch effect had to be corrected before
any analysis was carried out. Each microarray dataset was normalised with either
RMA or MAS5 separately then combined together into a single dataset, and the
batch effect was corrected with the ComBat function (an implementation of the
batch correcting method by Johnson et al. (2007)) from the sva package in R
(Leek et al., 2012).
ICGC cancer data were also corrected for batch effect for the pathway enrich-
ment analysis (Section 2.5). Two combined data sets were created with the ICGC
data. The first data set was created by voom normalising each cancer data set
separately, combine all of the normalised cancer data sets into one, then applied
batch correction to the data set (Section 2.3.4). The second data set was created
by first combining the cancer data sets into one, then the combined data was voom
normalised, and then the batch effect was corrected to obtain the final data set.
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2.3.5 Sample randomisation in simulation analysis
In some cases, an analysis was repeated a number of times to provide statistical
evidence that the observed results did not occur by chance. All of the simulated
results must be derived from a randomised data, and by comparing the observed
results with the results that occurred by chance, simulation analysis provides sta-
tistical evidence for the observed results. When a simulation was required, none
of the values in the original data were modified, but instead the values in the origi-
nal data were assigned randomly to different samples; in other words, the samples
were shuffled. This provided a random set of data in which a simulation could be
conducted with. The samples were shuffled with the sample function from the
base package in R, and were reshuffled for each simulation.
2.4 Gene expression analysis
For gene expression analysis, or differential expression analysis, the limma pack-
age in R was used (Ritchie et al., 2015). Since there were thousands of genes to be
hypothesis tested, adjustment for multiple hypothesis testing had to be considered
in order to identify the truly differentially expressed genes (DEGs).
2.4.1 Limma
limma is a package that contains variety of tools to analyse gene expression data
using linear models-based methods, developed by Ritchie et al. (2015). For gene
expression analysis, limma package fits a linear model in a gene-wise manner and
produce test statistics that allow the assessment of whether the gene is differen-
tially expressed or not between certain groups of samples (Ritchie et al., 2015).
In this project, the gene expression analysis was carried out to identify DEGs in
the samples that were obese compared to the samples that were non-obese group.
Before the data was analysed using the limma analysis pipeline, it was nor-
malised as described in Section 2.3.1: Data normalisation. In addition to this,
a design matrix that describes the experimental design (obese versus non-obese)
was created from the clinical data. To create the design matrix, the samples were
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divided into two groups, the obese group and the non-obese group, and the con-
structed group information was used in the model.matrix function (in limma
package) to form the design matrix.
The lmFit function (limma) was used to fit a linear model to the normalised
data, using the experimental design information from the design matrix. The
output of this function was used in the eBayes function (limma) to identify the
DEGs from the data. In the eBayes function, statistical parameters are estimated
from the data and these parameters are used in the empirical Bayes approach to
calculate the summary statistics used for the ranking and identification of DEGs
(Smyth, 2004).
The summary statistics from the eBayes function can be displayed with the
topTable function (limma) and includes the estimate of the fold change of the
gene expression in log2, average gene expression level in log2, moderated t-
statistic, raw p-value of the gene, multiple hypothesis testing adjusted p-value,
and B-statistic. The first value shows the estimate of the log2 fold change of the
gene expression compared with the reference group, so this represents the log2
fold change of the gene expression in the obese samples relative to the non-obese
group. The second value presents the log2 value of the average expression of the
gene across all of the arrays/samples. The moderated t-statistic is the same as
normal t-statistic, but its standard error has been adjusted (or “shrunk”) toward
a common value by a simple Bayesian method (Smyth, 2005). Raw p-value and
adjusted p-value represent the p-value of the gene before and after it has been cor-
rected for multiple hypothesis testing, respectively. Lastly, the value of B-statistic
represents the log-odds that the gene is differentially expressed, where B-statistic
of 0 shows that there is a 50% chance the gene is differentially expressed (Smyth,
2005).
From these summary statistics, the most likely DEGs were chosen from the
list of significant genes by setting the threshold of the p-value to be either less
than 1% or 5%. In the case where there were more than 1000 DEGs, the top 799
probe sets were picked from the list, as this was the number of genes found in
the Creighton et al. (2012) study; otherwise, as many significant genes identified
were taken from the list.
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2.4.2 Multiple hypothesis testing correction
In an experiment where there are multiple hypotheses being tested, the rate or
proportion of Type I error appearing from the experiment must be controlled. The
probability of Type I error occurring for a single hypothesis is usually controlled
at some significance threshold α , which is usually set at 0.05 (Shaffer, 1995). In a
typical microarray experiment, there are over 20,000 gene probes to be tested for
differential expression, and with a significance threshold of α = 0.05, this would
yield approximately 1,000 Type I errors. In other words, 1,000 gene probes would
be identified as differentially expressed, when in fact they are not.
There are two broad classes of methods to correct for this problem: family-
wise error rate (FWER) control and false discovery rate (FDR) control. With
FWER control, the method primarily aims to set the α-value for each hypothesis
testing (αi) such that the sum of all the αi is equal to α (Hochberg and Tamhane,
1987; Shaffer, 1995). Usually, αi is set to αn , where n is the number of hypoth-
esis tests carried out in the experiment (Shaffer, 1995). This highly conservative
approach significantly improves the certainty of the result from the experiment,
but at the same time it significantly increases the likelihood of missing the truly
DEGs, or Type II errors.
In contrast to the conservative FWER control methods, the FDR method de-
veloped by Benjamini and Hochberg (1995) control the Type I errors while main-
taining statistical power. The FDR method controls the “expected proportion of
errors among the rejected hypotheses” by adjusting the α-level (denoted as q∗
in FDR) depending on the rank of the p-value (Benjamini and Hochberg, 1995).
With FDR, the p-values are ordered and ranked from the lowest to the highest p-






where P(i) is the p-value of the ordered and ranked ith hypothesis, m is the total
number of hypotheses, and q∗ is the threshold value (Benjamini and Hochberg,
1995). From Equation 2, the adjusted p-value from FDR control is the product of
the p-value with the number of hypotheses, divided by its rank. Since FDR method
controls Type I error in a less conservative manner than the FWER methods, the
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FDR method was used to identify the DEGs for gene expression analyses.
2.5 Pathway enrichment analysis
Identification of DEGs provides a list of genes that may have a role in a particular
experimental setting. With that said, it is often difficult for the investigators to
provide a plausible biological explanation with just a long list of DEGs, as the
list lacks the link between the genes and the biological cause (Khatri et al., 2012).
Therefore, given a list of DEGs, it is important for any researcher to undertake
pathway enrichment analysis in order to obtain useful insights into the underlying
biological mechanisms the DEGs may be involved in. Both over representation
analysis (ORA) and functional class scoring (FCS) can be used to identify whether
certain pathways are enriched, given a list of DEGs.
2.5.1 Over representation analysis (ORA)
The common approach taken by ORA is to count the DEGs that are part of a
biological pathway and perform a statistical test to decide whether the pathway
is over- or under-represented in the list of genes (Khatri et al., 2012). Statistical
test used in ORA includes χ2-test, hypergeometric test, and binomial test (Khatri
et al., 2012).
There are several limitations to the ORA approach. Firstly, the statistical tests
are independent of the measured changes and therefore ignores the values asso-
ciated with the genes, such as intensities and significance of the change (Khatri
et al., 2012). Secondly, only the most significant genes are selected for the input
list of genes, which means that the almost significant genes are discarded from
the analysis and results in a loss of information (Khatri et al., 2012). Lastly, by
treating each gene individually, the analysis ignores the biological interaction and
complexity of the genes with the other genes, as well as between pathways (Khatri
et al., 2012).
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2.5.2 Functional class scoring (FCS)
In general, the FCS methods measure gene-level statistics from the given data,
then aggregate these statistics into pathway-level statistics, which is then used to
calculate the statistical significance of the pathway (Khatri et al., 2012). There are
two major classes of methods when calculating the statistical significance: self-
contained or competitive tests (Goeman and Bühlmann, 2007). Self-contained
tests are more appropriate in assessing whether a biological process is significantly
involved in an experiment, whereas the competitive tests are better for selecting
the most relevant biological processes from those that are not (Wu and Smyth,
2012).
The main difference between the two classes is the definition of the null hy-
pothesis. Letting G be the gene set of interest and Gc its compliment, then in the
self-contained tests, the null hypothesis is formulated as follows:
Hself0 : No genes in G are differentially expressed.
whereas in the competitive tests, the null hypothesis is defined as:
Hcomp0 : The genes in G are at most as often differentially expressed as
the genes in Gc.
These hypotheses show that the self-contained tests care only about the genes
defined in the gene set, but the competitive tests examine the genes in the defined
set as well as the genes not present in the set (Wu and Smyth, 2012). Due to the
fact that self-contained tests do not take into account the genes not defined in the
gene set, self-contained tests are more restrictive compared to competitive tests.
The restrictive property of the self-contained tests give it greater power, as they
are able to reject the null hypothesis at a higher accuracy for more gene sets than
the competitive tests (Goeman and Bühlmann, 2007). However, as Goeman and
Bühlmann (2007) stated in their paper, “the competitive types of test can be said to
voluntarily relinquish some power in order to make a stronger statement”. In fact,
the Gene Set Enrichment Analysis (GSEA) method (developed by Subramanian
et al. (2005)), one of the first and perhaps the most popular FCS methods, uses
the competitive test approach.
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The FCS approach addresses some of the limitations presented by the ORA
methods. By calculating the statistical significance per pathway, the FCS ap-
proach takes into account of all of the genes involved in the pathways, and not
just the genes that are differentially expressed. Furthermore, the FCS approach
also detects small but consistent and coordinated changes in the expression of the
genes, unlike in the ORA where molecular measurements are completely ignored
(Khatri et al., 2012).
Though the FCS approach improves on the ORA approach, there are still some
limitations. Since the analyses that use FCS compare the pathways independently
of one another, they ignores the interactive nature of biological pathways. Another
limitation is that the FCS methods use the molecular measurements to rank the
genes, but they do not consider these changes in further analysis (Khatri et al.,
2012). For example, if one gene was expressed with a 2-fold change, whereas
another gene was expressed with a 20-fold change, the FCS method will rank
these genes accordingly (first, second, and so on) and disregard the fact that the
second gene is much more highly expressed (Khatri et al., 2012). Although both
approaches have their own limitations, it is clear that FCS approach have more
advantages over ORA methods.
2.5.3 Correlation adjusted mean rank gene set test (CAMERA)
Correlation adjusted mean rank gene set test (CAMERA) is a competitive FCS-
based method developed by Wu and Smyth (2012), implemented as the camera
function in the limma package (Ritchie et al., 2015). Briefly, CAMERA fits a lin-
ear model in a gene-wise manner and calculates the gene-wise test statistics using
the logFC between the conditions (for example, obese and non-obese samples).
These gene-wise test statistics are used in the Wilcoxon-Mann-Whitney (WMW)
rank sum test to question whether a pathway is significantly enriched in the data
(Wu and Smyth, 2012).
One problem with the other FCS-based methods is that these methods do not
consider the inter-gene correlation of the gene set being tested (Wu and Smyth,
2012). Since other methods assume that all the genes are equivalent under the
null hypothesis, inter-gene correlation of the genes in a gene set will violate this
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assumption (Wu and Smyth, 2012). As a consequence, the Type I error rate is
increased in these methods. However, CAMERA accounts for this correlation by
estimating the variance inflation factor (VIF) from the gene-wise correlation and
the number of genes in the gene set (Wu and Smyth, 2012).
CAMERA was used in this project to identify the pathways that were enriched
in the samples from obese patients compared with the samples from non-obese
patients, as CAMERA provided a competitive FCS-based method.
2.5.4 Pathway databases
Gene Ontology (GO) database
Ontology is defined as a set of concepts and categories in a subject area or domain
that shows their properties and the relations between them. Gene Ontology (GO),
as the name suggests, is an ontology of the genes and biological pathways, cu-
rated and maintained by the GO Consortium (Gene Ontology Consortium, 2000,
2004). The goal of the GO Consortium is to “produce a structured, precisely
defined, common, controlled vocabulary for describing the roles of genes and
gene products in any organism” (Gene Ontology Consortium, 2000). The GO
database includes not only the human genetic information, but collates variety of
information from eukaryotic cells, including Arabidopsis thaliana and Drosophila
melanogaster (Gene Ontology Consortium, 2000, 2004).
GO provides three distinct ontologies to describe the role of a gene or its gene
product in the cell: biological process, molecular function, and cellular compo-
nent (Gene Ontology Consortium, 2000). Biological process categorises the genes
or its gene products into their overarching biological purpose or goal in the cell;
for example, “cell death” and “cell growth and maintenance”. Molecular function
describes the biochemical activity a gene or protein has, ignoring when or where
the activity takes place. The definition of “biochemical activity” is very broad as
it includes specific binding to ligands and structure. Examples of terms used in
molecular function are “kinase activity”, “transporter” and “ligands”. Lastly, cel-
lular components refers to the location in which the gene product is active, such
as “Golgi apparatus” and “nuclear membrane”.
The GO.db package was used to load the GO database into R (Carlson, 2016a).
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Only the human related GO terms were used in pathway enrichment analysis, and
these terms were organised into a format so that the pathways were able to be
queried using the gene symbol.
Kyoto Encyclopedia of Genes and Genomes (KEGG) database
KEGG is a genomic database constructed by Kanehisa and Goto (2000) that store
information about genes, pathways and ligands for a variety of species. The
KEGG database also curates other information such as the approved drugs in
US and Japan and genes related to diseases, making it a great tool for exploring
the biological significance of genes and pathways (Kanehisa et al., 2008). The
KEGG.db package was used to load the KEGG database into R (Carlson, 2016c).
Only the human related KEGG terms were used in pathway enrichment analysis,
and these terms were organised into a format so that the pathways were able to be
queried using the gene symbol.
Reactome database
The Reactome database is a “curated, peer-reviewed resource of human biological
processes” (Joshi-Tope et al., 2005). The Reactome database is constructed based
on the reactions that have direct evidence from the literature, which are connected
into higher order pathway structures (Joshi-Tope et al., 2005). The reactome.db
package was used to load the Reactome database into R (Lightenberg, 2016). Only
the human related Reactome terms were used in pathway enrichment analysis,
and these terms were organised into a format so that the pathways were able to be
queried using the gene symbol.
2.6 Metagene analysis
2.6.1 Singular value decomposition (SVD)
In order to determine whether a set of genes is up or down regulated by a sample,
some sort of score based on these genes must be calculated. SVD is a mathe-
matical method that splits a data matrix into several smaller matrices (Golub and
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Reinsch, 1970). These matrices, when multiplied together, are able to recreate
the original data matrix. With SVD, a matrix X of size n genes by m arrays (or
samples) can be represented as:
X =UDV T (3)
where the columns of U and V contain the left and right singular vectors of X
respectively, and D contains the singular values of X .
The term that is of the greatest importance is V , as this matrix contains the
principal components of the original data matrix X . Previous studies have used
the principal components to summarise the expression of the set of genes for each
sample in the experiment (Alter et al., 2000; West et al., 2001). This allows direct
comparison of the expressions of multiple different genes in different arrays or
experiments (Alter et al., 2000). Furthermore, this summary gene, or “metagene”,
can be used to sort the samples and provide a meaningful grouping of the data
which may help understand the underlying biology (Alter et al., 2000).
With respect to this project, SVD was used to assess whether the metagenes
created from various obesity or pathway-associated genes were significantly as-
sociated with certain clinical variables, such as BMI. To do this, the normalised
original expression data was reduced in size so that it only included the genes of
interest (either obesity or pathway-associated) and the samples, then svd function
from the base package in R was used to apply SVD to the matrix. The first princi-
pal component was taken from the V matrix and was used as the metagene scores
for each samples in the data set.
Another important property of SVD is that the signal used to create the meta-
gene in the first data set can be directly applied to other data sets to obtain the
metagene scores for the samples in those data set. Rearrangement of Equation 3
for V T gives the following equation:
V T =UT D−1X (4)
where UT D−1 will be referred to as the “transformation matrix” hereafter. Clearly,
by substituting the data matrix X with another data matrix, the transformation
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matrix allows for the generation of the metagene for that data set. The reason
why the transformation matrix is used instead of independently applying SVD to
the other data set is because the genetic signature, and therefore the metagene,
from a single data set is dependent on the signal within its data set. Therefore, the
metagenes created independently from different data sets using SVD do not have
the same weighting as the metagene from the original data set, and consequently
does not provide a fair comparison of the metagenes across different data sets. For
this reason, the transformation matrix for a given set of genes was created in the
data set in which the genes were first identified in, and then transformed into other
data sets to obtain the metagenes.
2.6.2 Ranking of the metagene scores
Two different approaches were taken in order to rank the metagene scores of the
samples. The first approach was to rank the metagene scores with the rank func-
tion from the base package in R, then divided the ranked scores with the total
number of samples in the data set to obtain a ranked metagene scores between
0 and 1 (known as fractional ranking). In most analyses, fractional ranking was
used to assess the association of the metagene with the sample gene expressions
and clinical variables.
An alternative approach called probit transformation was used by Gatza et al.
(2010). In this transformation, the sample metagene scores were transformed with
the probit function. To do this, the sample metagene scores were scaled and cen-
tered using the scale function from the base package in R, then the pnorm func-
tion from the stats package was used to transform the metagene scores so that the
scores were between 0 and 1. Unless stated otherwise, all of the metagenes in this
project were fractionally ranked.
2.6.3 Metagene direction
One thing to consider when analysing data with metagenes is the direction of
the metagene. When SVD creates the metagene from a given data set, it does
not consider the direction of the signal, but only the magnitude of the signal in
the data. Therefore, the metagene created by SVD can be either positively or
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negatively correlated to the phenotype that the set of genes reflect. For example, a
metagene created from a set of genes that are associated with the ER pathway may
have higher metagene scores in the samples with low expression of the ER gene,
and low metagene scores in the samples with high expression of the ER gene
(Figure 2, left heatmap). In this case, the direction of the generated metagene
must be corrected in order to reflect the phenotype with the metagene scores (low
metagene score with low gene expression and high metagene score with high gene
expression; Figure 2, right heatmap).
ESR1
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Figure 2: Heatmaps showing the direction of the uncorrected (left) and corrected (right) ER path-
way metagene with the gene expression of the ER pathway genetic signature in the
RMA-normalised Gatza et al. data. Level of gene expression is represented in the top
right histogram, where low and high gene expression are colour-coded with blue and
red, respectively. Each row of the heatmap represents a gene from the ER genetic sig-
nature, and each column of the heatmap represents a sample from the Gatza et al. data.
The ESR1 gene expressions of the samples are shown as a separate row at the top of the
heatmap with the sample ER metagene scores shown below the ESR1 gene expression,
and the tree diagram of the hierarchical clustering of the genes is shown on the left of
the heatmap.
In this project, two types of metagenes were created: obesity-associated and
pathway-associated metagenes. For obesity-associated metagenes, the direction
of each metagene was checked with the patient obesity status and BMI value from
the data in which the metagene was derived from. When the data set did not have
BMI or BMI status information for the patients (for example the Gatza et al. data
set), a set of genes that were common in all obesity-associated genetic signatures
were taken and the expression of these common genes were compared with the
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metagene scores. The genes that are common to all of the obesity-associated
genetic signatures will be related to the metagenes produced by these signatures,
and therefore the expression patterns of these genes should be in line with the
metagene scores.
Checking the direction of the pathway metagenes from Gatza et al. (2010)
study is not as simple as the obesity-associated metagenes, as the gene lists for
each pathway were derived from a separate study and per-gene directionality in-
formation was not provided. Due to this, it was not possible to validate whether
the generated pathway metagene was in the “correct” direction. As an alternative,
the pathway metagenes were visually compared with the gene that represent the
pathway using a heatmap, as the expression of this gene would likely be affected
the most by the pathway signature. For example, the ER pathway metagene was
compared with the ESR1 gene expression, and if the metagene was not in the
same direction as the ESR1 gene expression, the direction of the metagene was
corrected (Figure 2). Table 7 summarises the genes used to check the direction of
each of the pathway metagenes.
In addition to this, the correlation value of the pathway metagene with its
respective gene was checked to further aid the decision on whether the metagene is
going in the correct direction. This was due to the fact that some of the metagenes
were visually difficult to determine whether it was in the right direction or not.
Therefore, the direction as well as the magnitude of the correlation value was also
taken into account in making the decision of whether to change the direction of the
metagene. Lastly, the clustering of the pathway metagenes with the other pathway
metagenes were also considered. It was known from the Gatza et al. (2010) study
that some pathways clustered and grouped together with certain pathways, so the
direction of some of the metagenes were altered in order to keep the grouping of
the pathways matched to the results in their paper (Appendix B4).
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Table 7: 18 pathways from Gatza et al. (2010) and its respective genes used to check the direction
of the pathway metagene
Pathway Representative gene Brief pathway description
Akt AKT1 Also known as protein kinase B; involved in cell
survival
BCAT CTNNB1 β -catenin; involved in the Wnt signalling path-
way and cell-cell adhesion
E2F1 E2F1 Member of the E2F transcription factor family
in higher eukaryotes; involved in cell cycle reg-
ulation
EGFR EGFR Also known as ERBB1 or HER1; involved in
signalling the pathways for cell proliferation
ER ESR1 Involved in cell cycle regulation, cell prolifera-
tion and cell survival
HER2 ERBB2 Also known as ERBB2; involved in cell prolif-
eration and apoptosis
IFNα IFNA1 Cytokine involved in innate immune response
against viral infection
IFNγ IFNG Cytokine critical for innate and adaptive im-
mune response
Myc MYC Transcription factor involved in cell prolifera-
tion, cell growth and apoptosis
p53 TP53 Tumour suppressor protein involved in DNA re-
pair, cell cycle regulation and apoptosis
p63 TP63 Involved in development
PI3K PIK3CA Involved in cell growth, cell proliferation, cell
differentiation and cell survival
PR PGR Signal transducer that activates other signalling
pathways; involved in cell proliferation
Ras HRAS Involved in cell proliferation, cell differentia-
tion, cell adhesion, apoptosis and cell migration
STAT3 STAT3 Involved in cell growth and apoptosis
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Table 7 (continued)
Src SRC Involved in cell survival, angiogenesis, cell pro-
liferation and cell invasion
TGFβ TGFB1 Involved in cell proliferation, cell differentia-
tion and apoptosis
TNFα TNF Involved in immune response, inflammation
and apoptosis
2.7 Obesity metagene prediction with pathway meta-
genes
To determine whether the obesity metagene was associated with any of the path-
way metagenes, a linear model was constructed with some clinical variables and
pathway metagenes, which was then used to predict the obesity metagene. This
was based on the idea that, if a clinical variable or a pathway metagene was a
significant part of the model for the obesity metagene, then that clinical variable
or pathway metagene may be associated with the obesity metagene. Furthermore,
the model that was created based on the significant variables can be used to predict
the obesity metagene, which can be used to compare the values with the original
obesity metagene. If the predicted metagene was similar to the original metagene,
then it provides an evidence that the variables used to construct the model was
associated with the obesity metagene.
Since the NZBC data was the only data set (other than the Creighton et al. data
set) that had the patient BMI information, all of the linear models were constructed
in the NZBC data set. Eleven linear models were created in the NZBC to predict
the obesity-associated metagene from the Creighton et al. (2012) study. The first
seven models created were combinations of the sample BMI, BMI status and a
selection of pathway-associated metagene scores. The selected pathways used
in the linear model construction were BCAT, ER, IFNα , IFNγ , Myc and PR. In
deciding on the pathways to be used for the construction of the linear model,
the correlation of the SVD- and transformation matrix-derived pathway metagene
scores in different data sets were examined.
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When a transformation matrix is applied to the data set in which it was derived
from, the resulting metagene is identical to the one created from the direct appli-
cation of SVD. Therefore, if the metagene derived from a transformation matrix
is similar to the metagene created from SVD, then it shows that the genetic sig-
nature is consistent and reliable across different data sets. The above mentioned
pathways had high correlation value between the SVD-derived and transformation
matrix-derived pathway metagenes, and so it was used in the construction of the
linear model.
The last four linear models were constructed with the different combinations
of the sample BMI, BMI status and the PR pathway metagene. The reason that
the PR pathway metagene was used separately was because in the initial analysis,
the PR pathway metagene was the only pathway-associated genetic signature that
came up as significant in the other linear models (Section 4.3). All of the created
linear models are summarised in Table 8.





BMI and BMI status
BMI and selected pathways1
BMI status and selected pathways1
BMI, BMI status and selected pathways1
PR pathway only
PR pathway and BMI
PR pathway and BMI status
PR pathway, BMI and BMI status
1 BCAT, ER, IFNα , IFNγ , Myc and PR pathway
metagene scores were used.
In addition to these eleven linear models, a linear model was created with
the sample BMI, BMI status and all of the pathway-associated metagenes (Akt,
BCAT, E2F1, EGFR, ER, HER2, IFNα , IFNγ , Myc, p53, p63, PI3K, PR, Ras,
STAT3, Src, TGFβ and TNFα) using a stepwise approach. The stepwise approach
allows the construction of a linear model that best fits the data, given a set of
58
variables. There are three approaches in creating a linear model in a stepwise
method: forward, backward, and both.
In a backward (also known as “top-down”) approach, all of the variables are
first included in the linear model. At each step, a variable is removed from the
model and the Bayesian Information Criterion (BIC) of the model is compared
with the original model to determine whether the variable should remain in the
model or not. This will result in a model with the variables that are jointly most
predictive. In a forward, or “bottom-up”, approach, the model begins with no
variable and adds one variable at a time to the model. If the variable increased the
ability of the model to predict the response variable, then the variable is included
in the model. Again, this will result in a model with only the variables that are
contributing to predicting the response variable. Alternatively, both methods in
combination can be used, where the model begins with all or none of the variables,
and at each step a variable can be added to or removed from the linear model.
In this project, the combination of forward and backward approaches (beginning
with no variables in the model) was used to create the stepwise linear model.
The obesity metagenes that were predicted from the linear models in the NZBC
data set were compared with the original obesity metagene scores. Where appro-
priate, p-values, analysis of variance (ANOVA) p-values and R2-values were cal-
culated to assess the relationship between the predicted and the original metagene
scores. Scatter plots and box plots were also created to visually compare the two
metagene scores (Section 2.8.1).
2.8 Plot creation
2.8.1 Bar, box and scatter plots
Bar plots were plotted to visualise the correlation between the SVD- and trans-
formation matrix-derived obesity and pathway metagene scores in different data
sets. The barplot function from the graphics package in R was used to plot the
bar plots. Box plots and scatter plots were used to visualise the association of a
metagene with some of the clinical variables of the data. Box plots and scatter
plots were plotted using the boxplot and plot functions, respectively, from the
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graphics package in R. The p-value and ANOVA p-value in the box plots were
calculated using the t.test and aov functions from the stats package in R, re-
spectively. The line of best fit and the R2-value of the line were taken from the
summary statistics produced by the lm function from the stats package in R.
2.8.2 Heatmaps
To visualise the association of the sample metagene scores with the sample gene
expression, heatmaps were used. Heatmap is an effective method to visualise
such data, as the ordering of the genes and/or samples may be controlled based
on certain values, for example metagene scores. Furthermore, heatmaps are able
to cluster the samples and/or genes based on the “distance” between the data,
or in other words, how closely related the data are. Heatmaps were created us-
ing the heatmap.2 function from the gplots package in R (Warnes et al., 2016).
For the heatmaps that required two bars above the heatmap (like those that in-
vestigate the directionality of the pathway metagenes), the heatmaps were cre-
ated with the heatmap.2x function developed by Tom Kelly (https://github.com/
TomKellyGenetics/heatmap.2x).
2.8.3 Venn diagrams
To summarise the number of DEGs from the gene expression analyses of the
Creighton et al. data that overlapped with the original Creighton et al. obesity-
associated genetic signature, Venn diagrams were used. Venn diagrams were
plotted using the venn function from the gplots package in R (Warnes et al.,
2016). The overLapper function (from http://faculty.ucr.edu/~tgirke/Documents/
R_BioCond/My_R_Scripts/overLapper.R) was also used to help plot the Venn di-
agram (Girke, 2016).
2.8.4 Additional colours
Some colour palettes such as the colours used by MATLAB are not installed in
R by default. In the Gatza et al. (2010) study, Gatza et al. used MATLAB to
generate all of their plots in their paper. Since a visual comparison had to be made
with one of the plots from the Gatza et al. (2010) study, some of the heatmaps in
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this project required MATLAB-like colours for a more accurate comparison with
their results. For a colour palette used in MATLAB, the matlab.like function
from the colorRamps package in R was used (Keitt, 2012). For the pastel colour
palette used in the bar plots, the brewer.pal function from the RColorBrewer
package in R was used (Neuwirth, 2014).
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Chapter 3
Obesity-associated genetic signatures and
cancer
The obesity-associated genetic signatures are central to this project, as a means
to clarify the relationship between BMI and tumour biology. In this chapter, the
previously identified obesity-associated genetic signatures from the studies con-
ducted by Creighton et al. (2012) and Fuentes-Mattei et al. (2014) are examined
in turn to judge the agreement of these signatures with the patient BMI and BMI
status, as presented in their results. After this, novel obesity-associated genetic
signatures were identified in the Creighton et al. (CR) data set and was compared
with the obesity-associated genetic signatures from the Creighton et al. (2012) and
the Fuentes-Mattei et al. (2014) studies. Lastly, the presence of common genes or
pathways associated with obesity in multiple types of cancer is explored using the
data sets from ICGC (ICGC, 2016; Zhang et al., 2011).
3.1 Obesity-associated genetic signature from the
Creighton et al. (2012) study
An obesity metagene was created using the obesity-associated genetic signature
from the Creighton et al. (2012) study. There was no description about the normal-
isation method used by Creighton et al. when they first analysed their data, so the
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Creighton metagene





Figure 3: Heatmap showing the obesity metagene from the Creighton et al. (2012) study with
the sample gene expressions of the obesity-associated genes in the CR data. Level of
expression is represented in the top left histogram, where low and high gene expression
are colour-coded with blue and red, respectively. Each row of the heatmap represents
a gene from the obesity-associated genetic signature, and each column of the heatmap
represents a sample from the CR data. The obesity-associated metagene scores of the
samples are shown as a separate row at top of the heatmap, and the tree diagram of the
hierarchical clustering of the genes is shown on the left of the heatmap. For clarity,
the sign of the metagene scores were reversed in order to match the results from the
Creighton et al. (2012) study.
more popular RMA method was used to normalise the CR data set (Irizarry et al.,
2003). The obesity metagene was created in the standardised RMA normalised
CR data set, and was plotted above a heatmap with the sample gene expression
to check whether the metagene scores were in accordance with the overall gene
expression of the samples (Figure 3).
As shown in Figure 3, a high obesity-associated metagene score reflects low
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Creighton metagene vs. BMI











Figure 4: Box plot and scatter plot showing the association of the obesity metagene from the
Creighton et al. (2012) study with the sample BMI status and BMI, respectively, from
the CR data. In the box plot, the p-values above the groups represent the statistical sig-
nificance of the association of the obesity metagene with the overweight or obese group
compared with the normal weight group. The ANOVA p-value shows the statistical sig-
nificance of the association of the obesity metagene with the sample BMI groups. In
the scatter plot, R2- and p-values describe the adjusted coefficient of determination of
the regression line and the statistical significance of the linear model used to draw the
regression line, respectively.
associated metagene score reflects high expression in the majority of the genes
in the signature. This was consistent with the reported property of the obesity-
associated genetic signature by Creighton et al. (2012) (see Section 1.4.2). To
provide further evidence that the obesity metagenes were in fact associated with
both the BMI status and the BMI value of the patients, a box plot and a scatter
plot were created, respectively (Figure 4).
Figure 4 clearly showed that the obesity metagene from the Creighton et al.
(2012) study significantly associated with the obese group of patients, as well as
patient BMI value. It should be noted here that the obesity metagene significantly
associated with the samples from the patients that were obese, but not with the
sample from the patients that were overweight. This was due to the fact that the
obesity-associated genetic signature was originally identified from the comparison
of the patients that were obese with the patients that were not obese, and there-
fore the obesity metagene scores were significant with the obese group, but not
with the overweight group. Another thing to note here was that even though the
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regression line in the scatter plot showed statistically significant association with
the patient BMI, patient BMI values seem to be randomly dispersed across the
obesity metagene scores. This suggests that perhaps the obesity metagene from
the Creighton et al. (2012) study may not be associated with the patient BMI as
strongly as reported.
Now that the association of the obesity metagene from the Creighton et al. (2012)
study was established in the CR data set, the Creighton et al. obesity metagene
was generated in the ICGC cancer data. The direction of the obesity metagene was
checked in the CR data first, so that high metagene scores reflected high patient
BMI and low metagene scores reflected low patient BMI (Figure 4). The transfor-
mation matrix was then created in the RMA normalised CR data, as described in
Section 2.6.1.
All of the ICGC RNA-seq data were normalised as described in Section 2.3.1.
Before the transformation matrix was applied to the log10-normalised cancer data,
the obesity metagene was created from the standardised data or untouched (non-
standardised) ICGC data and compared with one another to determine which data
format was better for the application of the transformation matrix (Appendix A2).
From these results, the standardised data was found to be the most suitable format
for the application of the transformation matrix. The transformation matrix was
applied to each cancer data set in turn to generate an obesity metagene from each
of the data sets. Each obesity metagene was plotted in a heatmap with the cor-
responding ICGC data set from which the obesity metagene was generated from
(Figure 5; Appendix A7). These heatmaps confirmed that the obesity metagene
was able to capture the overall gene expression pattern in all of the ICGC cancer
data, where the metagene scores reflected the expression levels of the majority of
the genes in the signature. As before, association of the obesity metagene with the
patient BMI and BMI status was examined in their respective cancer data set (Fig-
ure 5; Appendix A7). Out of all the cancer types, only the BLCA data set showed
a significant association with the obesity metagene, and only for the overweight
group (not the obese group).
There could be several reasons for the apparent lack of association of the obe-
sity metagene with patient BMI in most of the ICGC data. First, the transforma-
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Creighton metagene (BLCA)
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Creighton metagene (BLCA) vs. BMI











Figure 5: Heatmap, scatter plot and box plot showing the association of the obesity metagene from
the Creighton et al. (2012) study with the sample gene expression, patient BMI and BMI
status, respectively, from the ICGC BLCA data. The results for the other ICGC cancer
types are shown in Appendix A7. Scales, p-values and R2-value are as described in
previous figures.
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tion matrix was derived from the CR microarray data, but the ICGC cancer data
were generated via RNA-seq. Though the log10-normalisation and standardisa-
tion of the data were the most appropriate adjustments to be made to the RNA-seq
data, these adjustments were not equivalent to the RMA-normalisation method
that was used on the microarray data. Secondly, none of the ICGC cancer data in
this project originated from breast tumours as in the CR data. Since the obesity-
associated genetic signature was identified in the breast cancer data, the signature
may be specific to breast cancer and may not be generalisable to other cancer
types.
To check whether the signature was specific to breast cancer microarray data,
the same transformation matrix used in the ICGC data was applied to the breast
cancer microarray data from the Muthukaruppan et al. (2016) study (referred to
as NZBC data hereafter). NZBC data was normalised with the RMA method
and the transformation matrix was applied to the normalised data to obtain the
Creighton et al. obesity metagene in the NZBC data set. The generated obesity
metagene was again compared with the gene expression of the samples with a
heatmap and the association of the metagene with the patient BMI and BMI status
was examined with box and scatter plots, respectively (Figure 6).
The Creighton et al. obesity metagene managed to reflect the overall gene
expression of the samples in the NZBC data (Figure 6). However, as with the
ICGC cancer data, the obesity metagene scores did not significantly associate
with patient BMI or BMI status (Figure 6). These results confirmed that the lack
of association of the obesity-associated genetic signature from the Creighton et al.
study was not due to the technology in which the data was gathered (microarray or
RNA-seq), nor the cancer type in which the genetic signature was derived from.
Taken together, these results suggest that the obesity-associated genetic signa-
ture identified in the study conducted by Creighton et al. (2012) correlated with
patient BMI and BMI status only in the CR data set. The lack of association
with patient BMI in other cancer data sets was not due to the type of technology
platform in which the data was gathered, as neither the ICGC RNA-seq data nor
the NZBC microarray data showed significant association of the obesity metagene
with the patient BMI. Furthermore, the obesity-associated genetic signature was
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Creighton metagene in NZBC data
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Creighton metagene in NZBC data vs. BMI











Figure 6: Heatmap, scatter plot and box plot showing the association of the obesity metagene from
the Creighton et al. (2012) study with the sample gene expression, patient BMI and BMI
status, respectively, from the NZBC data. Scales, p-values and R2-value are as described
in previous figures.
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not dependent on the cancer type in which it was generated from, since the obesity
metagene did not show significant association in either the ICGC cancer data or
in the NZBC data.
One possible reason why the obesity metagene from the Creighton et al. (2012)
study did not show significant association with other data sets could be because
the genetic signature was in fact not an obesity specific signature, but a signature
that was detected due to another clinical variable (investigated in Section 3.3).
Another reason for this apparent lack of association could be that the obesity-
associated genetic signature was too specific to the CR data and was not a broad
obesity-associated genetic signature, but an obesity-associated signature that was
specific to the patient cohort that was profiled in the Creighton et al. (2012) pub-
lication.
3.2 Obesity-associated genetic signature from the
Fuentes-Mattei et al. (2014) study
The obesity-associated genetic signature from the Creighton et al. (2012) study
was not associated with patient BMI or BMI status in majority of the cancer data
sets, so the obesity-associated genetic signature from the Fuentes-Mattei et al.
(2014) study (FM) was examined to see whether this obesity metagene was able
to significantly associate with the patient BMI and BMI status across different data
sets. Since the FM data set did not have patient BMI information, the FM obesity
metagene was not able to be compared with the patient BMI or BMI status in the
original FM data. Nevertheless, the transformation matrix was still generated in
the FM data and applied first to the microarray data (CR and NZBC data sets)
then to the ICGC data sets to see whether the FM obesity metagene associated
with patient BMI and BMI status in these data sets.
The FM data was normalised with the RMA method and SVD was performed
on the normalised FM data to obtain the transformation matrix. The transforma-
tion matrix was used to transform the RMA normalised CR data to extract the FM
obesity metagene scores in the CR data. The FM obesity metagene scores were
compared with sample gene expression levels, patient BMI and BMI status in the
CR data (Figure 7). Clearly, as with the CR obesity metagene, the FM obesity
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metagene was reflective of the overall gene expression of the samples, but did not
associate with patient BMI or BMI status, suggesting that this signature also does
not generalise to other data sets. The transformation matrix was then applied to
the NZBC microarray data. Again, FM obesity metagene scores reflected the gene
expression of the samples, but did not significantly associate with patient BMI or
BMI status (Figure 8).
Next, the transformation matrix was applied to the ICGC cancer data and the
resulting FM metagene was compared with the sample gene expression, patient
BMI and BMI status in each of the ICGC cancer data. As evident in Figure 9
and Appendix A3, the FM obesity metagene scores appeared to reflect the over-
all gene expression of the FM obesity-associated genetic signature. As with all
the results in this chapter so far, the FM obesity metagene did not significantly
associate with any of the ICGC cancer data, except in the BLCA data set (Fig-
ure 9; Appendix A3). The FM obesity metagene significantly associated with
the overweight group (but not with the obese group), and also had a significant
ANOVA p-value Figure 9. On the contrary to the association of the metagene
with the patient BMI status, the FM obesity metagene was not associated with the
patient BMI. These results suggested that the samples from the patients that were
overweight in the BLCA data set had similar biological properties as the samples
taken from the patients that were obese in the FM data set. However, due to the
fact that the FM obesity metagene lacked association with the patient BMI in the
BLCA data set, and that the metagene did not show any significant association
in any of the other ICGC cancer types, it was difficult to determine whether the
observed association of the FM obesity metagene with the overweight group was
truly reflective of the quality of the FM metagene or observed by chance.
These results showed that the obesity-associated genetic signature from the
Fuentes-Mattei et al. (2014) study was not generalisable to other cancer data sets,
similar to the obesity signature identified by Creighton et al.. This meant that
both the Creighton et al. and Fuentes-Mattei et al. obesity metagenes may have
been too specific to the original data set in which the signatures were identified in.
Furthermore, there was a possibility that these obesity-associated metagenes were
not related to obesity, but associated with a different clinical variable that may be
closely related to BMI (Section 3.3).
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FM metagene in CR data
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FM metagene in CR data vs. BMI











Figure 7: Heatmap, scatter plot and box plot showing the association of the FM obesity metagene
with the sample gene expression, patient BMI and BMI status, respectively, from the CR
data. Scales, p-values and R2-value are as described in previous figures.
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FM metagene in NZBC data
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FM metagene in NZBC data vs. BMI











Figure 8: Heatmap, scatter plot and box plot showing the association of the FM obesity-associated
metagene with the sample gene expression, patient BMI and BMI status, respectively,
from the NZBC data. Scales, p-values and R2-value are as described in previous figures.
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FM metagene (BLCA)
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FM metagene (BLCA) vs. BMI











Figure 9: Heatmap, scatter plot and box plot showing the association of the FM obesity metagene
with the sample gene expression, patient BMI and BMI status, respectively, from the
ICGC BLCA data. The results for other ICGC cancer types are shown in Appendix A3.
Scales, p-values and R2-value are as described in previous figures.
73
3.3 Novel obesity-associated genetic signatures from
the Creighton et al. (2012) data set
3.3.1 Identification of novel obesity-associated genetic signatures
Both the obesity-associated genetic signatures identified from the Creighton et al.
(2012) and Fuentes-Mattei et al. (2014) studies were able to capture the overall
gene expression patterns of the genetic signatures of the samples, but did not as-
sociate with patient BMI or BMI status in majority of the cancer data sets. One
possible reason for this result could be that the obesity-associated genetic signa-
tures from the Creighton et al. (2012) and Fuentes-Mattei et al. (2014) studies
may not have been truly associated with patient BMI, but with another clinical
variable. To investigate this possibility, novel obesity-associated genetic signa-
tures were identified in the CR data after controlling for all the clinical variables
in the data set. The FM data set was not used to get the obesity-associated genetic
signatures, as no BMI information was available for the patients in the FM data.
Firstly, an attempt was made to replicate the Creighton et al. obesity-associated
genetic signature from the original CR data. Creighton et al. (2012) originally
found their obesity-associated genetic signature by doing a gene expression anal-
ysis between the breast tumour samples from the obese and non-obese patients,
and from this list, Creighton et al. selected the 799 statistically significant DEGs
(p < 0.01) with log2-fold change greater than 1.2. Therefore, gene expression
analysis between the samples from obese and non-obese patients in the RMA nor-
malised CR data was carried out (described in Section 2.4). Without adjusting
the p-value to account for multiple hypothesis testing, 5278 gene probes and 1781
gene probes were significant at p < 0.05 and p < 0.01, respectively (Table 9).
After adjustments were made for multiple hypothesis testing, there were only 9
gene probes significant at p < 0.05 and no gene was significant at p < 0.01, which
suggest that the majority of the 799 probe sets reported by Creighton et al. may
actually be false positives.
Furthermore, there were only 61 gene probes that were significantly differen-
tially expressed at p < 0.05 with a log2-FC greater than 1.2. From these obser-
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vations, the log2-fold change of the gene probes were ignored and the threshold
p-value was set to 0.01 (unadjusted p-value) for the identification of the significant
probe sets. Additionally, when there were more than 799 gene probes identified,
only the most significant 799 gene probes were taken as the obesity-associated ge-
netic signature, as this many genes were originally identified by Creighton et al..
This was to include as many probe set as possible for the novel genetic signatures
to be comparable with the original Creighton et al. obesity-associated genetic
signature. These criteria were applied for the identification of other genetic signa-
tures as well.
The above analysis was repeated with the residual data (RMA normalised CR
data that had been controlled for other clinical variables; see Section 2.3.3). The
clinical variables controlled were age, ethnicity, menopause status, tumour grade,
receptor (ER, PR, and HER2) statuses and LN status. In the residual data, 1104
gene probes were significantly differentially expressed with unadjusted p-value (p
< 0.01; additional results shown in Table 9). Again, the most significant 799 gene
probes were taken as the obesity-associated genetic signature from this data.
In addition to the above two obesity-associated genetic signatures, two more
sets of genetic signatures were identified by taking the gene probes that were com-
mon between each of the above two signatures with the original obesity-associated
genetic signatures. There were 239 common gene probes between the original
Creighton et al. obesity-associated genetic signature and the gene probes iden-
tified from the unadjusted CR data, and 168 common gene probes between the
original signature and the gene probes from the residual CR data. The genetic
signatures identified were summarised as a Venn diagram, as shown in Figure 10.
There was a possible bias between the different ethnic groups, where African-
American patients were more likely to be obese compared with the Caucasian
patients (13 out of 16 were obese in African-American group, whereas 22 out of
77 were obese in Caucasian group; see Section 1.4.2 and Table 2 in Section 2.2.1).
Though ethnicity was controlled in the residual CR data, the effect of ethnicity on
the CR data was completely removed to prevent any possibility of ethnicity influ-
encing the analysis. Therefore, the effect of ethnicity was ignored by considering
only the Caucasian patients in the CR data, which left a total of 77 Caucasian
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Table 9: Summary of the number of DEGs identified using different unadjusted and FDR-adjusted
p-value thresholds in different versions of the RMA normalised CR data set
Number of DEGs identified
Unadjusted p-value FDR-adjusted p-value
0.01 0.05 0.01 0.05
CR data 1781 5278 0 9
Residual CR data 1104 4371 0 0
Caucasian-only CR data 2129 6029 0 0
Residual Caucasian-only CR data 1558 5427 0 0
Figure 10: Venn diagram showing the common gene probes between the signatures obtained from
the unadjusted and the clinical variable-adjusted CR data and the original obesity-
associated genetic signature from the Creighton et al. (2012) study
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Figure 11: Venn diagram showing the common gene probes between the signatures obtained from
the unadjusted and the clinical variable-adjusted CR data (Caucasian patients only) and
the original obesity-associated genetic signature from the Creighton et al. (2012) study
patients in the data set.
With the Caucasian-only CR data set, obesity-associated genetic signatures
were identified as described above. 2129 and 1558 gene probes were significantly
differentially expressed (unadjusted p-value < 0.01) in the unadjusted and clinical
variable-adjusted Caucasian patient data, respectively (Table 9). As before, the
most significant 799 gene probes were selected from these gene probes. There
were 148 and 92 common gene probes with the original Creighton et al. obesity-
associated genetic signatures and unadjusted or clinical variable-adjusted Cau-
casian patient data set, respectively. Again, Venn diagram was used to summarise
the genes identified from the Caucasian patient data set (Figure 11).
Additionally, the correlation of all of the obesity metagenes were examined
to see whether these metagenes were similar to one another. As clearly shown
in Figure 12, there were two distinct groups within the eight metagenes: the
first group contained the obesity metagenes that were not overlapped with the
Or metagene (Cr, Res, Ca and CaRes), while the other group had the overlapped
metagenes (CrOl, ResOl, CaOl and CaResOl). With that said, all eight metagenes
showed high correlation with one another (lowest correlation approximately at
0.85), which suggested that all of these metagenes were detecting similar under-













































Figure 12: Heatmap showing the Pearson correlation of all eight obesity-associated metagenes
from the CR data with one another. SVD was applied to the RMA normalised CR data
to generate each of the eight metagenes. High and low correlation were represented as
red and yellow, respectively, where the colours were matched with the values on the
scale shown in the top left histogram. The lowest correlation was 0.8469, between the
CrOl and the CaRes metagenes.
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Table 10: Summary of the abbreviations used to refer to the different obesity-associated genetic
signatures identified in the CR data
Abbreviation Definition No. of gene probes
Or Original obesity-associated genetic signa-
ture identified by Creighton et al. (2012)
799
Cr Obesity-associated genetic signature
identified from unadjusted CR data
799
CrOl Genes common between Or and Cr ge-
netic signatures
239
Res Obesity-associated genetic signature
identified from clinical variable-adjusted
CR data
799
ResOl Genes common between Or and Res ge-
netic signatures
168
Ca Obesity-associated genetic signature
identified from unadjusted Caucasian-
only CR data
799
CaOl Genes common between Or and Ca ge-
netic signatures
148
CaRes Obesity-associated genetic signature
identified from clinical variable-adjusted
Caucasian-only CR data
799
CaResOl Genes common between Or and CaRes
genetic signatures
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Since all of these obesity-associated genetic signatures were derived based on
the discrete values of the patient BMI status, an obesity-associated genetic signa-
ture was searched for using the correlation of the gene probe expression with the
patient BMI value (continuous variable) in the CR data with all of the samples
included, but no significant genes were identified (Appendix A8). All of these
obesity-associated genetic signatures (eight in total) were checked to see whether
these signatures had significant association with patient BMI or BMI status in the
NZBC and ICGC cancer data sets (Section 3.3.2). For simplicity, the abbrevia-
tions in Table 10 will be used to refer to the appropriate genetic signatures.
79
3.3.2 Novel obesity-associated signatures and patient BMI/BMI
status
As with the Or signature, all eight obesity-associated genetic signatures were vali-
dated in the CR data set first, and then compared in other cancer data sets by using
the transformation matrix that was generated in the RMA normalised CR data.
The CR data (unadjusted, all samples included) was normalised with the RMA
method and SVD was applied to generate the all of the obesity metagenes. The
direction of the metagenes were examined to make sure that all of the metagenes
were in line with one another (see Section 2.6.3; Appendix A4). The comparison
of the metagenes with the sample gene expression in the CR data were displayed
as heatmaps (Figure 13; Appendix A5). It was clear from the heatmaps that all
of the metagenes reflected the overall expression of the corresponding obesity-
associated genetic signatures. The association of the metagenes with patient BMI
and BMI status was significant for all eight of the obesity-associated genetic sig-
natures identified (Figure 13; Appendix A5). These results confirmed that all of
the obesity-associated genetic signatures identified in Section 3.3.1 significantly
associated with patient BMI and BMI status in the CR data in which the meta-
genes were derived from. In the NZBC data, the higher the metagenes scores of
the samples were, the more expressed the genes were (and vice versa), but lacked
the association with the patient BMI or BMI status (Figure 14; Appendix A6).
To confirm whether these metagenes showed significant association with pa-
tient BMI or BMI status in other cancer types, the transformation matrix was
applied to the ICGC cancer data. In all of the ICGC cancer data sets, all eight
metagene scores were reflective of the sample gene expression of the correspond-
ing obesity-associated genetic signatures (Figure 15; Appendix A7). In all cancer
types but BLCA, none of the obesity metagenes significantly associated with the
patient BMI or BMI status (Appendix A7). As shown in Figure 15, the BLCA data
set showed significant association with the Cr metagene with the patient BMI and
BMI status. Furthermore, Res and Ca metagenes also showed statistical signifi-
cance in the overweight group, ANOVA and the regression line p-values; CaRes
and Res metagenes were significant in overweight group and ANOVA p-value;
CrOl and CaResOl metagenes were significant in overweight group; and ResOl
80
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Cr obesity metagene vs. BMI











Figure 13: Heatmap, scatter plot and box plot showing the association of the Cr obesity-associated
metagene with the sample gene expression, patient BMI and BMI status, respectively,
from the CR data. The results for the other obesity metagenes are shown in Ap-
pendix A5. Scales, p-values and R2-value are as described in previous figures.
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Cr (NZBC data)
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Cr (NZBC data) vs. BMI











Figure 14: Heatmap, scatter plot and box plot showing the association of the Cr obesity-associated
metagene with the sample gene expression, patient BMI and BMI status, respectively,
from the NZBC data. The results for the other obesity metagenes are shown in Ap-
pendix A6. Scales, p-values and R2-value are as described in previous figures.
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and CaOl metagenes were not significantly associated with the sample BMI or
BMI status in BLCA data set (summarised in Table 11).
This was unexpected since all of the genetic signatures resulted from the gene
expression analysis between the non-obese group and the obese group of the sam-
ples in the CR data, and yet all of the obesity metagenes showed significant associ-
ation with the overweight group rather than the obese group in the BLCA data set.
These results suggested that the samples from the patients that were overweight in
the BLCA data were similar in genotype with the samples from the patients that
were obese in the CR data. Again, due to the fact that all of the metagenes lacked
association with the patient BMI and BMI status in all of the other ICGC cancer
types, it was difficult to conclude whether the observed association of many of the
obesity metagenes with the overweight group of the samples was truly reflective
of the effect resulted from these metagenes.
Taken together, these results showed that, even though all of the obesity meta-
genes significantly associated with the patient BMI and BMI status in the original
data where the genetic signatures were derived from, none of the metagenes were
generalisable in other cancer data sets. Furthermore, these results showed that the
lack of association with patient BMI and BMI status were not due to other clini-
cal variables in the CR data set. This raised a question of whether there was any
obesity-associated genetic signature that was common in multiple types of cancer
(Section 3.4).
3.4 Common genes across multiple cancer types
It was clear that all of the obesity-associated genetic signatures created from the
CR data set were not significantly associated with patient BMI across different
ICGC cancer data sets. To determine whether there was any obesity-associated
genetic signature that was expressed in multiple different cancer types, gene ex-
pression analysis was carried out on each of the eight ICGC cancer types, and
common genes were searched from the DEGs that were identified. All of the
ICGC cancer data sets were normalised with voom (Section 2.3.1), which were
then put through the gene expression analysis pipeline to identify the DEGs be-
tween the obese and non-obese groups of samples (Section 2.4). Table 12 sum-
83
Cr (BLCA)





























p = 0.01463 p = 0.1372















































































































































































































































































Cr (BLCA) vs. BMI











Figure 15: Heatmap, scatter plot and box plot showing the association of the Cr obesity metagene
with the sample gene expression, patient BMI and BMI status, respectively, from the
ICGC BLCA data. The results for other other metagenes and other ICGC cancer types
are shown in Appendix A7. Scales, p-values and R2-value are as described in previous
figures.
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marised the number of DEGs (unadjusted p < 0.05) found from each cancer type.
There were 9695 unique DEGs across the eight different cancer types, and
these genes were checked for any commonalities across the different cancer types.
There were 7330 genes that were differentially expressed in one cancer type, 2024
genes differentially expressed in any two cancer types, 320 genes expressed in
any three cancer types, and 21 genes expressed in any four cancer types. There
were no genes differentially expressed by five or more cancer types (see Table 13
for a summary). To confirm that these results were statistically significant, the
gene expression analysis was repeated 1000 times for each cancer type after the
samples were randomised in each analysis (see Section 2.3.5). The results from
the simulation were summarised together with the earlier results in Table 13.
The results from the simulation showed that, on average, 5732 genes were
found to be differentially expressed in any single cancer type, 1057 in any two
cancer types, 111 in any three cancer types, and 7 in any four cancer types. Unfor-
tunately, there were no DEGs expressed in all eight cancer types, which confirmed
that there was no common genes that were differentially expressed between the
samples that were obese and normal weight. When the results from the ICGC
gene expression analysis were compared with the simulation results, the number
of DEGs found were statistically significant, as the numbers of genes identified
exceeded the 95th percentile values for up to four cancer types. This result con-
firmed that the DEGs from the ICGC cancer data were not identified by chance.
However, this also showed that many of the DEGs identified in the gene expres-
sion analysis of the cancer types were observed by chance, and that the majority
of these genes were likely to be false positives.
3.5 Pathways enriched in ICGC data sets
To check whether there were any significant pathways enriched in any of the ICGC
cancer data sets that were associated with obesity, pathway enrichment analysis
was carried out on each cancer type separately and then all cancer types combined
(Section 2.5). Each cancer type was normalised with voom (Section 2.3.1) and
pathway enrichment analysis was carried out as described in Section 2.5.
When the pathway enrichment analysis was carried out with the KEGG path-
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Table 11: Statistics of all the obesity metagenes with the patient BMI and BMI status in the ICGC
BLCA cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.01341 0.1365 0.0387 0.0171 0.0195
Res 0.0055 0.1974 0.0196 0.0117 0.0446
CrOl 0.0383 0.4583 0.1096 0.0047 0.1374
ResOl 0.0909 0.7092 0.2125 0.0018 0.2254
Ca 0.0077 0.1973 0.0231 0.0116 0.0456
CaRes 0.0104 0.2712 0.0322 0.0101 0.0572
CaOl 0.0575 0.6185 0.1487 0.0022 0.2126
CaResOl 0.0463 0.5820 0.1263 0.0036 0.1660
1 All values in bold are statistically significant (p < 0.05).
Table 12: Summary of the number of DEGs identified in each of the ICGC cancer data set










Table 13: Summary of the number of DEGs identified by the gene expression analysis and simu-
lation analysis in the ICGC cancer data
No. of cancer types expressing the DEGs1
1 2 3 4 5 6 7 8
Results from gene expression analysis 7330 2024 320 21 0 0 0 0
Results from the simulation:2
Mean no. of DEGs identified 5732 1057 111 7 0 0 0 0
95th percentile 6965 1722 227 20 2 0 0 0
1 The numbers represent the number of cancer types a gene was expressed in.
2 The simulation was repeated 1000 times, each with randomised samples.
way database, only the “ABC transporter” pathway was significantly enriched
(FDR-adjusted p-value < 0.05) in the CESC data, and no other pathways were
enriched in any of the other ICGC cancer types (Appendix A9). With the Reac-
tome database, “Phosphatase bond hydrolysis by NUDT proteins” (in BLCA) and
“Mitochondrial ABC transporters” (in CESC) were significantly enriched (Ap-
pendix A9). With the GO database, there were 22 GO terms significantly enriched
in BLCA, 17 terms in CESC, 3 terms in KIRP, 21 terms in READ, 10 terms in
SKCM, 14 terms in UCEC, and no terms were significant in the COAD and LIHC
cancer types (Appendix A9).
Though there were many GO terms identified as significantly enriched with
the GO database in each of the cancer types, there were no terms that were com-
mon across all of the different cancer types. Furthermore, these terms were not
similar in terms of the biological activities involved. For example, GO terms en-
riched in the BLCA data suggested possible activation of the PI3K pathway, but
those enriched in the READ data were mainly involved in RNA processing (Ap-
pendix A9). One interesting result from this enrichment analysis was that the
“ABC transport” pathway was identified as significantly enriched in the CESC
data set by all three databases, suggesting that the “ABC transport” pathway may
be a core component in the CESC tumour biology. All of these results indicated
that the biological processes that drive tumour progression were unique to each
cancer type, and no one pathway was associated with obesity and tumour biology
across multiple cancer types.
Since there were no common pathway enriched in the ICGC cancer types
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when analysed individually, all of the ICGC cancer data sets were combined into
a single data set to see any enriched pathways could be identified in a collective
analysis. The combined data set was generated in two ways. The first combined
data set was created by normalising (via voom) each cancer data set separately,
combine all of the normalised cancer data sets into one, then applying batch cor-
rection to the data set (Section 2.3.4). The second combined data set was created
by combining the cancer data sets into one big data set first, then the combined
data was normalised, and finally batch correction was applied to obtain the final
data set. Each of the combined data sets were analysed for enriched pathways,
but there were no pathways significantly enriched in either data sets. These re-
sults suggested that there were no common biological pathways associated with
obesity in the ICGC cancer data sets.
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Chapter 4
Obesity-associated genetic signatures and
pathway signatures
In this chapter, the underlying biological mechanism of the obesity-associated
signatures from the CR data were investigated. In doing so, the pathway ge-
netic signatures from the Gatza et al. (2010) study (GT) were utilised to deter-
mine which biological pathways the obesity-associated genetic signatures were
most similar to. First, the direction of GT pathway-associated genetic signatures
were resolved, then the pathway-associated metagenes were compared with the
obesity-associated metagenes, and lastly linear models were constructed based on
the pathway metagenes and patient BMI to predict the obesity-associated meta-
genes.
4.1 Pathway-associated genetic signatures from the
Gatza et al. (2010) study
4.1.1 Ranking and normalisation methods for pathway metagenes
In the Gatza et al. (2010) study, their data comprised of samples from different
studies which were aggregated into a single data set that was MAS5 normalised,
and the metagene scores were transformed to a scale between 0 to 1 using a probit
function. However, the analyses so far have used the RMA-normalisation method
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and ranked based on the number of samples present in the data (fractional ranking;
Section 2.6.2). To decide which normalisation methods or ranking approaches
were suitable for the analysis, the different methods were compared in the GT
data (Appendices B1 and B2). Results shown in Appendix B1 clarified that there
was no substantive difference in the ranking approaches used.
Scatter plots were generated and the correlations were calculated for each
of the GT pathway metagenes derived from either RMA or MAS5 normalised
GT data (Appendix B2). The GT pathway metagenes were generated using the
transformation matrices that were derived from either the RMA or MAS5 nor-
malised GT data. From these results, it was clear the normalisation methods used
on the data set had the most significant effect on the resulting metagenes, rather
than the normalisation methods used to generate the transformation matrices (Ap-
pendix B2). This meant that all of the data sets had to be normalised with a single
normalisation method, so RMA was chosen as the normalisation method to be
used as this method is regarded as being more reliable than the MAS5 method
(Irizarry et al., 2003).
Another thing noted from these scatter plots was that there were some pathway
signatures that were more variable than the others (Appendix B2). As an exam-
ple, the TGFβ metagenes were significantly more dispersed compared to the PR
metagenes, even though both of these metagenes were generated in the same data
set through similar processes (Figure 16). These differences were seen in other
data sets as well (Figure S22 in Appendix B2). This result provided evidence
that some of the pathway genetic signatures from the Gatza et al. (2010) study
were less variable across different data sets than the others. Taken together, it was
decided that the GT data set should be batch corrected first (Section 2.3.4), then
normalised with the RMA method, and the metagene scores were ranked with
fractional ranking (Section 2.6.2).
4.1.2 Pathway metagene directionality
Before GT pathway metagenes were compared with the obesity-associated meta-
genes, the direction of the GT pathway metagenes had to be checked to make sure












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 16: Comparison of the pathway metagenes generated in the MAS5 normalised GT data set
from the application of the transformation matrices derived from either the RMA or
MAS5 normalised GT data. Only the PR (left) and the TGFβ (right) pathway meta-
genes are shown. The scatter plots for the other pathway metagenes are shown in
Appendix B2.
of all the pathway metagenes with one another were plotted as a heatmap in Fig-
ure 17. The most prominent group had five pathways (E2F1, PI3K, Myc, BCAT
and Ras) that clustered at the top left hand corner of the heatmap. Other groups
included IFNα/IFNγ/TNFα pathways, ER/PR/p53 pathways and p63/HER2 path-
ways. In addition to these highly correlated groups, STAT3/TGFβ /Src/EGFR/Akt
pathways showed little correlation with one another. Comparing these groups with
the results presented by Gatza et al. (2010) (Appendix B4), the identified clusters
approximately resembled the pathway groups identified in by Gatza et al., which
confirmed that the directions of GT pathway metagenes were consistent with those
used by Gatza et al..
To see whether the directionality of the GT pathway metagenes were being
transferred across to other data sets properly, pathway metagenes were generated
in other data sets with the same transformation matrices and the groupings of the
metagenes were examined. CR, FM and NZBC data were RMA normalised and
transformation matrices of the pathway genetic signatures (derived from the GT
data set) were applied to the data sets. The metagenes were plotted in a heatmap
(shown in Appendix B5), which showed similar groupings as seen in Figure 17.
















































































Figure 17: Heatmap showing the Pearson correlation of all the pathway metagenes from the Gatza
et al. (2010) study with one another in the RMA normalised GT data set. High and
low correlation were represented as red and blue, respectively, where the colours were
matched with the values on the scale shown in the top left histogram. Refer to Table 7
for the detailed descriptions of the abbreviations used.
the data sets in which the transformation matrices have been applied to.
4.2 Pathway-associated metagenes and obesity-associated
metagenes
Results from the previous section confirmed that the pathway metagenes from
the Gatza et al. (2010) study were in the correct directions, and that the path-
way metagenes were behaving as expected in the different data sets. Now that
the directions of the pathway metagenes were established, these metagenes were
ready for comparison with the obesity-associated metagenes. However, all of the
pathway metagenes were derived from the GT data, whereas the majority of the
obesity-associated metagenes were derived from the CR data, which presents a
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problem in terms of deciding which data set the transformation matrices should
be generated in.
4.2.1 Obesity and pathway metagene transformation matrices
Metagenes generated from the application of SVD and metagenes generated from
the transformation matrix are exactly the same if the transformation matrix is de-
rived from the same data set. For example, an obesity-associated metagene gen-
erated from the CR data with SVD would have the same values as the metagenes
generated in the CR data with the transformation matrix (since the transformation
matrix was derived from the CR data). Furthermore, if the SVD-derived meta-
genes and transformation matrix-derived metagenes were the same (or at least
similar) in a different data set, this suggests that the metagene-related biology
contained in the two data sets is highly similar. In other words, the transforma-
tion matrix can be made in either the original data set or in a different data set
if there was no difference in the SVD-derived or transformation matrix-derived
metagenes.
To decide which data set the transformation matrices for obesity and pathway-
associated genetic signatures should be generated in, the SVD- and transforma-
tion matrix(TM)-generated metagene scores were compared in all of the data sets.
As in Section 4.1, all data sets were normalised with the RMA method and meta-
genes were ranked with fractional ranking. TMs for the obesity-associated genetic
signatures were made in the CR data set and the TMs for pathway-associated ge-
netic signatures were made in the GT data set. Metagenes for all of the obesity
and pathway-associated genetic signatures were generated in all of the data sets
with SVD and TMs. The Spearman correlation of the SVD-generated and TM-
generated metagene scores were calculated for each genetic signatures (Tables 14
and 15).
In Tables 14 and 15, the obesity and pathway-associated genetic signatures
had a correlation of 1 in CR and GT data sets respectively, as the obesity and
pathway TMs were generated in the CR and GT data sets, respectively. The corre-
lations of the obesity and pathway metagenes were variable across different data
sets, which was as expected since all the data sets were different from one an-
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Table 14: Summary of the Spearman correlations of the SVD- and transformation matrix1-derived
pathway metagenes in the GT, CR, NZBC and FM data sets
GT CR NZBC FM
Akt 1.000 0.5190 0.5900 0.5563
BCAT 1.000 0.9897 0.9977 0.9905
E2F1 1.000 0.9646 0.8438 0.9193
EGFR 1.000 0.0430 0.3358 0.4040
ER 1.000 0.9978 0.9942 0.9966
HER2 1.000 0.9553 0.5817 0.9794
IFNα 1.000 0.9830 0.9991 0.9951
IFNγ 1.000 0.9086 0.9950 0.9718
Myc 1.000 0.9878 0.9852 0.9689
p53 1.000 0.3808 0.9981 0.7923
p63 1.000 0.8319 0.2951 0.8368
PI3K 1.000 0.9543 0.5989 0.9365
PR 1.000 0.9511 0.9887 0.9845
Ras 1.000 0.9078 0.9125 0.7229
Src 1.000 0.9575 0.7173 0.9548
STAT3 1.000 0.1902 0.9159 0.6167
TGFβ 1.000 0.9918 0.2543 0.9890
TNFα 1.000 0.6046 0.9365 0.4315
1 Transformation matrices were derived from the RMA
normalised GT data set.
Table 15: Summary of the Spearman correlations of the SVD- and transformation matrix1-derived
obesity metagenes in the GT, CR, NZBC and FM data sets
CR GT FM NZBC
Cr 1.000 0.9985 0.9872 0.9161
Res 1.000 0.9987 0.9898 0.9652
CrOl 1.000 0.9982 0.9926 0.9715
ResOl 1.000 0.9981 0.9927 0.9571
Ca 1.000 0.9985 0.9893 0.9468
CaRes 1.000 0.9988 0.9939 0.9865
CaOl 1.000 0.9983 0.9937 0.9677
CaResOl 1.000 0.9984 0.9952 0.9642
Original 1.000 0.9928 0.9862 0.9344
1 Transformation matrices were derived from the RMA
normalised CR data set.
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other. However, what was unexpected was the fact that there were some pathway
genetic signatures that were highly correlated in all of the data sets, and there were
others that varied considerably across different data sets. For example, the BCAT
pathway metagene was highly correlated in all of the data sets (> 0.98), whereas
the STAT3 pathway metagene was variable across different data sets, ranging from
0.1902 to 0.9159 (Table 14; Appendix B7). The fact that some pathway-associated
metagenes were consistent across different data sets suggested that some of these
genetic signatures were reliable and did not depend on the data set the transforma-
tion matrices were derived from. Adding to this, there were very little overlap in
the genes between the different pathway-associated genetic signatures, suggesting
that the consistency across the data sets were not due to an artefact that was affect-
ing the dominant probe set in the signatures (Appendix B8). On the other hand,
the genetic signatures that were not consistent across the data sets were likely to
be dependent on the data set in which they were derived from, and therefore the
transformation matrices for these signatures must be derived from the GT data set.
This also showed that the tumour biology may be different across the data sets,
likely due to the difference in the patient cohorts that were selected for each of the
studies.
In contrast to the pathway-associated genetic signatures, all of the obesity-
associated genetic signatures showed high correlation for the SVD- and transfor-
mation matrix-generated metagenes across the different data sets. This suggested
that the obesity-associated genetic signatures were relatively consistent across all
data sets, and the transformation matrices for these signatures could be made in
any of the data sets. For simplicity, it was decided that the transformation matrices
for all the genetic signatures would be made in the GT data set, since there were
some pathway-associated signatures that were specific to the GT data.
4.2.2 Comparison of the obesity and pathway-associated signa-
tures
To visually determine which pathway-associated genetic signatures were most
similar to the obesity-associated genetic signatures, heatmaps were created with




















































































































Figure 18: Heatmap showing the Pearson correlation of all the pathway and obesity metagenes
with one another in the RMA-normalised GT data set. High and low correlation were
represented as red and blue, respectively, where the colours were matched with the
values on the scale shown in the top left histogram. Refer to Tables 7 and 10 for the
detailed descriptions of the abbreviations used.
associated metagenes have already been determined in Section 4.1, and the di-
rections of the obesity-associated metagenes were checked in GT data set as de-
scribed in Section 2.6.3. All of the metagenes were created in the GT data set
(normalised with RMA) using SVD, and the metagene scores were plotted in a
heatmap and clustered into groups (Figure 18).
In Figure 18, all of the obesity-associated metagenes from the CR data set
cluster together into a group, but none of the pathway-associated metagenes had
a strong positive correlation with the obesity metagenes. Though the HER2 and
p63 pathway metagenes were grouped next to the cluster of obesity metagenes,
the similarity was at most about 0.6 (Pearson correlation; Figure 18). With that
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said, these obesity-associated metagenes seem to have a strong negative corre-
lation with some of the pathway-associated genetic signatures, such as the Akt,
ER, EGFR, PR, p53, Src and TGFβ pathways, and this strong negative correla-
tion was observed in the other data sets as well (Appendix B9). In fact, high Or
metagene scores related to lower levels of gene expression for the genes in the Or
signature (Figure 3; Section 3.1), and therefore it could be possible that many of
the genes in the Or signature (and the other obesity-associated signatures from the
CR data) may be positively correlated with the genes in these pathway signatures.
This suggests that the obesity-associated genetic signatures from the CR data may
be related to these pathway signatures, rather than the obesity phenotype of the
patients.
The FM obesity-associated metagene did not cluster together with the obesity
metagenes from the CR data set, nor with any of the other pathway metagenes.
The fact that the FM metagene did not cluster with any of the CR metagenes
showed that the signals captured by the FM metagene was different from those
metagenes found in the CR data set. Furthermore, the FM metagene did not cluster
with the Akt pathway in the heatmap, even though Fuentes-Mattei et al. (2014)
provided clear evidence that their metagene specifically activated the Akt/mTOR
signalling pathway in a mouse model. This may have been due to the lack of
consistency of the Akt pathway signature in the different data sets (Table 14).
Another likely reason could be that FM genetic signature was not comprised only
of the genes from the Akt pathway, but genes from the other pathways as well,
and so the metagene did not cluster together with the Akt pathway signature in
the heatmap.
The results in this section suggested that none of the obesity-associated genetic
signatures were positively correlated with any of the pathway-associated genetic
signatures from the Gatza et al. (2010) study. However, some pathway signatures
were negatively correlated with the obesity-associated genetic signatures, which
meant that the obesity signatures were likely capturing the signals from these
signatures rather than the biological signals from the obesity phenotype of the
patient.
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4.3 Prediction of obesity-associated metagenes with pathway-
associated metagenes
To confirm the biological relationship between the obesity-associated metagenes
with the pathway-associated metagenes from the Gatza et al. (2010) study, lin-
ear models were created to predict the obesity metagene scores with the pathway
metagene scores. If any of the pathway metagenes were significant in the lin-
ear model, this would provide evidence that the significant pathways in the linear
model were related to the obesity metagene. Since most of the obesity metagenes
were found in the CR data set, and only the CR and the NZBC data sets had BMI
information for the patients, NZBC data set was used as the training data set to
create the linear models for obesity metagene score prediction.
4.3.1 Linear model prediction in the NZBC and CR data sets
Metagene scores used for the construction of linear models were generated from
the application of the transformation matrices derived from the GT data (from
Section 4.2) to RMA normalised NZBC data. From Table 14, it was evident
that some pathway-associated genetic signatures could be variable across different
data sets. Therefore, only six pathways (BCAT, ER, IFNα , IFNγ , Myc and PR)
that were “consistent” (correlation > 0.9) across all of the data sets were used to
construct the linear models.
For each of the obesity metagenes identified, seven linear models were cre-
ated: BMI-only, BMI status-only, BMI and BMI status, pathway metagenes-only,
and the combinations of pathway metagenes with BMI and/or BMI status. The
only variables that showed significance in any of the models that predicted the
obesity metagenes taken from the CR data set were the PR metagene and whether
the patients were obese or not (Table 16). In the model that predicted the FM
metagene scores, the obesity status of the patients and Myc metagene score were
significant, but the PR metagene score was not (Appendix B10).
The models constructed from the patient BMI, BMI status and/or GT pathway
metagene scores confirmed that none of the pathways were significant, except for
the PR and Myc pathway metagene scores in the models for the CR metagenes
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Table 16: Description of the linear models constructed from the NZBC data to predict the Cr
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI -0.0016 0.717
BMI status only Overweight -0.0126 0.871
Obese -0.0981 0.166
BMI and BMI status BMI 0.0109 0.123
Overweight -0.0687 0.420
Obese -0.2481 0.0401






























1 All values in bold are statistically significant (p < 0.05).
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Table 17: Description of the linear models constructed from the NZBC data to predict the Cr
obesity, using only the patient BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR 0.477 6.06×10−71
BMI and PR BMI -0.002 0.586
PR 0.478 6.35×10−7
BMI status and PR Obese -0.085 0.176
Overweight -0.011 0.875
PR 0.471 8.25×10−7




1 All values in bold are statistically significant (p < 0.05).
and the FM metagene, respectively. It was not surprising that the PR pathway
metagene showed significance in the models generated in NZBC data set, as ma-
jority of the patients in the NZBC data set were PR+ (Table 3). The significance
of the Myc metagene in the model for FM metagene was difficult to interpret, as
there was no reported association of the FM metagene with the Myc pathway by
Fuentes-Mattei et al. (2014). MYC is an oncogene that encodes the Myc transcrip-
tion factor that, when overexpressed, disrupts various pathways that directly pro-
mote tumour growth and proliferation, and has a central role in many of the cancer
hallmarks (Coller et al., 2000; Hanahan and Weinberg, 2000). “Sustained cell pro-
liferation” was one of the cancer hallmarks that Fuentes-Mattei et al. (2014) had
shown to be related to their obesity-associated genetic signature, which could be
the reason that the Myc pathway metagene showed up as a significant variable in
the linear model. Since the PR pathway metagene showed significant association
in many of the linear models, linear models were made with each of the com-
binations of BMI, BMI status and PR pathway metagene for all of the obesity-
associated metagenes (Table 17; Appendix B10). As expected, all of the linear
models showed significant contribution of the PR metagene scores to the model
for all obesity metagenes (except FM metagene; Appendix B10).
To determine whether any of the linear models were able to predict the corre-
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sponding obesity metagene scores, the predicted metagene scores were generated
from the models and then compared with the original scores. The original obesity
metagene scores from the NZBC were generated from the application of TM that
were derived from the RMA-normalised GT data set. These NZBC obesity meta-
gene scores were then compared with the metagene scores that were predicted by
the linear models (Figure 19).
The predicted metagenes from all of the patient BMI-related linear models
were not significantly related to the original metagene scores in many of the obe-
sity metagenes (Figure 19; Appendix B10). On the other hand, all of the predicted
metagenes generated from the models that used the pathway metagene scores
showed significant association with the original metagene scores (Figure 19; Ap-
pendix B10). However, the R2 values for all of the predicted metagenes against
the original metagenes were very low (R2 < 0.4). All of the plots in Figure 19
and Appendix B10 showed clearly that the data points in the scatter plots were
highly variable, suggesting that even though the association between the predicted
and the true metagene scores were statistically significant, the variables in the
linear models may not be strongly associated to the obesity metagene. Further-
more, the fact that all of the predictions made with the models that contained the
PR metagene showed greater correlation with the true metagene values suggested
that most of the variations in the Cr (and other) obesity metagenes were being
explained by the PR metagene alone, and the patient BMI contributed very little
to the prediction.
To confirm the results shown in the NZBC data set (the training set), the linear
models were applied to CR data (the test set). As shown in Figure 20, all of the
predicted Cr metagene generated from the linear models were statistically signif-
icantly associated with the true Cr metagenes in CR data, but there were some
exceptions in the models for the other obesity metagenes (Appendix B12). Simi-
lar to the results from the NZBC data set, all of the R2 values were low (R2 < 0.43)
in the CR data set and the data points were widely spread out in the plots. Again,
these results suggested that the predicted metagene scores from the linear models
may be statistically significant, but may not be relevant to the obesity metagenes
which the models predict, as the predicted values were only weakly associated




























































































































































p = 0.2002 p = 0.1501










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 19: Box plot and scatter plots comparing the Cr metagene score predicted by the different
linear models constructed from the NZBC data, with the Cr metagene score from the
NZBC data. Only the results from the models used to predict the Cr metagene scores
are shown. The summary of the statistics for the other obesity metagene predictions
from the NZBC data are shown in Appendix B12. P-values and R2-value are as de-
scribed in previous figures.
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Another thing to note from Figure 20 was the apparent negative association
of the predicted metagenes with the original metagenes in the BMI-only, the BMI
status-only and the BMI and BMI status models. One possible explanation for
this was that these BMI-based models were overfitted in the NZBC data set, and
was not generalisable in the CR data set, and thus produced negative correla-
tions. In fact, it was evident from the metagene analyses in Chapter 3 that these
obesity-associated genetic signatures were not generalisable with the patient BMI
in different data sets, and overfitting of the model in the NZBC data was the likely
cause of this negative correlation.
4.3.2 Stepwise linear model prediction in NZBC and CR data sets
Lastly, since only the six most “consistent” pathway metagenes were picked from
a total of eighteen pathway metagene scores, linear models were constructed with
all eighteen pathway metagenes in a stepwise fashion. Step wise construction of
a linear model is where the variables for a model are selected computationally
depending on the contribution of the variable to the resulting linear model, and
thus contain only the variables that “matter” to the final linear model Section 2.7.
Patient BMI, BMI status and all of the pathway metagenes (Akt, BCAT, E2F1,
EGFR, ER, HER2, IFNα , IFNγ , Myc, p53, p63, PI3K, PR, Ras, STAT3, Src,
TGFβ and TNFα) were used to generate the stepwise linear model for each of the
obesity metagenes. The linear models that resulted from the stepwise selection of
the variables were summarised in Table 18.
These models were used to predict the obesity metagenes in the NZBC data
to test the performance of the models. All of the models were able to make statis-
tically significant prediction of the original obesity metagenes in the NZBC data
set (Figure 21). Unlike the previous models, the stepwise models showed very
high R2 values, where most predictions had R2 > 0.80. The statistical significance
and the strong association of the predicted metagenes were observed in the CR
data set as well (Figure 22). Though the R2 values were slightly lower than those
from the NZBC data set, the R2 values from the CR data predictions were more
































































































































































p = 3.005e−06 p = 0.0002419














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 20: Box plot and scatter plots comparing the Cr metagene score predicted by the different
linear models constructed from the NZBC data, with the Cr metagene score from the
CR data. Only the results from the models used to predict the Cr metagene scores are
shown. The summary of the statistics for the other obesity metagene predictions from
the CR data are shown in Appendix B12. P-values and R2-value are as described in
previous figures.
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Table 18: Description of the stepwise linear models constructed from the NZBC data to predict all
of the obesity metagenes
Obesity metagene Variables retained in the model Estimate P-value





CrOl Akt -0.3134 1.76×10−6
Src -0.5386 < 2×10−16
p53 0.3372 9.18×10−7
PR -0.1115 0.02760





ResOl Akt -0.2802 0.0001420
Src -0.5214 2.65×10−15
p53 0.2861 5.31×10−7
Ca TGFβ 0.7470 < 2×10−16
Akt -0.2985 2.83×10−10
CaOl Src -0.5595 3.88×10−16
Akt -0.4331 2.06×10−11
CaRes TGFβ 0.7843 < 2×10−16
EGFR 0.2418 2.19×10−6

















1 All values in bold are statistically significant (p < 0.05).
Clearly, the stepwise linear models were able to predict the obesity-associated
metagenes better than the models created in Section 4.3.1. This could be due to
the fact that many of the stepwise linear models included many pathways that had
a strong negative correlation with the obesity metagenes (Akt, ER, EGFR, PR,
p53, Src and TGFβ pathways; Figure 18). These pathway metagenes may have
been better predictors of the obesity metagenes than the six pathways that were
“consistent” across the data sets, and therefore generated better predictions than
those linear models. With that said, some of the predicted obesity metagenes from
the stepwise linear models were negatively correlated with the original metagene
values in the CR data (Figure 22). Again, this could have been due to the model
being overfit in the NZBC data, and thus making an incorrect prediction about the
obesity metagenes in the CR data.
Taken together, these results suggest that the variables included in these step-
wise models were relevant to the biology of the obesity metagenes identified in
the CR and FM data sets. However, there were no common pathways that were
present in all of the models; although Akt, EGFR, TGFβ and Src pathway meta-
genes were frequently included in many of the stepwise models. The role of the
pathways included in the models and the possible biological links of these path-













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 21: Scatter plots comparing all of the obesity metagene scores predicted by the stepwise
linear models constructed from the NZBC data, with the corresponding obesity meta-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 22: Scatter plots comparing all of the obesity metagene scores predicted by the stepwise
linear models constructed from the NZBC data, with the corresponding obesity meta-





To conclude this thesis, all of the results were re-examined and are summarised
here to highlight the key findings from this project. There were many limitations
to this project and these limitations are addressed either in the summary in Sec-
tion 5.1, or separately in Section 5.2. Lastly, conclusions are drawn from all of
the evidence from this project and suggestions for future aims and experiments
are made.
5.1 Summary of the results
5.1.1 Obesity-associated genetic signatures
Chapter 3 focussed mainly on establishing the link between the obesity-associated
genetic signatures from the Creighton et al. (2012) and the Fuentes-Mattei et al.
(2014) studies with the patient BMI and BMI status, as reported by their studies.
The obesity-associated genetic signature from the Creighton et al. (2012) study
was examined first. The obesity metagene generated from the Creighton et al.
obesity signature was able to “capture” the overall genetic expression patterns of
the samples, where low and high metagene scores corresponded to low and high
gene expressions, respectively. This result was in accordance with the character-
istics of the obesity metagene provided by Creighton et al. (2012). Furthermore,
the obesity metagene significantly correlated with the patient BMI and BMI status
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in the CR data set.
To see whether this obesity signature was able to show similar association with
the patient BMI and BMI status in other cancer data sets, metagenes were created
in the NZBC and ICGC cancer data sets with the transformation matrix generated
in the CR data set. Like in the CR data set, the obesity metagenes were reflective
of the gene expression patterns of the genes in the genetic signature in all of the
data sets. However, the obesity metagene was not significantly associated with
the patient BMI or BMI status in any of the other cancer data sets, except for
the BLCA data set which showed significant association only with the overweight
group (discussed later in Section 5.1.2).
Initially, these results were thought to be due to the obesity-associated genetic
signature being specific only to the CR data set. Therefore, a different obesity-
associated genetic signature from the Fuentes-Mattei et al. (2014) study was used
to see whether this signature was able to show significant association with the
patient BMI in the CR, NZBC and ICGC cancer data sets. The results were sim-
ilar to the obesity metagene from the Creighton et al. (2012) study; FM obesity
metagene scores reflected the gene expressions of the signature but the scores
were not significantly associated with the patient BMI or BMI status in any of
the cancer data sets investigated (except the BLCA data set). Together, these re-
sults suggested that both CR and FM genetic signatures were only significant in
the original data set in which the signature was derived in (though this was not
confirmed in the FM data set, as no patient BMI information was available).
The fact that neither CR nor FM obesity-associated genetic signatures showed
any sign of significant association with the patient BMI in the majority of the
cancer data sets raised a question of whether these signatures were actually related
to obesity, or to a different clinical variable within the data set. This question led
to the identification of various versions of obesity-associated genetic signatures in
Section 3.3.1. The CR data set was controlled for all the clinical variables (sex,
age, ethnicity, menopause status, tumour grade, ER/HER2/PR statuses and LN
status) to generate some of these signatures. All of the metagenes created from
these novel obesity-associated genetic signatures were consistent with the gene
expression patterns, but none of the metagenes showed significant association with
the patient BMI or BMI status in the data set other than the CR data set, with the
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exception of the overweight group in the BLCA data set.
It was possible that all of these results were due to the sample quality (and
hence due to the quality of the data), or perhaps many of the samples in these
data sets had breast cancers due to a cause unrelated to their obesity status. As
many epidemiological studies have pointed out, obesity is a strong risk factor for
cancer (covered in Section 1.3), but this does not necessarily mean that all cancer
in obese patients develop cancer as a result of obesity. As briefly mentioned in
Section 1.2.3, there are many other environmental factors that can cause cancer,
and patients in these studies may have been exposed to these factors, but this
exposure information is not recorded in the clinical data, so cannot be accounted
for in the analysis.
In other words, the cancer identified in obese patients may have been caused
by another, completely different biological mechanism. Thus the tumour sam-
ples taken from obese and overweight patients will be a mixture of samples that
are driven by obesity-related mechanisms and mechanisms that are not related to
obesity. These different subgroups of tumours (obesity-driven or not) cannot be
easily identified and isolated. This may affect the detection of the truly obesity-
associated genes, as some of the tumour samples from the patients will have noth-
ing to do with obesity and cancer, and hence will be misclassified into the wrong
groups.
5.1.2 BLCA data set and the obesity metagenes
In the BLCA data set, many of the obesity metagenes were associated with the
overweight group with significant p-value and/or ANOVA p-value, but never with
the obese group. This was unexpected, as all of the metagenes were generated
based on the list of DEGs between the obese and the non-obese groups in the
CR data set, and not the overweight group. In addition to the association of the
metagenes with the overweight group, some metagenes showed significant asso-
ciation with patient BMI in the BLCA data set. It was difficult to conclude with
confidence that those metagenes that showed significant association with the over-
weight group in the BLCA data set was truly due to the effect of the metagenes,
as these metagenes were generated from the obese group and not the overweight
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group in the original data sets. Furthermore, there were no significant association
of these metagenes in any other ICGC cancer data sets and provided no further
evidence that supported the results presented in the BLCA data set.
With that said, there is a possibility that the genotypes of the patients that are
overweight in the BLCA data set are similar to those patients that are obese in
the CR data set. In fact, Damrauer et al. (2014) have identified “basal-like” and
“luminal” subtypes in bladder cancer that resembled the corresponding subtypes
in breast cancer, and suggested that bladder and breast cancers may have common
physiological properties. Since all of the obesity-associated genetic signatures
were derived from breast cancer data sets, it makes some sense that these sig-
natures were significant in the BLCA data set, as there is evidence that bladder
cancer and breast cancer are biologically similar to one another (Damrauer et al.,
2014). However, the degree of similarity between these two cancer types are not
yet known and further analyses are required for a definitive explanation of the
results.
5.1.3 Use of SVD and transformation matrix as a valid method
From all of these results so far, one may question how robust or appropriate the use
of SVD and transformation matrices are to generate metagenes in other data sets.
The CR data-derived obesity-associated genetic signatures correlated significantly
in the CR data, but as soon as these metagenes were generated in the other data
sets via the application of transformation matrices, the correlation became non-
significant. One possible reason for this was that the obesity metagenes were
not actually associated to the obesity phenotype in the other data sets. Another
reason could be that the methodology used was not appropriate for investigating
the association between the phenotype and its associated phenotype.
The appropriateness of the use of SVD and transformation matrices were ex-
amined with different genetic signatures: ER and PR pathway-associated genetic
signatures from the Gatza et al. (2010) study (covered in Appendix A10). Three
data sets (CR, FM and NZBC) were used, as these data sets have both ER and PR
status information available for the patients. SVD was first applied to the RMA-
normalised CR data to obtain the ER and PR metagenes, along with the transfor-
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mation matrices for each of the genetic signatures. Both the ER and PR metagenes
showed good concordance with the gene expression profiles of the genetic signa-
ture in the heatmap, and also showed significant association with patient ER and
PR statuses (Appendix A10).
Transformation matrices were applied to the FM and NZBC data sets to gener-
ate the appropriate pathway metagenes in the data sets. Both the ER and PR path-
way metagenes showed similar overall gene expression patterning in the heatmap
as the CR data (Appendix A10). Furthermore, both the ER and PR pathway meta-
genes from these data sets show significant association with patient ER and PR
statuses, respectively (Appendix A10). These results clearly showed that the gen-
eral approach of using SVD and transformation matrices was appropriate for ex-
amining the association of the genetic signatures with the patient phenotype.
5.1.4 Common obesity-associated genes and pathways across mul-
tiple cancer types
The results so far have provided strong evidence that the obesity-associated ge-
netic signatures from the CR and the FM data sets were not associated with pa-
tient BMI. In a last attempt to identify any obesity-associated genes that were
common across multiple cancer types, gene expression analyses were carried out
on the ICGC cancer data sets using samples for which patient BMI information
was available (Section 3.4). There were many DEGs identified in each of the
ICGC cancer types, but there were no genes in common for all eight cancer types,
and this observation was supported by the results from the simulation.
The simulation results also showed that the number of DEGs identified in
these cancer types were greater than one would expect by chance. However, as
observed by the results from the simulation, there were many genes identified by
chance alone, which suggested that majority of the DEGs found in the eight cancer
types were false positives. This apparently high level of Type I errors was not only
observed in the ICGC data sets, but also in the CR data set when gene expression
analyses were carried out to generate various obesity-associated genetic signatures
in Section 3.3.1 (discussed in more detail in Section 5.1.5).
Finally, pathway enrichment analysis was carried out in the ICGC data sets
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(first with each cancer type separately, then all cancer types combined) to inves-
tigate whether there were any pathways that significantly associated with obesity
(Section 3.5). There were not many pathways identified from the KEGG and the
Reactome pathway databases that were significantly enriched in the ICGC cancer
data sets. There were a substantial number of GO terms that were significantly en-
riched in the ICGC data, but there were no pathways that were common across all
cancer types. One thing noted from these results was that all three databases (GO,
KEGG and Reactome) identified the “ABC transport” pathway as significantly en-
riched in the CESC data set. This suggests that the “ABC transport” pathway may
have an important role in CESC tumour development in obese patients. There
was no significantly enriched pathway that was associated with obesity in the
combined ICGC data sets.
Although there was no common pathway that associated with obesity in the
ICGC data sets, it was evident from the CR and FM obesity metagenes that the
obesity metagenes were associated with the gene expression of the obesity signa-
tures. This suggested that the metagenes were able to identify some sort of genetic
pattern in the data, even though these metagenes were not significantly associated
with obesity.
5.1.5 False positives in the gene expression analyses
The fact that there were so many false positives in the DEGs from the ICGC data
sets indicated that the use of the patient BMI and BMI status as the “treatment”
conditions (in other words independent variable) for gene expression analysis was
prone to Type I errors. This meant that there was very little evidence of true
obesity-associated genetic signatures in any of the data sets that were explored
in this project, or perhaps the patient BMI and BMI status was not enough to
pinpoint the underlying biological relationship between obesity and cancer (also
see Section 5.2.1).
Evidence of a large number of false positives was also seen in Section 3.3.1,
where there were many DEGs identified from the gene expression analyses when
obesity-associated genetic signatures were sought for in the CR data set. This
suggested that there was a significant number of genes that were not related to
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obesity (false positives) in the genetic signatures. Furthermore, the fact that about
a third of the genes in any one of the obesity signatures were “unique” to each
of the individual obesity signatures supported the apparent abundance of false
positives in the signatures (Figures 10 and 11). From these results, it was likely
that the obesity signatures that resulted from the CR data set had many genes that
were false positives, perhaps due to the poor quality of the data set (Section 5.2.2).
Even if the patient BMI and/or BMI status was enough to identify the genes
that were truly associated with obesity, it would not be a trivial task to identify
the truly obesity-associated genes from those that were not, given a list of DEGs.
This raises an important question of whether the patient BMI was an appropriate
clinical variable to uncover the true association between obesity and cancer (more
in Sections 5.2 and 5.4).
5.1.6 Genetic signature captured by the obesity metagenes
In Chapter 4, analyses were carried out to determine what the genetic pattern the
obesity metagenes from Chapter 3 were associating with. The pathway-associated
genetic signatures from the Gatza et al. (2010) study were used to establish the
biological connection with the obesity-associated genetic signatures. In order to
make the obesity- and pathway-associated genetic signatures comparable with one
another, the orientations of the metagenes were examined so that all of the meta-
genes were in a consistent orientation (see Section 4.1).
Once the directions of the metagenes were determined, the obesity metagenes
were clustered together in the heatmap to visualise the similarity of the obesity
metagenes with the pathway metagenes. The heatmap revealed that all of the obe-
sity metagenes that have originated from the CR data clustered together in a group
with no other pathway metagenes correlating with these metagenes, which meant
that the obesity metagenes were not similar to any of the pathway metagenes from
the Gatza et al. (2010) study. The clustering of the obesity metagene was not
surprising, as the results from Section 3.3.2 already showed that the metagenes
were highly correlated with one another. This result showed that all of the obesity
metagenes created from the CR data associated with an unknown genetic signa-
ture that was not related to any of the pathway-associated genetic signatures from
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the Gatza et al. (2010) study.
The obesity metagene from the Fuentes-Mattei et al. (2014) study was a cluster
of its own, where the metagene did not group with any of the obesity metagenes
derived from the CR data set, nor with any of the GT pathway metagenes. Though
Fuentes-Mattei et al. suggested a biological link with the Akt/mTOR pathway in
their study, the result from the heatmap did not support that finding. This may have
been due to the inconsistency of the pathway metagene scores across different data
sets as mentioned in Section 4.2. In fact, the Akt pathway metagene scores were
variable across different cancer data sets (Appendix B), which suggested the Akt
pathway genetic signature was of poor quality.
5.1.7 Linear models to predict the obesity metagenes
To further investigate whether there was any evidence of a pathway signature be-
ing related to the obesity-associated genetic signatures, linear models were created
in the NZBC data set with the pathway metagene scores. First, linear models were
created with the patient BMI, BMI status and a selection of the most “consistent”
pathway metagene scores (based on the consistency across different data sets).
From these linear models, PR pathway metagene scores showed a significant con-
tribution to the model in predicting the obesity-associated metagene scores in all
of the linear models, with the exception of the FM obesity metagene (where Myc
was the significant variable; Appendix B10).
This was not surprising since all but the FM obesity metagene were derived
from the CR data set, and therefore the FM obesity metagene was likely to be dif-
ferent to those from the CR data set. Adding to this, differences between the CR
and FM metagenes were also shown in the heatmap of the obesity and pathway
metagenes mentioned earlier, where the FM metagene clustered with neither the
CR obesity metagenes nor with any other pathway metagenes. This implied that
the FM metagene differed fundamentally from the CR obesity metagenes. Never-
theless, to clarify the significance of the PR pathway with the obesity metagenes,
linear models were also created with PR pathway metagene in combination with
the patient BMI and/or BMI status.
The predictions of the obesity metagene scores were made using the linear
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models created in the NZBC data set. All of the predicted obesity metagene scores
significantly correlated with the true obesity metagene scores in both the NZBC
(training) and CR (testing) data sets. However, the R2-values for all of these pre-
dictions were low (highest R2 ≈ 0.42; Appendix B12) with highly variable data
points in the scatter plots. It was unclear from these predictions and plots whether
the models explained the true underlying biological mechanisms of the obesity-
associated genetic signatures. Nevertheless, the models did explain some varia-
tions in the obesity metagenes, but there may be some other unknown biological
processes that provide more information about the signatures.
Since linear models were created only with the “consistent” pathway meta-
gene scores, a step wise method was used to generate linear models that included
the patient BMI, BMI status and all of the pathway metagenes that allowed the
model to predict the true obesity metagene the best. As shown by the results in
Section 4.3, all of the models predicted the true obesity metagene scores with high
R2-value in the CR data set (highest R2 ≈ 0.89) and were statistically significant.
This meant that the variables that were significant in the linear models played a
role in the obesity-associated genetic signatures. There was no single pathway sig-
nature that was common to all of the linear models, but Akt, EGFR, TGFβ and Src
pathway metagenes were included in many of the models, which suggested that
these pathway signatures may have an important role in the obesity-associated
genetic signatures (Section 4.3.2).
5.1.8 Significance of the pathway-associated signatures with the
obesity-associated signatures
The linear models that were created from the “consistent” pathway signatures in
the NZBC data set showed significant association of the PR pathway with the
obesity metagenes. But was this due to the true biological relationship between
the PR pathway and the obesity metagenes, or only because the models were
created in the NZBC data set? In fact, the proportion of patients that were PR+
was greater in the NZBC data set (62 PR+ and 37 PR− patients) compared with
the CR data set (48 PR+ and 50 PR− patients), which implied that the patients
in the NZBC data set were more likely to show association with the PR pathway
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metagene.
However, with this logic, the ER pathway signature would as likely to be as-
sociated, as the patient ER status was similar to the PR status in either data sets:
72 ER+ and 27 ER− patient in the NZBC data, and 58 ER+ and 42 ER− patients
in the CR data set. The fact that the ER pathway signature was not significant in
the models suggested that the obesity metagenes were related to the PR pathway
irrespective of the patient PR status. Furthermore, both the NZBC and the CR data
sets showed strong association between the PR and ER pathway metagenes with
the patient PR and ER status, respectively (Appendix A10). Since both ER and
PR signatures were significantly associated with the patient ER and PR statuses,
both signatures would have been as equally likely to show up significant in the
models, supporting the idea that the ER and PR statuses were independent of the
apparent significance of these signatures in the models.
In the step wise linear models, many variables were identified to be signifi-
cantly associated with the obesity metagenes. This suggested that the pathway-
associated genetic signatures that were significant in these models may be biolog-
ically related to the obesity phenotype, or perhaps the obesity-associated genetic
signatures were detecting signals from these pathways rather than the signals from
the obesity phenotype. In fact, many of the variables included in the linear models
were pathway metagenes that negatively correlated with the obesity metagenes in
Figure 18 (Section 4.2.2). Since all of the obesity metagenes failed to show signif-
icant association with patient BMI, it may be possible that these pathways (Akt,
ER, EGFR, PR, p53, Src and TGFβ ) are actually what was being detected by the
“obesity” metagenes.
With that said, even if these pathway signatures were related to the underlying
biology of breast cancer, the fact that these results depended on the pathway-
associated genetic signatures from the Gatza et al. (2010) study makes the results
questionable. This was due to the lack of consistency of the metagenes across
different cancer data sets, where more than half of the pathway metagenes showed
a correlation of less than 0.8 in at least one data set (Section 4.2). This meant
that at least half of the signatures were specific to the GT data set and could be
highly variable in the other data sets, reflecting the potential differences in the
cohorts (at the molecular level). Thus, without further validation of the quality
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of the pathway-associated genetic signatures and verification of the roles of these
signatures in the biological relationship between obesity and cancer, these results
should be interpreted with care.
5.2 Limitations
5.2.1 Definition of obesity
First and possibly the most important limitation to this project was the use of
BMI as a measurement for obesity and its subsequent classification of the patients
based on BMI. Obesity is a term given to those individuals with excessive amount
of fat and can be defined in various ways. It was important to define the obese
phenotype accurately, as all of the obesity-associated genetic signatures, gene ex-
pression analyses and pathway enrichment analysis were dependent on the patient
BMI status. BMI is perhaps the most popular measurement to estimate obesity
owing to the relative ease of measurement in clinical settings, and hence used
in various clinical trials and large epidemiological studies as an indication of the
patients’ metabolic state. However, there have been studies that showed other
measurements, such as waist-to-height ratio and waist-to-hip ratio, to be a better
representation of the patients’ obesity status (Dalton et al., 2003; Lee et al., 2008).
Perhaps the reason why there were so many false positives when gene ex-
pression analyses were carried out in Section 5.1.5 was because BMI was used
to classify the patients into their corresponding BMI statuses, instead of another
measurement. It was likely that the patient BMI (and therefore BMI status) was
not good enough a phenotypic characteristic to describe the underlying biology
driven by obesity. Since the gene expression analyses were based on such “vague”
parameter, it may have picked up many genes that were apparently related to obe-
sity when in fact the genes were not related to obesity at all.
Ideally, multiple measurements that are indicative of obesity should be made
in order to determine the obesity status of the patients to make a more accurate
classification. Additional measurements such as blood lipid profiles and insulin
levels may also help understand the underlying biological state in which the pa-
tients are in, and would greatly help focus on the genes that are truly affecting the
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patients. However, these measurements are difficult to carry out in a systematic
fashion in a clinical setting, and to collate existing patient data with these mea-
surements to make a data set that is large enough for the analyses done in this
project may be impossible. Nevertheless, even the measurement of waist circum-
ference in addition to BMI may significantly help describe the obesity phenotype
more accurately in future investigations.
5.2.2 Quality of the data
Another limitation of this work was the quality of the data sets. All of the data
sets used in this project were from an online and publicly available source, and
the types of data sets used were either microarray or RNA-seq data. The first
potential problem with using open source data from other research groups is that
the data are generated by multiple different groups with different technologies and
experimental protocols. Since different laboratories have their own way to carry
out certain experiments, the sequence data from each of the studies used in this
project may have been produced and processed in a completely different manner,
not to mention the use of different patient cohorts in each experiment.
For example, in the Creighton et al. (2012) study, the patient breast tumour
biopsies were “trimmed such that all the samples had ≥ 70% tumour cells” in
the samples. Fuentes-Mattei et al. (2014) only mentioned that they used breast
tumour biopsies from patients with no comment about the quality or quantity of
the biopsies. Without a doubt, the difference in how the samples were handled
can affect the quality of the data, and make it challenging to compare different
data sets (Irizarry et al., 2005). In fact, observations were made in this project that
suggested the data set from the Creighton et al. (2012) study was of poor quality
(see Section 5.1.5).
Although the underlying quality of the data provided by these studies could not
be improved in any way, best efforts were made to ensure the data sets were free of
other factors that may affect the results. This leads to the second problem: the dif-
ferent technologies used in the studies. All of Creighton et al., Fuentes-Mattei et
al., NZBC and Gatza et al. data sets were analysed using microarray technology,
whereas all of the ICGC cancer data sets were generated with NGS technology.
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As mentioned in Section 2.3.1, the two technologies use fundamentally different
principals to output the sequence information of the sample; microarray uses light
intensity and NGS uses count data.
In order to make these two different types of data comparable to one another,
normalisation methods from the limma package were used (see Section 2.3.1).
This enabled the standard limma analysis pipelines, normally used for the analysis
of microarray data, to be used by the ICGC cancer RNA-seq data sets. In this
way, the results from the two types of data sets were fairly reliable and consistent,
as the same analysis methods were applied to the data sets. In addition to the
difference in the sequencing technologies, the Gatza et al. data set comprised
multiple different data sets, each from different sources. Since individual data
sets had their own experimental differences (for example, “batch effects”), it was
important to correct for these differences when multiple data sets were combined
into one (see Section 2.3.4). In this project, batch corrections were made in the
Gatza et al. data set and the combined ICGC cancer data sets (used in Section 3.5)
to eliminate the batch effects.
5.2.3 Quality of the genetic signatures
The final limitation to consider was the quality of the genetic signatures used in
this project. This limitation is partly related to Section 5.2.2, as the identifica-
tion of the genetic signatures depended on the quality of the data as well as the
definition of the signature in the first instance (for example, obesity or Akt over-
expression).
Firstly, the obesity signatures identified by both Creighton et al. and Fuentes-
Mattei et al. relied on the definition of obesity based on the patient BMI values.
As discussed in Section 5.2.1, the use of BMI may not have been the best mea-
surement for obesity. In fact, both CR and FM obesity signatures associated with
different pathway signatures in Sections 4.2 and 4.3, which suggested that obesity
as defined by BMI was not enough to reveal the underlying biological character-
istics of obesity, and hence showed association with different pathway signatures.
Furthermore, as mentioned in Section 5.2.2, it was likely that the CR data set (and
perhaps other data sets as well) was of poor quality and may have affected the
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ability of the generated signatures as a marker for obesity in cancer.
Secondly, the method in which the pathway-associated genetic signatures was
defined in the Gatza et al. (2010) study may have been questionable. In their stud-
ies, Gatza et al. used model cell lines to identify the pathway-associated genetic
signatures by altering the expression of the representative gene for the pathway
and assigned all of the genes affected by the change in representative gene ex-
pression to be associated with that pathway (Bild et al., 2006; Gatza et al., 2010).
However, some of these pathway-associated genetic signatures were derived in
different cell lines to one another, which meant that some pathway signatures may
not reflect the true pathway activity in vivo. In fact, as seen in Sections 4.1 and 4.2,
some pathway signatures produced more consistent metagenes from the data sets
than the other signatures. These results were merely an indication that the pathway
signatures may have reflected the pathway activities poorly, and it was not possi-
ble to determine whether these signatures were truly related to the corresponding
pathways, as the original data was not available to reference the signatures back
for validation. With that said, few of the pathway signatures correlated well with
some clinical variables (such as ER and PR), so not all signatures may have been
of poor quality (Appendix A10).
5.3 Conclusion
There were two main aims to this project: firstly to determine whether there were
any obesity specific genetic signatures that could be transferred across multiple
cancer types; and secondly to investigate whether there were any biological path-
ways dysregulated in the tumour samples from the patients that were obese com-
pared to the samples from non-obese patients. These aims were addressed in
Chapters 3 and 4, respectively.
As shown clearly by the results from Chapter 3, there seemed to be no genetic
signatures that were able to differentiate between the tumour samples from the
patients that were obese from those that were not, across different cancer types.
Furthermore, there were no genes differentially expressed between obese and non-
obese patients that were common across multiple cancer types. These results have
suggested that there were no obesity specific genetic signatures that were common
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across different cancer types. The results from Chapter 4 showed that the obesity-
associated genetic signatures generated from the Creighton et al. data set were
different from those generated from the Fuentes-Mattei et al. data set. None of the
pathway-associated genetic signatures showed positive correlation with any of the
obesity-associated genetic signatures in the heatmap. However, all of the obesity
metagenes derived from the Creighton et al. showed strong negative correlation
with the Akt, ER, EGFR, PR, p53, Src and TGFβ pathways. This suggested that
the obesity-associated genetic signatures were picking up the signals from these
pathways, rather than the signals from the obesity phenotype of the patients.
To summarise, there were no common genetic signatures that significantly as-
sociated with the obesity status of the patients. However, the Akt, EGFR, TGFβ
and Src pathways may have a role in promoting the tumour progression in pa-
tients that are obese. Further investigations with good quality data sets and larger
patient cohorts are required to clarify the biological relationship between obesity
and cancer.
5.4 Future directions
This project has managed to show that there were no obesity specific genes that
were common across multiple cancer types. Although this study failed to identify
obesity specific genes that affected tumour biology, it is likely that there is some
complex mechanism underlying the relationship between obesity and cancer; oth-
erwise many of the clinical and epidemiological associations between obesity and
cancer risk would not make any sense. Since Akt, EGFR, TGFβ and Src path-
ways were significant in the linear models that predicted the obesity metagenes,
more thorough investigation of these pathways may be a good start to clarify the
relationship. Further analyses of BLCA may help clarify the similarity between
bladder and breast cancer types and provide insight into the association between
the obesity-associated genetic signatures and BLCA.
In this project, the lack of association of the obesity-associated genetic signa-
tures with any of the cancer types could have been due to the quality of both the
raw data sets and the genetic signatures used in this project. Furthermore, the use
of BMI may have been insufficient to describe the patients’ obesity status, and
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would likely require more informative clinical measurements (such as waist cir-
cumference) to aid the classification. Therefore, careful selection of the raw data
sets with sufficient, and if possible, additional information (such as waist circum-




Additional results from Chapter 3
A1 Comparison of the Creighton et al. obesity meta-

















































































































Creighton metagene comparison (raw values)




































































































































Creighton metagene comparison (ranked values)
















Figure S1: Scatter plots showing the raw and ranked Creighton et al. obesity metagene scores
from the standardised or non-standardised CR data. The RMA-normalised CR data
was standardised or used as is to generate the obesity metagene scores. The metagene
scores were ranked based on the number of samples in the CR data set.
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A2 Comparison of the Creighton et al. obesity meta-
gene in standardised or non-standardised ICGC data
As shown in Figure S2, the Creighton et al. obesity metagene values generated
from the transformation matrices (from standardised or non-standardised CR data)
were more consistent (or less variable) in the standardised ICGC BLCA data,
compared with the non-standardised data. Results from Figure S3 suggested that
there was no obvious difference in the quality of the metagenes generated from
standardised or non-standardised TM. Only the results from BLCA data set are


















































































































































































































































































CR obesity metagene in non−standardised BLCA data



































































































































































































































































































CR obesity metagene in standardised BLCA data




















Figure S2: Scatter plots comparing the Creighton et al. obesity metagene generated from the
transformation matrix (from standardised or non-standardised CR data) in the non-
standardised (left) and standardised (right) ICGC BLCA data.
A3 Remainder of the results of FM obesity metagenes
in the ICGC cancer data sets
Figure S4 shows the association of the FM obesity metagene with the gene ex-
pression pattern of the FM obesity-associated genetic signature in the other ICGC


















































































































































































































































































Non−standardised TM−generated CR obesity metagene in BLCA data



































































































































































































































































































Standardised TM−generated CR obesity metagene in BLCA data




















Figure S3: Scatter plots comparing the Creighton et al. obesity metagene from the non-
standardised and standardised ICGC BLCA data, generated by the application of the
transformation matrix from the non-standardised (left) or standardised (right) CR data.
scores with the patient BMI and BMI status. Clearly, the FM metagene was able
to capture the overall gene expression patterns, but was not significantly associ-
ated with the patient BMI or BMI status.
A4 Direction of all the obesity metagenes from the CR
data
The direction of the obesity metagenes identified from the CR data were examined
and corrected for (Figure S6). Gene probes that were common to all obesity-
associated genetic signatures were used to examine whether the metagene was in
the correct direction, relative to the other obesity metagenes
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FM metagene (CESC)











































Figure S4: Heatmaps showing the association of the FM obesity metagenes with the sample gene

























p = 0.7888 p = 0.3629












































































































































































































































FM metagene (CESC) vs. BMI











Figure S5: Box plots and scatter plots showing the association of the FM obesity metagene with
the patient BMI status and BMI, respectively, in the ICGC data sets. P-values and
R2-value are as described in previous figures.
A5 Remainder of the results of the other CR obesity
metagenes in the CR data set
All of the other obesity metagenes identified from the CR data set were able to
capture the overall gene expressions of the samples in the CR data set (Figure S7).
Furthermore, all of the CR obesity metagenes were significantly associated with
the patient BMI/BMI status in the CR data set (Figure S8).
A6 Remainder of the results of the other CR obesity
metagenes in NZBC data set
All of the other obesity metagenes from the CR data set were able to capture
the overall gene expressions of the samples in the NZBC data set (Figure S9).
However, none of the CR obesity metagenes were able to significantly associate

























p = 0.7903 p = 0.4622










































































































































































































































FM metagene (COAD) vs. BMI


































p = 0.3921 p = 0.7525










































































































































FM metagene (KIRP) vs. BMI


































p = 0.2751 p = 0.9284

















































































































































































































































































FM metagene (LIHC) vs. BMI




































p = 0.9735 p = 0.7204























































































FM metagene (READ) vs. BMI


































p = 0.9551 p = 0.2098





































































































































































































































FM metagene (SKCM) vs. BMI


































p = 0.3247 p = 0.1345

























































































































































































































































































































































































































































































FM metagene (UCEC) vs. BMI













































































Figure S6: Heatmaps showing the gene expression of the obesity-associated genetic signatures
with the obesity metagene in RMA-normalised CR data set. The gene probes that were
common to all of the obesity-associated genetic signatures were used to determine the
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S7: Heatmaps showing the association of the other obesity metagenes identified from the
CR data with the sample gene expressions from the NZBC data set. Scales are as

























p = 0.3777 p = 0.0007809





















































































































Cr obesity metagene vs. BMI











Figure S8: Box plots and scatter plots showing the association of the other CR obesity metagenes
with the sample BMI status and BMI from the NZBC data set, respectively. P-values
and R2-value are as described in previous figures.
A7 Remainder of the results of the other CR obesity
metagenes in the ICGC cancer data sets
As shown in Figure S11, the original obesity metagene from the Creighton et al.
study was reflective of the sample gene expression levels of the obesity-associated
genetic signature in all of the other ICGC cancer data sets. However, none of the
ICGC cancer data sets (other than the BLCA data set; Figure 5 in Section 3.1)
showed any significant association of the sample BMI or BMI status with the Or
obesity metagene (Figure S12). The heatmaps, box plots and scatter plots for the
other CR obesity metagenes in other ICGC cancer types are not shown, as many
of the plots were very similar to the plots from the BLCA data set. The statistics
from the results of the box and scatter plots in the other ICGC cancer types were
summarised in Tables S1 to S7.
A8 Obesity-associated genetic signature using sample
BMI values
Since all of these obesity-associated genetic signatures were derived based on the

























p = 0.3771 p = 2.83e−05





















































































































CrOl obesity metagene vs. BMI


































p = 0.3305 p = 0.003513





















































































































Res obesity metagene vs. BMI


































p = 0.375 p = 0.000251





















































































































ResOl obesity metagene vs. BMI




































p = 0.3635 p = 0.005981





















































































































Ca obesity metagene vs. BMI


































p = 0.2427 p = 0.0006367





















































































































CaOl obesity metagene vs. BMI


































p = 0.3493 p = 0.01279





















































































































CaRes obesity metagene vs. BMI



























































Figure S9: Heatmaps showing the association of the other obesity metagenes identified from the
CR data with the sample gene expressions from the NZBC data set. Scales are as

























p = 0.9072 p = 0.2047

















































































































CrOl (NZBC data) vs. BMI











Figure S10: Box plots and scatter plots showing the association of the other CR obesity metagenes
with the sample BMI status and BMI from the NZBC data set, respectively. P-values
and R2-value are as described in previous figures.
Table S1: Statistics of all the obesity metagenes in the ICGC CESC cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.9332 0.5302 0.7622 -0.003950 0.7265
Res 0.9205 0.3369 0.6043 0.004249 0.8122
CrOl 0.8940 0.1430 0.2959 -0.0004927 0.3465
ResOl 0.9930 0.1705 0.3078 0.003263 0.1898
Ca 0.8861 0.3616 0.6426 -0.003307 0.6073
CaRes 0.8323 0.3330 0.6167 -0.003832 0.7001
CaOl 0.9124 0.1602 0.2600 -0.001612 0.4242
CaResOl 0.9646 0.1663 0.2863 0.003097 0.1946
Table S2: Statistics of all the obesity metagenes in the ICGC COAD cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.2843 0.8176 0.5460 -0.004373 0.8865
Res 0.4091 0.8473 0.7064 -0.004243 0.8245
CrOl 0.4063 0.9295 0.6150 -0.00397 0.7400
ResOl 0.3748 0.8484 0.5295 -0.004020 0.7532
Ca 0.6507 0.7692 0.7579 -0.002493 0.5075
CaRes 0.4565 0.9808 0.7161 -0.004278 0.8385
CaOl 0.2931 0.9217 0.4621 -0.00425 0.8273

























p = 0.9087 p = 0.2035

















































































































Res (NZBC data) vs. BMI


































p = 1 p = 0.2287

















































































































ResOl (NZBC data) vs. BMI


































p = 0.6283 p = 0.2298

















































































































Ca (NZBC data) vs. BMI




































p = 0.5518 p = 0.4305

















































































































CaOl (NZBC data) vs. BMI


































p = 0.578 p = 0.2613

















































































































CaRes (NZBC data) vs. BMI


































p = 0.6717 p = 0.3719

















































































































CaResOl (NZBC data) vs. BMI





























































Figure S11: Heatmaps showing the association of obesity metagene from the Creighton et al.
(2012) study with sample gene expression from the other ICGC data sets. Level
of expression is represented in the top left histogram, where low and high gene ex-
pression were colour-coded with blue and red, respectively. Each row of the heatmap
represents a gene from the obesity-associated genetic signature, and each column of
the heatmap represents a sample from the ICGC data. The obesity-associated meta-
gene scores of the samples are shown in a separate row at top of the heatmap, and


























p = 0.9756 p = 0.1548













































































































































































































































Creighton metagene (CESC) vs. BMI


































p = 0.524 p = 0.9131










































































































































































































































Creighton metagene (COAD) vs. BMI











Figure S12: Box plots and scatter plots showing the association of obesity metagene from the
Creighton et al. (2012) study with the sample BMI status and BMI from the other
ICGC data sets, respectively. In the box plot, the p-values above the groups represent
the statistical significance of the association of the metagene with the overweight or
obese group compared with the normal weight group. The ANOVA p-value shows the
statistical significance of the association of the metagene with the sample BMI groups.
In the scatter plot, R2- and p-values describe the adjusted coefficient of determination
of the regression line and the statistical significance of the linear model used to draw

























p = 0.296 p = 0.2444










































































































































Creighton metagene (KIRP) vs. BMI


































p = 0.8477 p = 0.7185

















































































































































































































































































Creighton metagene (LIHC) vs. BMI


































p = 0.9916 p = 0.1507























































































Creighton metagene (READ) vs. BMI




































p = 0.6606 p = 0.1886





































































































































































































































Creighton metagene (SKCM) vs. BMI


































p = 0.4978 p = 0.1151



































































































































































































































































































































































































































































































Creighton metagene (UCEC) vs. BMI












Table S3: Statistics of all the obesity metagenes in the ICGC KIRP cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.1853 0.2590 0.3387 -0.005657 0.5798
Res 0.1063 0.1825 0.2128 -0.005037 0.5368
CrOl 0.2576 0.1757 0.3162 -0.005763 0.5879
ResOl 0.3120 0.1738 0.3198 -0.004513 0.5048
Ca 0.2431 0.2142 0.3591 -0.005582 0.5743
CaRes 0.2327 0.2344 0.3738 -0.006250 0.6279
CaOl 0.3426 0.2775 0.4693 -0.007333 0.7747
CaResOl 0.2643 0.1315 0.2410 -0.001408 0.3649
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Table S4: Statistics of all the obesity metagenes in the ICGC LIHC cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.4033 0.2900 0.5221 0.006348 0.1028
Res 0.5008 0.8743 0.8004 -0.0003709 0.3430
CrOl 0.7599 0.8562 0.9189 -0.001554 0.4424
ResOl 0.9238 0.9773 0.9938 -0.001283 0.4162
Ca 0.4898 0.8221 0.7917 0.0005899 0.2834
CaRes 0.5976 0.9929 0.8638 -0.001090 0.3990
CaOl 0.8717 0.8834 0.9679 -0.002010 0.4925
CaResOl 0.5369 0.7185 0.7073 -0.0004212 0.3465
Table S5: Statistics of all the obesity metagenes in the ICGC READ cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.9129 0.4008 0.5942 -0.0132 0.8038
Res 0.7737 0.2244 0.4308 -0.008917 0.5484
CrOl 0.8439 0.1283 0.2643 0.001024 0.3036
ResOl 0.6953 0.06841 0.1766 0.01099 0.1840
Ca 0.6298 0.1326 0.2960 -0.001242 0.3432
CaRes 0.6302 0.1053 0.2453 0.001989 0.2885
CaOl 0.6871 0.1411 0.3358 -0.004847 0.4219
CaResOl 0.8821 0.08474 0.1817 0.001095 0.3025
Table S6: Statistics of all the obesity metagenes in the ICGC SKCM cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.7115 0.3329 0.6264 0.002887 0.2033
Res 0.7604 0.5408 0.6396 -0.001725 0.4296
CrOl 0.4719 0.1224 0.2913 0.01261 0.05347
ResOl 0.8640 0.1668 0.3051 0.01541 0.03721
Ca 0.8792 0.2084 0.3739 0.006674 0.1184
CaRes 0.8098 0.1950 0.3677 0.005746 0.1347
CaOl 0.9478 0.2726 0.4471 0.01009 0.07449
CaResOl 0.7309 0.2561 0.2830 0.01606 0.03421
1 All values in bold are statistically significant (p < 0.05).
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Table S7: Statistics of all the obesity metagenes in the ICGC UCEC cancer data
P-values Regression line statistics
Metagenes Overweight Obese ANOVA R2 P
Cr 0.8357 0.08117 0.1039 0.006952 0.037161
Res 0.8664 0.2023 0.3131 0.001998 0.1619
CrOl 0.9251 0.3800 0.5800 -0.000311 0.3569
ResOl 0.5826 0.09608 0.2156 0.003487 0.1021
Ca 0.7491 0.1103 0.1905 0.003811 0.09260
CaRes 0.8086 0.2002 0.3419 0.0005824 0.2584
CaOl 0.9068 0.2672 0.4153 0.00305 0.1166
CaResOl 0.8360 0.2440 0.4034 0.00022898 0.2863
1 All values in bold are statistically significant (p < 0.05).
sample BMI value (continuous variable). Gene probe expressions were correlated
with the sample BMI values and were corrected for multiple hypothesis testing
with FDR. There were no significant gene that correlated with the sample BMI (p
< 0.05).
With that said, the top 799 gene probes that correlated the most with the sam-
ple BMI were examined to see if there was any association. The results were
similar to the other obesity-associated genetic signatures: the continuous BMI
signature significantly associated with sample BMI and BMI status in the CR
data, but did not show any significance in any of the other cancer data.
A9 Pathways significant in each of the cancer types
The complete list of all the pathways significantly enriched using different path-
way databases (FDR adjusted p-value < 0.05) are summarised in Tables S8 to S10.
146
Continuous BMI genes (CR data)




























p = 0.8508 p = 7.83e−05




















































































































Continuous BMI genes (CR data) vs. BMI











Figure S13: Heatmap, box plot and scatter plot showing the association of the continuous BMI
metagene with the sample gene expression, BMI and BMI status, respectively, in var-
ious cancer data. Scales, p-values and R2-value are as described in previous figures.
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Continuous BMI genes (BLCA)





























p = 0.543 p = 0.584

















































































































































































































































































Continuous BMI genes (BLCA) vs. BMI













Continuous BMI genes (NZBC data)




























p = 0.5259 p = 0.1202

















































































































Continuous BMI genes (NZBC data) vs. BMI























1 Not available (no pathway enriched)
Table S9: Significantly enriched Reactome pathways in ICGC cancer data
Cancer type Pathway
BLCA Phosphate bond hydrolysis by NUDT proteins







1 Not available (no pathway enriched)
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Table S10: Significantly enriched GO pathways in ICGC cancer data
Cancer type Pathway
BLCA Nucleobase-containing small molecule catabolic process
SUMO-specific protease activity
Diphosphoinositol-polyphosphate diphosphatase activity


















Pyrimidine deoxyribonucleotide catabolic process
Nucleotidase activity
G-protein coupled neurotensin receptor activity








CESC ATP-binding cassette (ABC) transporter complex
Protein delipidation
Atg8 ligase activity
Cyclin-dependent protein kinase 5 holoenzyme complex
Molybdopterin synthase complex
Negative regulation of nodal signaling pathway
Aspartate-tRNA ligase activity
Peroxisomal long-chain fatty acid import
Sterol-transporting ATPase activity
Negative regulation of intestinal phytosterol absorption
Negative regulation of intestinal cholesterol absorption
Apolipoprotein A-I receptor activity
Sulfonylurea receptor activity
Atg12 transferase activity
Superior olivary nucleus maturation
Cyclin-dependent protein kinase 5 activator activity
ATPase activity, coupled to transmembrane movement of sub-
stances
COAD NA
KIRP Trace-amine receptor activity
Regulation of viral release from host cell
Nuclear import
LIHC NA
READ Nuclear polyadenylation-dependent rRNA catabolic process
Nuclear polyadenylation-dependent tRNA catabolic process
Sodium channel complex
U1 snRNA 3’-end processing




Hydroxymethylglutaryl-CoA reductase (NADPH) kinase activity
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Table S10 (continued)
Acetyl-CoA carboxylase kinase activity
rRNA modification
Rab GDP-dissociation inhibitor activity
Nuclear retention of pre-mRNA with aberrant 3’-ends at the site
of transcription
Cellular polysaccharide biosynthetic process





Regulation of RIG-I signaling pathway
Regulation of cysteine-type endopeptidase activity









Posterior mesonephric tubule development
Regulation of stem cell differentiation




Rab GDP-dissociation inhibitor activity
UCEC SUMO-specific protease activity
Regulation of dendritic cell cytokine production
Detection of triacyl bacterial lipopeptide
153
Table S10 (continued)
Cellular response to triacyl bacterial lipopeptide
Toll-like receptor 1-Toll-like receptor 2 protein complex
Detection of diacyl bacterial lipopeptide
Cellular response to diacyl bacterial lipopeptide
Toll-like receptor 2-Toll-like receptor 6 protein complex
Diacyl lipopeptide binding
Coagulation
Polo kinase kinase activity
Regulation of protein serine/threonine kinase activity
DNA-dependent protein kinase complex
Methylosome
1 Not available (no pathway enriched).
A10 Results for ER and PR metagene analysis
To determine whether the results from all of the obesity metagene analyses were
not showing association with patient BMI because of the SVD/transformation
matrix approach used, the same approach was used with ER and PR pathway-
associated genetic signatures from the Gatza et al. (2010) study. Firstly, both the
ER and PR metagenes were generated in the RMA normalised CR data set. The
generated metagenes were compared with the gene expressions of the correspond-
ing pathway-associated genetic signatures, and the association with the patient ER
and PR statuses were also examined. As shown in Figures S14 and S15, both the
ER and PR metagenes in the CR data showed assocation with the gene expression
pattern of the pathway, and also showed significant association with the patient
ER and PR statuses.
The transformation matrices for the ER and PR metagenes were created in
the CR data, and was applied to the NZBC and FM data sets (RMA normalised).
As clearly shown by Figures S16 to S19, both the ER and PR metagenes asso-
ciated with the gene expressions of the corresponding pathway signature. More
importantly, both metagenes were significantly associated with the patient ER and
154
ER metagene in CR data






























p = 2.537e−15 p = 0.2077
ANOVA p = 3.052e−14
Figure S14: Heatmap and box plot showing the association of the ER metagene with the sample
gene expression and patient ER status, respectively, in the CR data. Scales for the
heatmap is as described in previou figures. P-values are calculated relative to the ER−
group.
PR metagene in CR data




























p = 4.901e−06 p = 0.7268
ANOVA p = 8.502e−06
Figure S15: Heatmap and a box plot showing the association of the PR metagene with the sample
gene expression and patient PR status, respectively, in the CR cancer data. Scales and
p-values are as described in previous figures.
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PR statuses, even though these metagenes were generated with the transforma-
tion matrices from the CR data. These results show that the approach taken in
this project does not affect the link between the genetic signature and the patient
phenotype, if such link exists between them.
ER metagene in NZBC data





























ANOVA p = 1.273e−15
Figure S16: Heatmap and box plot showing the association of the ER metagene with the sample
gene expression and patient ER status, respectively, in the NZBC data. Scales for the
heatmap is as described in previou figures. P-values are calculated relative to the ER−
group.
PR metagene in NZBC data
































ANOVA p = 4.866e−13
Figure S17: Heatmap and a box plot showing the association of the PR metagene with the sample
gene expression and patient PR status, respectively, in the NZBC cancer data. Scales
and p-values are as described in previous figures.
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ER metagene in FM data






























ANOVA p = 6.611e−38
Figure S18: Heatmap and box plot showing the association of the ER metagene with the sample
gene expression and patient ER status, respectively, in the FM data. Scales for the
heatmap is as described in previou figures. P-values are calculated relative to the ER−
group.
PR metagene in FM data





























ANOVA p = 6.102e−09
Figure S19: Heatmap and a box plot showing the association of the PR metagene with the sample
gene expression and patient PR status, respectively, in the FM cancer data. Scales and
p-values are as described in previous figures.
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Appendix B
Additional results from Chapter 4
B1 Ranking method for the pathway-associated genetic
signatures
To determine whether it was the best to rank the metagene scores based on the
number of samples or rank the scores with the probit method, the two ranking
methods were compared in scatter plots with the GT pathway metagenes in RMA
or MAS5 normalised GT data. Since the results from the RMA and MAS5 nor-
malised GT data were so similar to one another, only the results from the RMA
normalised data are presented (Figure S20). Figure S20 showed that the metagene
scores for all of the GT pathway-associated genetic signatures were approximately
the same in either of the ranking methods used.
B2 Normalisation method for the pathway-associated
genetic signature transformation matrices
To investigate whether the normalisation methods were important in the creation
of the pathway-associated genetic signature transformation matrices, and whether
the normalisation methods of the data affected the resulting metagenes, transfor-




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S20: Scatter plots comparing the GT pathway metagenes ranked with probit and ranked








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































then applied to the RMA or MAS5 normalised GT data set. The results in Fig-
ure S21 showed less variability of the metagene scores when the metagenes were
derived from the data with the same normalisation method, regardless of the trans-
formation matrix used to produce the metagenes. This was most clearly demon-
strated by the BCAT, ER, IFNα , IFNγ , p53 and PR pathway-associated genetic
signatures.
As mentioned in Section 4.1 some of the pathway metagenes showed greater
variability than the other pathway metagene scores. This was also seen in other











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S21: Scatter plots comparing the GT pathway metagenes derived from the transformation
matrices in RMA- or MAS5-normalised GT data set. All of the transformation matri-

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S22: Comparison of the pathway metagenes generated in the MAS5 normalised CR, FM
and NZBC data sets from the application of the transformation matrices derived from
either the RMA or MAS5 normalised GT data. Only the PR (top) and the TGFβ
(bottom) pathway metagenes are shown, due to the large number of scatter plots gen-
erated.
170
B3 Additional results used to determine the direction-
ality of the pathway metagenes
The directionality of the pathway metagenes were determined by comparing the
metagene values with the gene expression of the representative gene for the pathway-
associated genetic signature, as well as the gene expression pattern of the pathway
signature (Figure S23). Together with the original results presented by Gatza
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B4 Original result from the Gatza et al. (2010) study
The original result from the Gatza et al. (2010) study was used to determine the
directions of the GT pathway-associated genetic signatures in Section 4.1 (Fig-
ure S24).
Figure S24: Heatmap showing the correlation of all of the GT pathway-associated genetic signa-
tures with one another. Figure adapted from the Gatza et al. (2010) study.
B5 Correlation of the GT pathway metagenes in other
cancer data sets
The correlation of the pathway-associated genetic signatures were plotted as heatmaps
for the CR, FM and NZBC data sets to confirm that the pathway transformation
matrices from the GT data set were generating metagenes that were similar to
those in the original RMA normalised GT data. Most importantly, the pathway
metagenes generated from the transformation matrices had to cluster in a similar
pattern as the pathway metagenes in the GT data set. This was to confirm that
173
the directionality of the metagenes were conserved even after the transformation
matrices were applied to the data set
B6 Directionality of the obesity metagenes in the GT
data
The directionality of the CR obesity-associated genetic signatures were deter-
mined in the RMA normalised GT data set to make sure these signatures were
in the “correct” direction, and therefore able to be compared with the pathway-
associated genetic signatures appropriately. As clearly shown in Figure S26, the
Res metagene was flipped as the Res metagene was in the oppsite direction com-





























































































































































Figure S25: Heatmaps showing the correlation of all of the pathway metagenes with one another
in RMA normalised CR, NZBC and FM data sets. High and low correlation were
represented as red and blue, respectively, where the colours were matched with the


















































































B7 Visual comparison of the correlation of SVD and
TM generated pathway metagenes
This section provides visual comparison of the Spearman correlation of the SVD-
and TM-generated pathway and obesity metagenes in the CR, FM, GT and NZBC
data sets (Figure S27). The Akt, EGFR, HER2, p53, p63, PI3K, Ras, Src, STAT3,
TGFβ and TNFα pathway signatures showed a correlation of 0.8 or less in at least

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S26: Heatmaps showing the obesity metagenes from the CR data set with the gene expres-
sion of the obesity-associated genetic signatures in the RMA normalised GT data set.
High and low correlation were represented as red and blue, respectively, where the
colours were matched with the values on the scale shown in the top left histogram.




















































































































Figure S27: Visual comparison of the Spearman correlations of the SVD-derived and transforma-
tion matrix-derived pathway and obesity metagenes across different data sets
177



























































































































































































































































































































































































































































































































































































































































































































































































Figure S28: Heatmap showing the overlap of genes between the different pathway-associated sig-
natures. For each pair of pathway-associated signatures, the overlap of genes was
counted and divided by the total number of unique genes from the two signatures to
get a ratio. This ratio was then scaled and plotted as shown
B9 Correlation of the pathway and obesity metagenes
in other cancer data sets
Correlation of the pathway and obesity-associated genetic signatures were plotted
in a heatmap for the GT data in Section 4.2. In this section, the correlation of
these genetic signatures were plotted as heatmaps for the CR, FM and NZBC data
179
sets. Though each of the heatmaps show slightly different clustering patterns, the
results were similar to that in the GT data set; the CR obesity metagenes clustered





















































































































Figure S29: Heatmaps showing the correlation of all of the pathway and obesity metagenes with











































































































































































































































B10 Summary of the remainder of the linear models in
NZBC data
All of the linear models for the other CR and FM obesity metagenes were sum-
marised in this section. In all of the CR data set-derived obesity metagenes, the
PR metagene showed up as a significant variable in the linear models (Tables S11
to S18). For the linear model that predicted the FM obesity metagene scores, the
Myc pathway metagene was significant (Table S19).
182
Table S11: Description of the linear models constructed from the NZBC data to predict the CrOl
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI -0.001629 0.6900
BMI status only Overweight -0.02165 0.7800
Obese -0.1055 0.1360
BMI and BMI status BMI 0.01128 0.1092
Overweight -0.07985 0.3480
Obese -0.2611 0.0304






























1 All values in bold are statistically significant (p < 0.05).
183
Table S12: Description of the linear models constructed from the NZBC data to predict the Res
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI -0.001422 0.7280
BMI status only Overweight -0.001804 0.9810
Obese -0.09683 0.1710
BMI and BMI status BMI 0.01126 0.1099
Overweight -0.05990 0.4810
Obese -0.2522 0.0364






























1 All values in bold are statistically significant (p < 0.05).
184
Table S13: Description of the linear models constructed from the NZBC data to predict the ResOl
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI -0.0009922 0.8080
BMI status only Overweight -0.01515 0.8450
Obese -0.09063 0.2010
BMI and BMI status BMI 0.01105 0.1178
Overweight -0.07219 0.3978
Obese -0.2432 0.0442






























1 All values in bold are statistically significant (p < 0.05).
185
Table S14: Description of the linear models constructed from the NZBC data to predict the Ca
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI -0.001147 0.7790
BMI status only Overweight 0.01804 0.8160
Obese -0.08982 0.2030
BMI and BMI status BMI 0.01171 0.0957
Overweight -0.04241 0.6168
Obese -0.2515 0.0365






























1 All values in bold are statistically significant (p < 0.05).
186
Table S15: Description of the linear models constructed from the NZBC data to predict the CaOl
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI −3.953×10−5 0.9920
BMI status only Overweight 0.02958 0.7040
Obese -0.06411 0.3650
BMI and BMI status BMI 0.01136 0.1080
Overweight -0.02903 0.7334
Obese -0.2209 0.0671






























1 All values in bold are statistically significant (p < 0.05).
187
Table S16: Description of the linear models constructed from the NZBC data to predict the CaRes
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI 0.001442 0.72408
BMI status only Overweight -0.01840 0.8120
Obese 0.09338 0.1860
BMI and BMI status BMI -0.01141 0.1043
Overweight 0.04047 0.6328
Obese 0.2508 0.0369






























1 All values in bold are statistically significant (p < 0.05).
188
Table S17: Description of the linear models constructed from the NZBC data to predict the
CaResOl obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI 0.0004131 0.9194
BMI status only Overweight 0.02453 0.7520
Obese -0.06913 0.3290
BMI and BMI status BMI 0.01335 0.0582
Overweight -0.04436 0.6008
Obese -0.2533 0.0352






























1 All values in bold are statistically significant (p < 0.05).
189
Table S18: Description of the linear models constructed from the NZBC data to predict the Or
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI 0.001654 0.68532
BMI status only Overweight 0.005772 0.9410
Obese 0.1009 0.1540
BMI and BMI status BMI -0.01106 0.1162
Overweight 0.06284 0.4598
Obese 0.2535 0.0354






























1 All values in bold are statistically significant (p < 0.05).
190
Table S19: Description of the linear models constructed from the NZBC data to predict the FM
obesity metagene
Linear Model Variables Estimate P-value
BMI only BMI 0.002314 0.5708
BMI status only Overweight -0.1483 0.05670
Obese -0.08452 0.22910
BMI and BMI status BMI 0.01503 0.03091
Overweight -0.2258 0.007940
Obese -0.2920 0.01419






























1 All values in bold are statistically significant (p < 0.05).
191
B11 Summary of the remainder of the PR linear mod-
els in NZBC data
The PR-only linear models for the other obesity-associated genetic signatures that
were generated in the NZBC data were summarised in Tables S20 to S28. The
PR pathway metagene was significant in all of the linear models that predicted
the obesity metagenes derived from the CR data set Tables S20 to S27. On the
other hand, the sample BMI/BMI status were significant in the linear model that
predicted the FM obesity metagene Table S28.
Table S20: Description of the linear models constructed from the NZBC data to predict the CrOl
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR 0.4484 3.26×10−6 1
BMI and PR BMI -0.002084 0.5699
PR 0.4497 3.36×10−6
BMI status and PR Obese -0.09307 0.1440
Overweight -0.01989 0.7750
PR 0.4418 4.32×10−6




1 All values in bold are statistically significant (p < 0.05).
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Table S21: Description of the linear models constructed from the NZBC data to predict the Res
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR 0.4926 2.22×10−7 1
BMI and PR BMI -0.001923 0.5904
PR 0.4938 2.35×10−7
BMI status and PR Obese -0.08315 0.1790
Overweight 0.0001257 0.9990
PR 0.4862 3.00×10−7




1 All values in bold are statistically significant (p < 0.05).
Table S22: Description of the linear models constructed from the NZBC data to predict the ResOl
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR 0.4581 1.86×10−6 1
BMI and PR BMI -0.001457 0.6897
PR 0.4590 1.99×10−6
BMI status and PR Obese -0.07789 0.2200
Overweight -0.01336 0.8480
PR 0.4526 2.56×10−6




1 All values in bold are statistically significant (p < 0.05).
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Table S23: Description of the linear models constructed from the NZBC data to predict the Ca
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR 0.3850 8.34×10−5 1
BMI and PR BMI -0.001538 0.6848
PR 0.3859 8.67×10−5
BMI status and PR Obese -0.07917 0.2274
Overweight 0.01954 0.7857
PR 0.3782 0.0001060




1 All values in bold are statistically significant (p < 0.05).
Table S24: Description of the linear models constructed from the NZBC data to predict the CaOl
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR 0.3425 0.0005200 1
BMI and PR BMI -0.0003869 0.9201
PR 0.3428 0.0005530
BMI status and PR Obese -0.05462 0.4147
Overweight 0.03092 0.6742
PR 0.3373 0.0006470




1 All values in bold are statistically significant (p < 0.05).
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Table S25: Description of the linear models constructed from the NZBC data to predict the CaRes
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR -0.4255 1.13×10−5 1
BMI and PR BMI 0.001874 0.6140
PR -0.4267 1.17×10−5
BMI status and PR Obese 0.08159 0.2040
Overweight -0.02006 0.7760
PR -0.4186 1.44×10−5




1 All values in bold are statistically significant (p < 0.05).
Table S26: Description of the linear models constructed from the NZBC data to predict the
CaResOl obesity, using only the sample BMI, BMI status and the PR pathway meta-
gene score
Linear Model Variables Estimate P-value
PR only PR 0.4094 2.58×10−5 1
BMI and PR BMI -1.809d-06 0.9996
PR 4.094d-01 2.85×10−5
BMI status and PR Obese -0.05775 0.3740
Overweight 0.02613 0.7140
PR 0.4041 3.36×10−5




1 All values in bold are statistically significant (p < 0.05).
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Table S27: Description of the linear models constructed from the NZBC data to predict the Or
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR -0.4463 3.66×10−6 1
BMI and PR BMI 0.002108 0.5660
PR -0.4476 3.77×10−6
BMI status and PR Obese 0.088520 0.1650
Overweight 0.004028 0.9540
PR -0.4396 4.82×10−6




1 All values in bold are statistically significant (p < 0.05).
Table S28: Description of the linear models constructed from the NZBC data to predict the FM
obesity, using only the sample BMI, BMI status and the PR pathway metagene score
Linear Model Variables Estimate P-value
PR only PR -0.1285 0.2050
BMI and PR BMI 0.002446 0.5479
PR -0.1301 0.2012
BMI status and PR Obese -0.08819 0.2080
Overweight -0.1488 0.05500
PR -0.1306 0.1940




1 All values in bold are statistically significant (p < 0.05).
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B12 Summary statistics of the predicted obesity meta-
genes with sample BMI/BMI status in the NZBC
and CR data
Instead of presenting 11 scatter plots for the 10 obesity metagenes used in this
project, all of the R2- and p-values were summarised in Table S29.
Table S29: Table summarising the linear model statistics from the comparison of the various linear
model-predicted obesity metagenes scores with the corresponding obesity metagene
scores from the NZBC data set for all of the obesity metagenes
Obesity metagene Model R2 P-value
Cr BMI only 0.001852 0.2797
BMI and BMI status 0.02834 0.05237
Pathways only 0.2416 1.431×10−71
BMI and pathways 0.2466 1.031×10−7
BMI status and pathways 0.2719 1.883×10−8
BMI, BMI status and pathways 0.2814 9.811×10−9
PR only 0.2041 1.604×10−6
BMI and PR 0.2047 1.54×10−6
BMI status and PR 0.2249 4.237×10−7
BMI, BMI status and PR 0.2372 1.908×10−7
CrOl BMI only 0.001295 0.2910
BMI and BMI status 0.03509 0.03517
Pathways only 0.2041 1.604×10−6
BMI and pathways 0.2173 6.941×10−7
BMI status and pathways 0.2411 1.48×10−7
BMI, BMI status and pathways 0.2597 4.308×10−8
PR only 0.2024 1.786×10−6
BMI and PR 0.2056 1.458×10−6
BMI status and PR 0.2212 5.398×10−7
BMI, BMI status and PR 0.2336 2.417×10−7
Res BMI only 0.0008245 0.3011
BMI and BMI status 0.02452 0.06579
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Table S29 (continued)
Pathways only 0.2785 1.196×10−8
BMI and pathways 0.2780 1.233×10−8
BMI status and pathways 0.2914 4.887×10−9
BMI, BMI status and pathways 0.3195 6.576×10−10
PR only 0.2331 2.492×10−7
BMI and PR 0.2349 2.215×10−7
BMI status and PR 0.2538 6.38×10−8
BMI, BMI status and PR 0.2631 3.421×10−8
ResOl BMI only -0.002442 0.3851
BMI and BMI status 0.03878 0.02835
Pathways only 0.2384 1.762×10−7
BMI and pathways 0.2371 1.927×10−7
BMI status and pathways 0.2670 2.616×10−8
BMI, BMI status and pathways 0.2878 6.263×10−9
PR only 0.2251 4.198×10−7
BMI and PR 0.2257 4.044×10−7
BMI status and PR 0.2392 1.675×10−7
BMI, BMI status and PR 0.2568 5.207×10−8
Ca BMI only -0.0004067 0.3296
BMI and BMI status 0.03576 0.03383
Pathways only 0.2043 1.585×10−6
BMI and pathways 0.2077 1.28×10−6
BMI status and pathways 0.2342 2.321×10−7
BMI, BMI status and pathways 0.2487 8.927×10−8
PR only 0.1362 0.0001009
BMI and PR 0.1364 9.944×10−5
BMI status and PR 0.1643 1.876×10−5
BMI, BMI status and PR 0.1744 1.012×10−5
CaOl BMI only -0.006593 0.5509
BMI and BMI status 0.0301 0.04718
Pathways only 0.1323 0.0001273
BMI and pathways 0.1347 0.0001106
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Table S29 (continued)
BMI status and pathways 0.1487 4.802×10−5
BMI, BMI status and pathways 0.1657 1.725×10−5
PR only 0.1103 0.0004599
BMI and PR 0.1106 0.0004539
BMI status and PR 0.1235 0.0002134
BMI, BMI status and PR 0.1383 8.92×10−5
CaRes BMI only 0.001142 0.2943
BMI and BMI status 0.03048 0.04612
Pathways only 0.2181 6.586×10−7
BMI and pathways 0.2373 1.902×10−7
BMI status and pathways 0.2431 1.298×10−7
BMI, BMI status and pathways 0.2501 8.152×10−8
PR only 0.1566 2.979×10−5
BMI and PR 0.1586 2.654×10−5
BMI status and PR 0.1844 5.485×10−6
BMI, BMI status and PR 0.1957 2.707×10−6
CaResOl BMI only -0.006037 0.5225
BMI and BMI status 0.0413 0.02449
Pathways only 0.1719 1.183×10−5
BMI and pathways 0.1721 1.167×10−5
BMI status and pathways 0.1961 2.642×10−6
BMI, BMI status and pathways 0.2095 1.141×10−6
PR only 0.1571 2.894×10−5
BMI and PR 0.1574 2.843×10−5
BMI status and PR 0.17 1.327×10−5
BMI, BMI status and PR 0.1939 3.044×10−6
Or BMI only 0.0008035 0.3015
BMI and BMI status 0.03699 0.03147
Pathways only 0.2554 5.738×10−8
BMI and pathways 0.2568 5.234×10−8
BMI status and pathways 0.28 1.075×10−8
BMI, BMI status and pathways 0.2974 3.194×10−9
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Table S29 (continued)
PR only 0.2388 1.717×10−7
BMI and PR 0.2382 1.79×10−7
BMI status and PR 0.2531 6.663×10−8
BMI, BMI status and PR 0.2684 2.382×10−8
FM BMI only -0.008238 0.6563
BMI and BMI status 0.07438 0.003652
Pathways only 0.268 2.449×10−8
BMI and pathways 0.2645 3.106×10−8
BMI status and pathways 0.3067 1.654×10−9
BMI, BMI status and pathways 0.3653 2.112×10−11
PR only -0.004177 0.4434
BMI and PR 0.007149 0.1946
BMI status and PR 0.0394 0.02734
BMI, BMI status and PR 0.1166 0.0003183
1 All values in bold are statistically significant (p < 0.05).
Table S30: Table summarising the linear model statistics from the comparison of the predicted
obesity metagenes scores from the BMI status-only model with the corresponding obe-
sity metagene scores from the NZBC data set for all of the obesity metagenes
P-values
Obesity metagene Overweight Obese ANOVA
Cr 0.2002 0.1501 0.2591
CrOl 0.3126 0.1532 0.3134
Res 0.9708 0.1764 0.2576
ResOl 0.4001 0.1919 0.3950
Ca 0.1847 0.1099 0.2000
CaOl 0.3466 0.2325 0.4273
CaRes 0.1713 0.1154 0.2017
CaResOl 0.2976 0.1742 0.3439
Or 0.2669 0.1621 0.3074
FM 0.4191 0.05207 0.1206
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Table S31: Table summarising the linear model statistics from the comparison of the various linear
model-predicted obesity metagenes scores with the corresponding obesity metagene
scores from the CR data set for all of the obesity metagenes
Obesity metagene Model R2 P-value
Cr BMI only 0.1239 0.0001571
BMI and BMI status 0.0471 0.01568
Pathways only 0.1756 6.307×10−6
BMI and pathways 0.1407 5.596×10−5
BMI status and pathways 0.05509 0.009721
BMI, BMI status and pathways 0.04186 0.02147
PR only 0.1327 9.191×10−5
BMI and PR 0.1116 0.0003317
BMI status and PR 0.03887 0.02571
BMI, BMI status and PR 0.04176 0.02161
CrOl BMI only 0.18 4.738×10−6
BMI and BMI status 0.06523 0.005312
Pathways only 0.1296 0.000111
BMI and pathways 0.09006 0.00121
BMI status and pathways 0.02455 0.06179
BMI, BMI status and pathways 0.01941 0.08532
PR only 0.1817 4.249×10−6
BMI and PR 0.1558 2.188×10−5
BMI status and PR 0.07293 0.003359
BMI, BMI status and PR 0.07116 0.003732
Res BMI only 0.09072 0.001163
BMI and BMI status 0.04082 0.02287
Pathways only 0.2263 2.275×10−7
BMI and pathways 0.2012 1.206×10−6
BMI status and pathways 0.1184 0.0002191
BMI, BMI status and pathways 0.1005 0.0006487
PR only 0.1419 5.195×10−5
BMI and PR 0.1224 0.0001718
BMI status and PR 0.05342 0.01074
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Table S31 (continued)
BMI, BMI status and PR 0.05419 0.01026
ResOl BMI only 0.1535 2.536×10−5
BMI and BMI status 0.0466 0.01615
Pathways only 0.1581 1.899×10−5
BMI and pathways 0.1329 9.083×10−5
BMI status and pathways 0.05085 0.01252
BMI, BMI status and pathways 0.04523 0.01754
PR only 0.2067 8.421×10−7
BMI and PR 0.1936 1.979×10−6
BMI status and PR 0.1149 0.0002723
BMI, BMI status and PR 0.1097 0.0003713
Ca BMI only 0.07979 0.002233
BMI and BMI status 0.05026 0.01297
Pathways only 0.2379 1.042×10−7
BMI and pathways 0.2081 7.653×10−7
BMI status and pathways 0.09383 0.0009655
BMI, BMI status and pathways 0.07756 0.00255
PR only 0.09938 0.000692
BMI and PR 0.08114 0.00206
BMI status and PR 0.01059 0.1512
BMI, BMI status and PR 0.008212 0.1774
CaOl BMI only 0.1242 0.0001542
BMI and BMI status 0.05609 0.009156
Pathways only 0.08453 0.001683
BMI and pathways 0.07397 0.003157
BMI status and pathways 0.003647 0.244
BMI, BMI status and pathways 0.0003557 0.3111
PR only 0.1253 0.0001444
BMI and PR 0.1243 0.0001534
BMI status and PR 0.02838 0.04876
BMI, BMI status and PR 0.02625 0.0556
CaRes BMI only 0.05877 0.007805
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Table S31 (continued)
BMI and BMI status 0.0415 0.02194
Pathways only 0.2438 6.952×10−8
BMI and pathways 0.2037 1.023×10−6
BMI status and pathways 0.1132 0.0003018
BMI, BMI status and pathways 0.0995 0.0006872
PR only 0.1096 0.0003748
BMI and PR 0.08751 0.001409
BMI status and PR 0.02671 0.05406
BMI, BMI status and PR 0.02392 0.06429
CaResOl BMI only 0.1167 0.0002439
BMI and BMI status 0.04905 0.01395
Pathways only 0.07821 0.002453
BMI and pathways 0.06736 0.004681
BMI status and pathways -0.0005575 0.3338
BMI, BMI status and pathways -0.003248 0.4151
PR only 0.1632 1.377×10−5
BMI and PR 0.1628 1.412×10−5
BMI status and PR 0.05905 0.007678
BMI, BMI status and PR 0.05391 0.01043
Or BMI only 0.1246 0.0001508
BMI and BMI status 0.03912 0.02533
Pathways only 0.1649 1.237×10−5
BMI and pathways 0.1311 0.0001014
BMI status and pathways 0.05614 0.009131
BMI, BMI status and pathways 0.04897 0.01402
PR only 0.1805 4.604×10−6
BMI and PR 0.1626 1.431×10−5
BMI status and PR 0.08503 0.001634
BMI, BMI status and PR 0.08819 0.001353
FM BMI only -0.004507 0.4632
BMI and BMI status 0.01947 0.08502
Pathways only 0.4202 8.085×10−14
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Table S31 (continued)
BMI and pathways 0.4213 7.317×10−14
BMI status and pathways 0.3386 6.885×10−11
BMI, BMI status and pathways 0.2734 8.759×10−9
PR only 0.09798 0.0007529
BMI and PR 0.09642 0.0008267
BMI status and PR -0.00988 0.9634
BMI, BMI status and PR -0.008862 0.7478
1 All values in bold are statistically significant (p < 0.05).
Table S32: Table summarising the linear model statistics from the comparison of the predicted
obesity metagenes scores from the BMI status-only model with the corresponding obe-
sity metagene scores from the CR data set for all of the obesity metagenes
P-values
Obesity metagene Overweight Obese ANOVA
Cr 3.005×10−6 1 0.0002419 6.931×10−6
CrOl 2.924×10−7 8.516×10−6 1.467×10−7
Res 0.2783 2.146×10−5 5.715×10−5
ResOl 2.023×10−6 3.31×10−5 1.052×10−6
Ca 0.00283 8.769×10−5 0.0002354
CaOl 0.0001869 3.328×10−6 4.371×10−6
CaRes 0.008582 0.0004552 0.001334
CaResOl 0.0004192 5.338×10−6 8.806×10−6
Or 5.806×10−6 0.0002258 8.092×10−6
FM 0.8573 0.185 0.3568
1 All values in bold are statistically significant (p < 0.05).
B13 Code used in this project
All of the R source code used in this project is publicly available at: https://github.
com/rikutakei/bmi-cancer-code.git. This thesis was written with LATEX, and the
source code is publicly available at https://github.com/rikutakei/mastersDoc.git.
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